{
  "questions": [
    {
      "exact_answer": [
        [
          "Achondroplasia"
        ],
        [
          "FGFR3 gene"
        ],
        [
          "Mutation"
        ],
        [
          "shared attribute"
        ],
        [
          "Restriction Mapping"
        ]
      ],
      "id": "52b2e498f828ad283c000010",
      "ideal_answer": "Achondroplasia comes from the genetic point mutations in the fibroblastic growth factor receptor 3 gene (FGFR3), which enables abnormal cartilage growth-plate differentiation and insufficient bony development. Detecting FGFR 3 gene mutation with PCR-SSCP and restriction enzymes analysis is a convenient, rapid and reliable molecular diagnostic assay for prenatal and early diagnosis of achondroplasia. To investigate the mutation at the transmembrane domain of fibroblast growth factor receptor 3 (FGFR3) nucleotide 1138 site for identifying the major pathologic mechanism of achondroplasia (ACH) and to evaluate the efficacy of denaturing gradient gel electrophoresis(DGGE) method for screening the point mutations. The diagnosis of achondroplasia was based on the presence of clinical and radiographic findings and confirmed by the presence of a common FGFR3 gene mutation (Gly380Arg) detected by restriction enzyme analysis and sequencing of the polymerase chain reaction products. The most common genetic mutations in this receptor are G to A at position 1138 (G1138A), which result in the substitution of glycine to arginine at codon 380. Recent studies mapped the achondroplasia gene on chromosome region 4p16.3 and identified a common mutation in the gene encoding the fibroblast growth factor receptor 3 (FGFR3). "
    },
    {
      "exact_answer": "yes",
      "id": "52b2f3b74003448f5500000c",
      "ideal_answer": "Purified calsequestrin inhibited junctin/triadin-associated, or junctin-associated, ryanodine receptors and the calsequestrin re-associated channel complexes were further inhibited when luminal Ca(2+) fell from 1mM to. The junctional face of the jSR, facing the transverse tubules, is occupied by a molecular complex composed of the transmembrane Ca2+ release channels (ryanodine receptors); the luminal protein calsequestrin (CSQ); the 2 membrane proteins, junctin (Jct), and triadin (Tr), which mediate CSQ-ryanodine receptor interactions; and several other components. Junctin is a 26 kDa membrane protein that binds to calsequestrin, triadin, and ryanodine receptors (RyRs) within the junctional sarcoplasmic reticulum of calcium release units. Calsequestrin, the main calcium buffer in the sarcoplasmic reticulum, provides a pool of calcium for release through the ryanodine receptor and acts as a luminal calcium sensor for the channel via its interactions with triadin and junctin. We show here that purified skeletal ryanodine receptors are similarly activated by purified triadin or purified junctin added to their luminal side, although a lack of competition indicated that the proteins act at independent sites. We examined the influence of phosphorylation of calsequestrin on its ability to store calcium, to polymerise and to regulate ryanodine receptors by binding to triadin and junctin. "
    },
    {
      "exact_answer": "yes",
      "id": "52bf1db603868f1b06000011",
      "ideal_answer": "Denosumab is a RANK-ligand antibody that was approved by the FDA in 2010 for the prevention of skeletal fractures in patients with bone metastases from solid tumors. A fourth agent, denosumab (bone targeted therapy) was also recently approved by the FDA for patients with bone metastasis after showing a reduction in the occurrence of skeletal-related events. Several of these therapies have recently been approved by the FDA to treat bone cancer pain (bisphosphonates, denosumab) and others are currently being evaluated in human clinical trials (tanezumab). Denosumab (ProliaÂ®) is a fully human monoclonal antibody for RANKL, which selectively inhibits osteoclastogenesis, being recently approved for the treatment of postmenopausal osteoporosis in women at a high or increased risk of fracture by the FDA in the United Sates and by the European Medicines Agency in Europe since June 2010. AHRQ published an updated review in March 2012 that summarized the benefits and risks of osteoporosis medications in treatment and prevention of osteoporosis, including bisphosphonates (aledronate, risedronate, ibandronate, zoledronic acid), parathyroid hormone, teriparatide, calcitonin, estrogens (for prevention in postmenopausal women), selective estrogen receptor modulators (raloxifene), and denosumab(approved by the FDA in 2010). "
    },
    {
      "exact_answer": [
        [
          "nalmefene"
        ],
        [
          "Magnesium Cation"
        ],
        [
          "Dosage"
        ],
        [
          "Lightheadedness"
        ],
        [
          "User Group"
        ],
        [
          "aspects of adverse effects"
        ],
        [
          "Receive"
        ],
        [
          "Only - dosing instruction fragment"
        ],
        [
          "Mild (qualifier value)"
        ],
        [
          "Unmarried person"
        ],
        [
          "Pharmaceutical Preparations"
        ],
        [
          "Rating (action)"
        ],
        [
          "Transitory"
        ],
        [
          "Fatigue"
        ],
        [
          "Good"
        ],
        [
          "Having administered"
        ],
        [
          "Placebo Control"
        ],
        [
          "Choose (action)"
        ],
        [
          "Human Study Subject"
        ],
        [
          "Nausea"
        ],
        [
          "Male population group"
        ],
        [
          "Plasma specimen"
        ],
        [
          "48 hour time frame"
        ],
        [
          "Including (qualifier)"
        ],
        [
          "Sedation procedure"
        ],
        [
          "Seven-Day Report"
        ],
        [
          "Preposition For"
        ],
        [
          "Observed"
        ],
        [
          "Elation"
        ],
        [
          "Sleeplessness"
        ],
        [
          "Equus caballus"
        ],
        [
          "Treated with"
        ],
        [
          "Study"
        ],
        [
          "Alertness"
        ],
        [
          "Milligram percent"
        ],
        [
          "Men\u0027s Health (attribute)"
        ],
        [
          "Dizziness Adverse Event"
        ],
        [
          "penis"
        ],
        [
          "shared attribute"
        ],
        [
          "Stat (do immediately)"
        ],
        [
          "Weighing patient"
        ],
        [
          "Feces"
        ],
        [
          "Desire for food"
        ],
        [
          "Extrinsic"
        ],
        [
          "Sequencing - Ascending"
        ],
        [
          "Vomiting"
        ],
        [
          "Meal (occasion for eating)"
        ],
        [
          "Subject - topic"
        ],
        [
          "Schedule (document type)"
        ],
        [
          "Unlikely Related to Intervention"
        ],
        [
          "Intermittent"
        ],
        [
          "Nutrient (property)"
        ],
        [
          "Every twelve hours"
        ],
        [
          "Administration occupational activities"
        ],
        [
          "Retained"
        ],
        [
          "Started"
        ],
        [
          "Largest"
        ],
        [
          "Relaxation"
        ],
        [
          "Science of Etiology"
        ],
        [
          "Absolute"
        ],
        [
          "Collection (action)"
        ],
        [
          "Consequence of"
        ],
        [
          "Indirect"
        ],
        [
          "Feeding behaviors"
        ],
        [
          "Changed status"
        ],
        [
          "Stimulus"
        ],
        [
          "Minor (value)"
        ],
        [
          "2+ Score"
        ],
        [
          "Initially"
        ],
        [
          "Infusion procedures"
        ],
        [
          "Appearance"
        ],
        [
          "Time Interval"
        ],
        [
          "Adverse event"
        ],
        [
          "Channel"
        ],
        [
          "Energy Intake"
        ],
        [
          "Prolonged"
        ],
        [
          "Materials"
        ],
        [
          "apparent"
        ],
        [
          "With intensity"
        ],
        [
          "account - ActClass"
        ],
        [
          "Adverse effects"
        ],
        [
          "Continuous"
        ],
        [
          "Specificity"
        ],
        [
          "Duration"
        ],
        [
          "Course"
        ],
        [
          "per second"
        ],
        [
          "Decrease"
        ],
        [
          "Term (lexical)"
        ],
        [
          "Drug dose"
        ],
        [
          "High dose"
        ],
        [
          "Period (temporal qualifier)"
        ],
        [
          "population health"
        ],
        [
          "Large"
        ],
        [
          "Health"
        ],
        [
          "Performed"
        ],
        [
          "Increase"
        ],
        [
          "Thinking, function"
        ],
        [
          "Double-Blind Method"
        ],
        [
          "Some (qualifier value)"
        ],
        [
          "First (number)"
        ]
      ],
      "id": "52bf1dea03868f1b06000012",
      "ideal_answer": "Side effects to nalmefene were of greater duration and intensity in the subjects receiving 10 mg of nalmefene vs. those receiving 6 or 2 mg. Thus the apparent nutrient specificity of nalmefene appeared to be an indirect consequence of its effect on palatability. Nalmefene also caused slight increases in self-rated alertness, and decreases in ratings of tiredness and elation, although it was thought unlikely that these accounted for observed changes in eating behaviour. The nalmefene treated group ate 22% less, both in terms of absolute weight and caloric intake, of a standardised buffet-meal than did the placebo group. In the first study, single ascending doses of 50, 100, 200, and 300 mg of nalmefene HCl were administered in double-blind fashion to four groups of healthy men. In the second study, six healthy men were initially administered a single 50-mg dose of drug, and plasma samples were obtained at selected time intervals for 48 hours. These side effects included some passage of semifluid fecal material, intermittent penile relaxation, and mild sedation. A dosing schedule of 20 mg q12h was then started and continued for seven days. "
    },
    {
      "exact_answer": [
        [
          "Levodopa"
        ],
        [
          "Benserazide"
        ],
        [
          "Benserazide / Levodopa"
        ],
        [
          "Dopa"
        ],
        [
          "Blood group antibody I"
        ]
      ],
      "id": "52bf1f2d03868f1b06000015",
      "ideal_answer": "The present study utilizes in vivo amperometry to investigate the impact from unilateral 6-hydroxydopamine lesions and l-DOPA (4 mg/kg, including benserazide 15 mg/kg) -induced dyskinetic behavior on striatal basal extracellular glutamate concentration and potassium-evoked glutamate release in urethane-anesthetized rats. In experiment 1, l-DOPA-primed rats were pre-treated with Vehicle (0.9% NaCl), various doses of the partial 5-HT(1A) agonist, buspirone (0.25, 1.0 or 2.5 mg/kg, ip) or buspirone (2.5 mg/kg, ip)+the 5-HT(1A) antagonist, WAY100635 (0.5 mg/kg, ip) 5 min prior to l-DOPA (12 mg/kg+15 mg/kg benserazide, ip). Chronic L-DOPA-treated rats received the D1 receptor antagonist SCH23390 (0.01, 0.1, and 1.0 mg/kg; i.p.), the D2 receptor antagonist Eticlopride (0.01, 0.1, and 1.0 mg/kg; i.p.), a mixture of both antagonists (0.01, 0.1, 1.0 mg/kg each; i.p.), or vehicle 30 min prior to L-DOPA (6 mg/kg; i.p.)+Benserazide (15 mg/kg; i.p.). Co-administration of L-Dopa with peripheral DDC inhibitors (carbidopa or benserazide) is the most effective symptomatic treatment for PD. Tolcapone (30 mg/kg p.o.), given as adjunct to both doses of L-dopa, markedly enhanced the elevation or extracellular L-dopa, while it completely prevented the formation of 3-O-methyl-DOPA. "
    },
    {
      "exact_answer": [
        [
          "Atypical antipsychotic"
        ],
        [
          "Antipsychotic Agents"
        ],
        [
          "Clozapine"
        ],
        [
          "Therapeutic procedure"
        ],
        [
          "Haloperidol"
        ],
        [
          "Schizophrenia"
        ],
        [
          "Negation"
        ],
        [
          "haloperidol decanoate"
        ],
        [
          "Risperidone"
        ],
        [
          "Usual"
        ],
        [
          "atypia morphology"
        ],
        [
          "Prodromal Stage"
        ],
        [
          "Adolescent (age group)"
        ],
        [
          "combination of objects"
        ],
        [
          "Atypical"
        ],
        [
          "Preposition For"
        ],
        [
          "Patients"
        ],
        [
          "Negativism in catatonia"
        ],
        [
          "Polypharmacology"
        ],
        [
          "Nonorganic psychosis"
        ],
        [
          "Handwriting"
        ],
        [
          "Science of neurochemistry"
        ],
        [
          "Psychologist - Psychotherapy"
        ],
        [
          "Upper case Roman letter O"
        ],
        [
          "Delusional disorder"
        ],
        [
          "Schizoaffective Disorder"
        ],
        [
          "Delusions"
        ],
        [
          "Enrich"
        ],
        [
          "Hallucinations"
        ],
        [
          "Singular"
        ],
        [
          "Widening"
        ],
        [
          "Agitation"
        ],
        [
          "Preferred - Specimen Appropriateness"
        ],
        [
          "acceptability"
        ],
        [
          "Multimodal Imaging"
        ],
        [
          "Patient chart"
        ],
        [
          "suggestion"
        ],
        [
          "Typical Antipsychotic [EPC]"
        ],
        [
          "Comorbidity"
        ],
        [
          "Choose (action)"
        ],
        [
          "Approximate"
        ],
        [
          "DSM III-R"
        ],
        [
          "Conduct Disorder"
        ],
        [
          "User Group"
        ],
        [
          "The science and art of healing"
        ],
        [
          "Capability"
        ],
        [
          "Profound"
        ],
        [
          "Requirement"
        ],
        [
          "Modulated"
        ],
        [
          "Hospital admission Dx:Impression/interpretation of study:Point in time:^Patient:Nominal"
        ],
        [
          "Relevance"
        ],
        [
          "Perceived quality of life"
        ],
        [
          "Symptom modification"
        ],
        [
          "Complicated"
        ],
        [
          "Aggressive behavior"
        ],
        [
          "Scientific Study"
        ],
        [
          "Psychiatric problem"
        ],
        [
          "classical example"
        ],
        [
          "Childhood"
        ],
        [
          "Weight Gain"
        ],
        [
          "motor movement"
        ],
        [
          "Movement"
        ],
        [
          "Learning"
        ],
        [
          "Presentation"
        ],
        [
          "Child"
        ],
        [
          "Male child"
        ],
        [
          "Clinical setting"
        ],
        [
          "mental health"
        ],
        [
          "Relationships"
        ],
        [
          "Effectiveness"
        ],
        [
          "Positive Finding"
        ],
        [
          "Frequent"
        ],
        [
          "Adverse effects"
        ],
        [
          "Disease management program (regime/therapy)"
        ],
        [
          "intervention program"
        ],
        [
          "Late"
        ],
        [
          "Reviewed"
        ],
        [
          "strategy"
        ],
        [
          "Having administered"
        ],
        [
          "Resistant (qualifier value)"
        ],
        [
          "Surgical and medical procedures"
        ],
        [
          "Oral"
        ],
        [
          "Comparison"
        ],
        [
          "Late-Onset Disorders"
        ],
        [
          "Activation action"
        ],
        [
          "Evaluation"
        ],
        [
          "Symptoms"
        ],
        [
          "Contrast used"
        ],
        [
          "Brain"
        ],
        [
          "acute"
        ],
        [
          "Population at Risk"
        ],
        [
          "described"
        ],
        [
          "year"
        ],
        [
          "Early"
        ],
        [
          "Examined"
        ],
        [
          "Clinical"
        ],
        [
          "HL7CommitteeIDInRIM \u003cPatient Administration\u003e"
        ]
      ],
      "id": "52bf1f4503868f1b06000016",
      "ideal_answer": "The handwriting of 18 schizophrenic patients before and during treatment with typical (haloperidol, haloperidol decanoate) and atypical (clozapine, risperidone) neuroleptic drugs was examined. Further clinical implications are described (capability of learning the therapeutic strategies, deliverability in broader clinical settings, acceptability by patients, combination with atypical neuroleptic drugs,and treatment of choice in risk populations). Monotherapeutic treatment with new atypical neuroleptic drugs had a more positive effect on the mental health related quality of life (MCS) in comparison to treatment with polypharmacological treatment but not with oral conventional antipsychotics. Only the group of boys presented other comorbidities such as negativism and conduct disorders; approximately 25% of them required treatment with atypical neuroleptic drugs. Recent studies suggest that clozapine is more effective than typical neuroleptics for patients with treatment-resistant schizophrenia. o prove whether weight gain is a relevant side effect of atypical neuroleptics, the charts of all patients admitted with DSM-III-R diagnoses of schizophrenia, schizoaffective disorder, or delusional disorder in the years 1991 to 1995 were evaluated. Acute and late onset movement disorders frequently complicate the treatment of psychosis with typical neuroleptic drugs like haloperidol, but not with atypical neuroleptic drugs like clozapine. "
    },
    {
      "exact_answer": [
        [
          "lacosamide"
        ],
        [
          "gabapentin"
        ],
        [
          "Lymphocytic Choriomeningitis"
        ],
        [
          "Carbamazepine"
        ],
        [
          "topiramate"
        ],
        [
          "Epilepsy"
        ],
        [
          "mechanism of action qualifier"
        ],
        [
          "Picrotoxin"
        ],
        [
          "Seizures"
        ],
        [
          "Induce (action)"
        ],
        [
          "valnoctamide"
        ],
        [
          "eslicarbazepine acetate"
        ],
        [
          "DPYSL2 gene"
        ],
        [
          "suggestion"
        ],
        [
          "Pharmaceutical Preparations"
        ],
        [
          "House mice"
        ],
        [
          "Onset of (contextual qualifier)"
        ],
        [
          "harkoseride"
        ],
        [
          "Seizures, Focal"
        ],
        [
          "Automated External Defibrillators"
        ],
        [
          "tianeptine"
        ],
        [
          "Model"
        ],
        [
          "Cystamine Dihydrochloride"
        ],
        [
          "Valproic Acid"
        ],
        [
          "Pentylenetetrazole"
        ],
        [
          "Rattus norvegicus"
        ],
        [
          "diphenyl (fungicide)"
        ],
        [
          "Potential"
        ],
        [
          "clobazam"
        ],
        [
          "Bicuculline"
        ],
        [
          "Primidone"
        ],
        [
          "concise"
        ],
        [
          "Ethosuximide"
        ],
        [
          "zonisamide"
        ],
        [
          "oxcarbazepine"
        ],
        [
          "Effectiveness"
        ],
        [
          "Dual - RoleCode"
        ],
        [
          "homocysteine"
        ],
        [
          "Levetiracetam"
        ],
        [
          "Indication of (contextual qualifier)"
        ],
        [
          "lamotrigine"
        ],
        [
          "Anticonvulsants"
        ],
        [
          "Phenytoin"
        ],
        [
          "Amino Acids"
        ],
        [
          "Phenobarbital"
        ],
        [
          "Unresponsive to Treatment"
        ],
        [
          "Analgesics"
        ],
        [
          "Antiepileptic Agents"
        ],
        [
          "Clinical Trial [Publication Type]"
        ],
        [
          "Seizures, refractory"
        ],
        [
          "Experimental Result"
        ],
        [
          "Target Awareness - partial"
        ],
        [
          "Make - Instruction Imperative"
        ],
        [
          "Adjunctive Orthodontic Procedure"
        ],
        [
          "Application procedure"
        ],
        [
          "Therapeutic procedure"
        ],
        [
          "RFFL gene"
        ],
        [
          "Animal Model"
        ],
        [
          "Preposition For"
        ],
        [
          "Patients"
        ],
        [
          "utilization qualifier"
        ],
        [
          "Tonics"
        ],
        [
          "Current (present time)"
        ],
        [
          "lanthionine ketimine"
        ],
        [
          "Somalia"
        ],
        [
          "Dispense Method - Traditional"
        ],
        [
          "Antidepressive Agents"
        ],
        [
          "Assortment"
        ],
        [
          "literary novel"
        ],
        [
          "Pyrazole derivative"
        ],
        [
          "N-Methylaspartate"
        ],
        [
          "Electroconvulsive Shock"
        ],
        [
          "Seizures, Clonic"
        ],
        [
          "Diabetic Neuralgia"
        ],
        [
          "atypia morphology"
        ],
        [
          "Widening"
        ],
        [
          "Mus"
        ],
        [
          "Licensed - Location characteristic ID"
        ],
        [
          "Referring"
        ],
        [
          "Type - attribute"
        ],
        [
          "Add - instruction imperative"
        ],
        [
          "Sedentary"
        ],
        [
          "Discontinued"
        ],
        [
          "Uncontrolled"
        ],
        [
          "Firstly"
        ],
        [
          "Genetic Predisposition to Disease"
        ],
        [
          "Overall Publication Type"
        ],
        [
          "Generations"
        ],
        [
          "Neuroprotective Effect"
        ],
        [
          "Series - set of composite instances"
        ],
        [
          "Rodent"
        ],
        [
          "Market"
        ],
        [
          "Neuropathy"
        ],
        [
          "Salivary"
        ],
        [
          "Initiate (source type)"
        ],
        [
          "Reflecting"
        ],
        [
          "Kindling, Neurologic"
        ],
        [
          "Sound - physical agent"
        ],
        [
          "Various patch test substance"
        ],
        [
          "Epilepsy, Temporal Lobe"
        ]
      ],
      "id": "52bf202003868f1b06000018",
      "ideal_answer": "Furthermore, first generation AEDs were often discontinued, while lacosamide and topiramate were most likely to be initiated. Two additional AEDs, lacosamide and eslicarbazepine acetate, have been licensed recently for a more traditional indication, refractory partial-onset seizures. These results suggest that lacosamide may have the potential to be clinically useful for at least the treatment of generalized tonic-clonic and partial-onset epilepsies, and support ongoing clinical trials in these indications. The current article presents a concise review of network theory and its application to the characterization of AED use in children with refractory epilepsy. A discussion is made of recent findings that the atypical antidepressant tianeptine increases CRMP2 expression, whereas other, neuroactive small molecules including the epilepsy drug lacosamide and the natural brain metabolite lanthionine ketimine appear to bind CRMP2 directly with concomitant affects on neural structure. Lacosamide was effective against sound-induced seizures in the genetically susceptible Frings mouse, against maximal electroshock test (MES)-induced seizures in rats and mice, in the rat hippocampal kindling model of partial seizures, and in the 6Hz model of psychomotor seizures in mice. "
    },
    {
      "exact_answer": [
        [
          "Aging"
        ],
        [
          "Fishes"
        ],
        [
          "Biological Models"
        ],
        [
          "Oryzias latipes"
        ],
        [
          "Relationships"
        ]
      ],
      "id": "52bf217003868f1b0600001b",
      "ideal_answer": "The short-lived annual fish Nothobranchius furzeri shows extremely short captive life span and accelerated expression of age markers, making it an interesting model system to investigate the effects of experimental manipulations on longevity and age-related pathologies. In the last three years, N. furzeri has moved from biological curiosity to a promising model system for drug validation. Owing to large differences in aging phenotypes in different lines, N. furzeri could represent a model system for studying the genetic control of life-history traits in natural populations. This result identifies resveratrol as the first molecule which consistently retards aging in organisms as diverse as yeast, worm, fly and fish, but it also reveals the potential of this short-lived fish as an animal model for pharmacological research. They can be employed to test the effects of experimental manipulation on aging at a pace comparable with that of Drosophila and to probe the effects of natural selection on the evolution of aging-related genes. "
    },
    {
      "exact_answer": "yes",
      "id": "52cae04c03868f1b06000024",
      "ideal_answer": "A large-scale trial comparing a first-generation antipsychotic (molindone) with newer agents did not find significant differences in treatment response, although the newer antipsychotics were associated with more severe weight gain. Although weight gain and metabolic adverse events had occurred more often with olanzapine and risperidone during the acute trial, no significant between-drug differences emerged in most of these parameters during maintenance treatment. Among conventional agents, mean weight change ranged from a reduction of 0.39 kg with molindone to an increase of 3.19 kg with thioridazine. On average, molindone patients lost 5 pounds over the 6 weeks of treatment, whereas thioridazine patients gained 6 pounds. Monthly weights and neuroleptic dosages during the first three months of psychiatric hospitalization were compared between matched groups of patients receiving molindone, a combination of molindone and other neuroleptics, or other neuroleptic drugs. The weight-reducing property of molindone, a recently introduced antipsychotic drug, was tested in 9 hospitalized chronic schizophrenic patients. There was an average weight loss of 7.6 kg after 3 months on molindone; most of the loss occurred during the first month. The three treatment arms did not significantly differ in symptom decrease or time to discontinuation. "
    },
    {
      "id": "52d3cc5203868f1b06000037",
      "ideal_answer": "Recent genome-wide descriptions of CpG methylation patterns in mammalian cells identified many differentially methylated regions (DMRs) located at CpG island \"shores.\". Here we show that most methylation alterations in colon cancer occur not in promoters, and also not in CpG islands, but in sequences up to 2 kb distant, which we term \u0027CpG island shores\u0027. This analysis revealed leukemia-associated differentially methylated regions that included gene promoters, gene bodies, CpG islands and CpG island shores. We observed that methylation probes associated with expression in cis were more likely to be located outside CpG islands, whereas specificity for CpG island shores was present when methylation, associated with expression, was under local genetic control. In particular, neuronal-type differential methylation was overrepresented in CpG island shores, enriched within gene bodies but not in intergenic regions, and preferentially harbored binding motifs for a distinct set of transcription factors, including neuron-specific activity-dependent factors. Aberrant DNA methylation of CpG islands, CpG island shores and first exons is known to play a key role in the altered gene expression patterns in all human cancers. Here, we find substantial hypermethylation and hypomethylation of cytosine-phosphate-guanine (CpG) island shores in nine human iPS cell lines as compared to their parental fibroblasts. "
    },
    {
      "exact_answer": [
        [
          "National Cancer Institute"
        ],
        [
          "Homo sapiens"
        ],
        [
          "Structure of parenchyma of lung"
        ],
        [
          "Malignant neoplasm of lung"
        ],
        [
          "Tumor cells, malignant"
        ]
      ],
      "id": "52d63b2803868f1b0600003a",
      "ideal_answer": "NCI-H520 and NCI-H596 lung cancer cells. on human non-small cell lung cancer cell lines, A549, NCI-H460 and NCI-H520. "
    },
    {
      "id": "52d783bf98d0239505000001",
      "ideal_answer": "Hutchinson-Gilford progeria syndrome is a syndrome that involves premature aging, leading usually to death at the age between 10 to 14 years predominatly due to a myocardial infarction or a stroke. Hutchinson-Gilford progeria syndrome is a rare, sporadic, autosomal dominant syndrome that involves premature aging, generally leading to death at approximately 13 years of age due to myocardial infarction or stroke. The genetic basis of most cases of this syndrome is a change from glycine GGC to glycine GGT in codon 608 of the lamin A (LMNA) gene, which activates a cryptic splice donor site to produce abnormal lamin A; this disrupts the nuclear membrane and alters transcription. The genetic basis in most cases is a mutation at the nucleotide position 1824 of the lamin A gene. This results in a production of abnormal lamin A, termed progerin. At this position, cytosine is substituted for thymine so that a cryptic splice site within the precursor mRNA for lamin A is generated. "
    },
    {
      "exact_answer": "yes",
      "id": "52d7b45e98d0239505000002",
      "ideal_answer": "In current RCTs, levothyroxine replacement therapy for subclinical hypothyroidism did not result in improved survival or decreased cardiovascular morbidity. Treatment of SCH with levothyroxine was associated with fewer IHD events in younger individuals, but this was not evident in older people. However, whether SH confers a high risk for cardiovascular disease, and whether LT4 therapy has a long-term benefit that clearly outweighs the risks of overzealous treatment in these individuals, remain topics of controversy. In conclusion, the multiplicity and the possible reversibility of subclinical hypothyroidism-associated cardiovascular abnormalities suggest that the decision to treat a patient should depend on the presence of risk factors, rather than on a TSH threshold. The decision to treat elderly people is still an unresolved clinical challenge--first, due to a lack of appropriately powered randomized controlled trials of L-T4 in sHT patients, examining cardiovascular hard endpoints in various classes of age; and second, because of the negative effects of possible overtreatment. "
    },
    {
      "exact_answer": [
        [
          "Phosphoserine"
        ],
        [
          "Serine"
        ],
        [
          "casein kinase I"
        ],
        [
          "Threonine"
        ],
        [
          "Sodium Dodecyl Sulfate"
        ],
        [
          "Residue"
        ],
        [
          "Consensus"
        ],
        [
          "CSNK1A1 protein, human"
        ],
        [
          "Protein Domain"
        ],
        [
          "Phosphotransferases"
        ],
        [
          "CSNK1A1 gene"
        ],
        [
          "Closed"
        ],
        [
          "N not otherwise specified Antibody"
        ],
        [
          "Cluster"
        ],
        [
          "Acids"
        ],
        [
          "THRSP gene"
        ],
        [
          "PRB2 gene"
        ],
        [
          "Incised wound"
        ],
        [
          "literary novel"
        ],
        [
          "Phosphoric Acid Esters"
        ],
        [
          "Singular"
        ],
        [
          "Positioning Attribute"
        ],
        [
          "shared attribute"
        ],
        [
          "Adoptive Immunotherapy"
        ],
        [
          "S prime"
        ],
        [
          "T prime"
        ],
        [
          "Priming"
        ],
        [
          "chain of objects"
        ],
        [
          "Consensus Sequence"
        ],
        [
          "Downstream"
        ],
        [
          "Direction"
        ],
        [
          "Family member"
        ],
        [
          "Feature"
        ],
        [
          "Protein phosphorylation"
        ],
        [
          "Providing (action)"
        ],
        [
          "Recognition (Psychology)"
        ],
        [
          "Clear"
        ],
        [
          "Side"
        ],
        [
          "Relative"
        ],
        [
          "Target"
        ],
        [
          "Experimental Result"
        ],
        [
          "Including (qualifier)"
        ],
        [
          "Data"
        ],
        [
          "End-stage"
        ]
      ],
      "id": "52d832dd98d0239505000003",
      "ideal_answer": "Members of the protein kinase CK1 family usually phosphorylate residues of serine that are close to other phosphoserine in a consensus motif of pS-X-X-S,. The protein kinase CK1 phosphorylates serine residues that are located close to another phosphoserine in the consensus pSer-Xaa-Xaa-Ser. CK1 acts as a \u0027phosphate-directed\u0027 kinase whose targeting is primed by a single phosphorylated side chain at position n-3 or n-4 relative to serine/threonine. The common features include an SLS motif followed two to five residues downstream by a cluster of acidic residues. The results demonstrate that SLS and acidic cluster motifs are crucial for CK1 recognition. These data provide the clear-cut demonstration that the consensus sequence with N-terminal prephosphorylated residue(s), SerP/ThrP-Xaa-Xaa-Ser/Thr. a novel consensus phosphorylation motif (K/R-X-K/R-X-X-S/T) for CK1. "
    },
    {
      "id": "52d946c798d023950500000a",
      "ideal_answer": "We reported the first small molecule inhibitors of the interaction between the clathrin N-terminal domain (TD) and endocyctic accessory proteins (i.e., clathrin inhibition1). Clathrin immunohistochemistry and immunoblotting showed increased immunoreactivity of clathrin protein in the placental tissues of mice treated with 20- and 50-nm gold nanoparticles; clathrin immunopositivity was observed in syncytiotrophoblasts and fetal endothelial cells. Tubulobulbar complexes are elaborate clathrin/actin related structures that form at sites of intercellular attachment in the seminiferous epithelium of the mammalian testis. Macromolecules gain access to the cytoplasm of eukaryotic cells using one of several ways of which clathrin-dependent endocytosis is the most researched. Clathrin-mediated endocytosis is a central and well-studied trafficking process in eukaryotic cells. Clathrin-coated vesicles (CCVs) are formed at the plasma membrane and act as vectors for endocytosis. They also assemble at the trans-Golgi network (TGN), but their exact function at this organelle is unclear. "
    },
    {
      "exact_answer": "yes",
      "id": "52e01f8f98d023950500000f",
      "ideal_answer": "we developed an approach to biochemically isolate the pseudopodium from the cell body using 3.0-micrometer porous filters for large-scale quantitative proteomic and phosphoproteomic analysis. These methods are compatible with current mass spectrometry-based protein identification technologies and can be utilized for the large-scale identification of the pseudopodium pY proteome in various migratory cell lines, including primary and cancer cells. we describe methods for the immunoaffinity purification of phosphotyrosine proteins (pY) from pseudopodia that have been isolated from migratory cells. tumor cells were placed on a fibronectin-coated porous membrane to form pseudopodia. Recent work using unique subcellular fractionation methodologies combined with spatial genomic, proteomic, and phosphoproteomic profiling has provided insight into the invadopodiome and pseudopodiome signaling networks. According to the motile potentials of the cells, the cells formed pseudopodial microprocesses in the pores. ere, we purified the pseudopodial proteomes. An excimer laser, which was used for ophthalmic refractive surgeries, horizontally ablated cells at the membrane surface to remove the cell body. "
    },
    {
      "exact_answer": "yes",
      "id": "52e8e96698d023950500001f",
      "ideal_answer": "a spectrum of sudden cardiac death (SCD)-predisposing heritable cardiac arrhythmia syndromes, including long QT syndrome (LQTS), short QT syndrome (SQTS), Brugada syndrome (BrS), and catecholaminergic polymorphic ventricular tachycardia (CPVT). Stress or anxiety-induced release of endogenous catecholamines causes a dysfunction in the myocytic calcium-ion channel, leading to ventricular arrhythmias that can cause dizziness, syncope, or sudden cardiac death. Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a cardiac channelopathy characterized by altered intracellular calcium handling resulting in ventricular arrhythmias and high risk of cardiac sudden death in young cases with normal structural hearts. Aberrant spontaneous, diastolic Ca2+ leak from the SR due to dysfunctional RyR2 contributes to the formation of delayed after-depolarisations, which are thought to underlie the fatal arrhythmia that occurs in both heart failure (HF) and in catecholaminergic polymorphic ventricular tachycardia (CPVT). Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare arrhythmogenic disorder characterized by syncopal events and sudden cardiac death at a young age during physical stress or emotion, in the absence of structural heart disease. Among the five major arrhythmogenic disorders occurring in the absence of a structural heart disease is catecholaminergic polymorphic ventricular tachycardia (CPVT), which is a highly lethal form of inherited arrhythmias. "
    },
    {
      "id": "52ed27c098d0239505000030",
      "ideal_answer": "Thyroid hormone signaling acts as a neurogenic switch by repressing Sox2 in the adult neural stem cell niche. Thus, c-erbA/TR appears to act as a binary switch affecting erythroid cell fate: unliganded c-erbA/TR supports growth while ligand-activated c-erbA/TR induces differentiation. Terminal erythroid maturation was significantly improved by adding human serum and thyroid hormone (3,5,3\u0027-triiodothyronine [T3]) to the differentiation medium. Although no difference of in vitro proliferation of NSCs was observed in the presence of epidermal growth factor, maturation of oligodendrocytes (defined by process number and length) was enhanced in hyperthyroidism, suggesting a more mature state than in control animals. Our results revealed that T3 induces distinct tissue-specific gene regulation programs associated with the remodeling of the intestine, particularly the formation of the ASCs, and further suggested the existence of potentially many novel stem cell-associated genes, at least in the intestine during development. Exposure of embryos at this developmental stage for 24 h to either a TH antagonist, NH-3, or to tetrabromobisphenol A, a flame retardant and known TH disruptor, differentially modulated the expression of a number of TH target genes implicated in neural stem cell function or neural differentiation. "
    },
    {
      "exact_answer": [
        [
          "Jervell-Lange Nielsen Syndrome"
        ],
        [
          "Autosomal recessive inheritance"
        ],
        [
          "Congenital deafness"
        ],
        [
          "Characterization"
        ],
        [
          "quart - US"
        ]
      ],
      "id": "52eea4dcc8da89891000000c",
      "ideal_answer": "Homozygous or compound heterozygous mutations in KCNQ1 cause Jervell and Lange-Nielsen syndrome, a rare, autosomal-recessive form of long-QT syndrome characterized by deafness, marked QT prolongation, and a high risk of sudden death. Jervell and Lange-Nielsen syndrome (JLNS) is characterized by sensorineural deafness, QT prolongation, abnormal T waves, ventricular tachyarrhythmias, and autosomal recessive inheritance. KCNQ1 is associated with two different entities of LQTS, the autosomal-dominant Romano-Ward syndrome (RWS), and the autosomal-recessive Jervell and Lange-Nielsen syndrome (JLNS) characterized by bilateral deafness. Jervell and Lange-Nielsen syndrome (MIM 220400; JLNS), is a rare form of profound congenital deafness combined with syncopal attacks and sudden death due to prolonged QTc; it is an autosomal recessive trait. Different mutations in KVLQT1 cause the dominant Romano-Ward (RW) syndrome and the recessive Jervell and Lange-Nielsen (JLN) syndrome, which, in addition to cardiac abnormalities, includes congenital deafness. Jervell and Lange-Nielsen syndrome (JLNS) is an autosomal recessive syndrome characterised by profound congenital sensorineural deafness and prolongation of the QT interval on the electrocardiogram, representing abnormal ventricular repolarisation. "
    },
    {
      "exact_answer": [
        [
          "KCNQ1 gene"
        ],
        [
          "KCNQ1 wt Allele"
        ],
        [
          "KCNH2 gene"
        ],
        [
          "Person Name"
        ],
        [
          "Locus"
        ],
        [
          "KCNE2 gene"
        ],
        [
          "Romano-Ward Syndrome"
        ],
        [
          "Voltage-Gated Potassium Channel"
        ],
        [
          "Mutation"
        ],
        [
          "SCN5A gene"
        ],
        [
          "Genes"
        ],
        [
          "KCNE1 gene"
        ],
        [
          "shared attribute"
        ],
        [
          "Cardiac - anatomy qualifier"
        ],
        [
          "KCNJ5 gene"
        ],
        [
          "Long QT Syndrome"
        ],
        [
          "Mutation Abnormality"
        ],
        [
          "Formation"
        ],
        [
          "Long Qt Syndrome 2"
        ],
        [
          "A Kinase Anchor Protein 9"
        ],
        [
          "Involvement with"
        ],
        [
          "Histidine"
        ],
        [
          "Type - attribute"
        ],
        [
          "Act Code - Ward"
        ],
        [
          "Potassium Ion"
        ],
        [
          "Autosomal dominant inheritance"
        ],
        [
          "Channel"
        ],
        [
          "Sodium Cation"
        ],
        [
          "Disease"
        ],
        [
          "Sodium Channel"
        ],
        [
          "Ion Channel"
        ],
        [
          "Family"
        ],
        [
          "Links List"
        ],
        [
          "Responsible to"
        ],
        [
          "Science of Etiology"
        ],
        [
          "Family member"
        ],
        [
          "HIST1H1C gene"
        ],
        [
          "Frequent"
        ],
        [
          "KCNA4 gene"
        ],
        [
          "SNTA1 gene"
        ],
        [
          "SCN4B gene"
        ],
        [
          "Gene Products, Protein"
        ],
        [
          "ANK2 gene"
        ],
        [
          "Preposition For"
        ],
        [
          "MTSS1 gene"
        ],
        [
          "quart - US"
        ],
        [
          "Specific qualifier value"
        ],
        [
          "Alpha subunit - qualifier value"
        ],
        [
          "Congenital qualifier"
        ],
        [
          "CAV3 gene"
        ],
        [
          "Negation"
        ],
        [
          "Jervell-Lange Nielsen Syndrome"
        ],
        [
          "Patients"
        ],
        [
          "Tachyarrhythmia"
        ],
        [
          "INA gene"
        ],
        [
          "Shaker"
        ],
        [
          "Homozygote"
        ],
        [
          "kindred"
        ],
        [
          "Unmarried person"
        ],
        [
          "QTC interval"
        ],
        [
          "Lengthened (qualifier value)"
        ],
        [
          "Brothers"
        ],
        [
          "Race - Taiwanese"
        ],
        [
          "Heterozygote"
        ],
        [
          "Proband (person)"
        ],
        [
          "Associated with"
        ],
        [
          "Prolonged QT interval"
        ],
        [
          "LONG QT SYNDROME 3"
        ],
        [
          "LONG QT SYNDROME 5"
        ],
        [
          "Congenital long QT syndrome"
        ],
        [
          "LONG QT SYNDROME 9 (disorder)"
        ],
        [
          "Long Qt Syndrome 10"
        ],
        [
          "Long Qt Syndrome 12"
        ],
        [
          "Long Qt Syndrome 11"
        ],
        [
          "Logical Condition"
        ],
        [
          "Swedish"
        ],
        [
          "Generations"
        ],
        [
          "Call (Instruction)"
        ],
        [
          "Investigates"
        ],
        [
          "Encode (action)"
        ],
        [
          "Hereditary"
        ],
        [
          "Pore"
        ],
        [
          "Sign or Symptom"
        ],
        [
          "autosomal dominant trait"
        ],
        [
          "Pharmaceutical Preparations"
        ],
        [
          "Nucleotides"
        ],
        [
          "Sudden death"
        ],
        [
          "Genetic Carriers"
        ],
        [
          "defects aspect"
        ],
        [
          "Genus Cis"
        ],
        [
          "Alteration"
        ],
        [
          "Mental Suffering"
        ],
        [
          "Qualitative form"
        ],
        [
          "Consequence of"
        ],
        [
          "Substance amount"
        ],
        [
          "Etiology aspects"
        ],
        [
          "THYROID HORMONE PLASMA MEMBRANE TRANSPORT DEFECT"
        ],
        [
          "Search - action"
        ],
        [
          "Electrical Current"
        ],
        [
          "Persons"
        ]
      ],
      "id": "52eea509c8da89891000000d",
      "ideal_answer": "Long QT syndrome (LQTS) 1 is the most common type of inherited LQTS and is linked to mutations in the KCNQ1 gene. In order to search for mutations (using mSSCP and sequencing), genomic DNA was obtained from patients to determine the expression levels of the genes KCNQ1 and KCNH2 (HERG), involved in the occurrence of clinical signs of disease. These findings provide the first evidence for a recessive form of the Romano-Ward long-QT syndrome and indicate that homozygous mutations on KVLQT1 do not invariably produce the Jervell and Lange-Nielsen syndrome. This report describes a three-generation family with a severe phenotype of long-QT syndrome-1 (LQTS-1) caused by a single nucleotide mutation in the KQT-like, voltage-gated potassium channel-1 gene (KCNQ1; MIM 607542). We describe a Swedish family with the proband and his brother suffering from severe Romano-Ward syndome (RWS) associated with compound heterozygosity for two mutations in the KVLQT1 (also known as KCNQ1 and KCNA9). Other, less frequently involved genes are KCNE1 (locus name LQT5), KCNE2 (locus name LQT6), CAV3 (locus name LQT9), SCN4B (locus name LQT10), AKAP9 (locus name LQT11), SNTA1 (locus name LQT12) and KCNJ5 (locus name LQT13). "
    },
    {
      "id": "52fa74252059c6d71c00005b",
      "ideal_answer": "An attractive solution to the problem of oncogene activation is the inclusion of insulators/enhancer-blockers in the viral vectors. Studies on the chicken hypersensitive site-4 (cHS4) element, a prototypic insulator, have identified CTCF and USF-1/2 motifs in the proximal 250 bp of cHS4, termed the \"core\", which provide enhancer blocking activity and reduce position effects. Chromatin insulators are protein-binding DNA elements that lack intrinsic promoter/enhancer activity but shelter genes from transcriptional influence of surrounding chromatin. The design and incorporation of effective chromatin insulator sequences in the next generation of gene therapy vectors should lead to improved and more predictable expression of therapeutic transgenes and constitute an important step toward clinically effective gene therapy. We propose the incorporation of chromatin insulators in the design of gene therapy vectors to overcome the problem of position effects. hromatin insulators separate active transcriptional domains and block the spread of heterochromatin in the genome. "
    },
    {
      "id": "52fb19ab2059c6d71c00005c",
      "ideal_answer": "There is increased obstetrical and neonatal morbidity in Canadian women with RA or SLE. Women with SLE, RA, and pregestational DM had significantly increased rates of hypertensive disorders compared with the general obstetric population (23.2%, 11.1%, 27.4%, and 7.8%, respectively), longer hospital stays, and significantly higher risk of cesarean delivery. Although women with SLE, RA, and pregestational DM were significantly older than women in the general obstetric population, disparities in the risk of adverse outcomes of pregnancy remained statistically significant after adjustment for maternal age. women with SLE and RA appear to have a higher age-adjusted risk of adverse outcomes of pregnancy and longer hospital stays than do pregnant women in the general population, and careful antenatal monitoring should be performed. CONCLUSIONS: compared to pre-RA obstetric events, a higher frequency and number of adverse outcomes was found in pregnancies that occurred after RA onset. Although the sample size is small, these data do not support the notion that there is a substantial increased risk of adverse pregnancy outcomes due to leflunomide exposure among women who undergo cholestyramine elimination procedure early in pregnancy. "
    },
    {
      "exact_answer": [
        [
          "Hydrogen Peroxide"
        ],
        [
          "SOD1 gene"
        ],
        [
          "Cell Aging"
        ],
        [
          "superoxide dismutase activity"
        ],
        [
          "telomere"
        ],
        [
          "Elevation"
        ],
        [
          "Ratio"
        ],
        [
          "Young"
        ],
        [
          "Protein Component"
        ],
        [
          "Characteristics"
        ],
        [
          "Senility"
        ],
        [
          "GPX1 gene"
        ],
        [
          "Cells"
        ],
        [
          "*Activity (kind of quantity)"
        ],
        [
          "Central Minus"
        ],
        [
          "Insert (solid dose form)"
        ],
        [
          "TERT gene"
        ],
        [
          "Replicate"
        ],
        [
          "Round shape"
        ],
        [
          "Biologic Development"
        ],
        [
          "Exhibits as Topic"
        ],
        [
          "Aberrant"
        ],
        [
          "Usual"
        ],
        [
          "Timing"
        ],
        [
          "Cardiac Arrest"
        ],
        [
          "Changing"
        ],
        [
          "Device Display Device Component"
        ],
        [
          "Mechanism Component of Device"
        ],
        [
          "Slow"
        ],
        [
          "Morphology"
        ],
        [
          "Prolonged"
        ],
        [
          "Value Above Reference Range"
        ],
        [
          "Cultured Cell Line"
        ],
        [
          "Biological Markers"
        ],
        [
          "Cell Cycle Progression"
        ],
        [
          "environmental stress"
        ],
        [
          "Proliferation"
        ],
        [
          "Length"
        ],
        [
          "Behavior"
        ],
        [
          "Critical"
        ],
        [
          "Research Activities"
        ],
        [
          "Good"
        ],
        [
          "Cellular"
        ],
        [
          "Response process"
        ],
        [
          "Identified"
        ],
        [
          "Health"
        ],
        [
          "Gene Expression"
        ],
        [
          "Levels (qualifier value)"
        ],
        [
          "Human cells"
        ],
        [
          "Data"
        ],
        [
          "Other cells"
        ]
      ],
      "id": "53061af558348c0f52000002",
      "ideal_answer": "Cellular senescence is recognized as a critical cellular response to prolonged rounds of replication and environmental stresses. Our data demonstrate that Sod1 transfected cell lines that have an elevation in the ratio of Sod1 activity to Gpx1 activity produce higher levels of H2O2 and exhibit well characterised markers of cellular senescence viz. Recent research has shown that inserting a gene for the protein component of telomerase into senescent human cells reextends their telomeres to lengths typical of young cells, and the cells then display all the other identifiable characteristics of young, healthy cells. telomeres are the central timing mechanism for cellular aging. Its defining characteristics are arrested cell-cycle progression and the development of aberrant gene expression with proinflammatory behavior. slower proliferation and altered morphology. "
    },
    {
      "exact_answer": [
        [
          "Senility"
        ],
        [
          "Cell Aging"
        ],
        [
          "Induce (action)"
        ],
        [
          "TP53 wt Allele"
        ],
        [
          "Carcinogens"
        ],
        [
          "ras Oncogene"
        ],
        [
          "Oncogenes"
        ],
        [
          "Immature"
        ],
        [
          "cytokine"
        ],
        [
          "CAV1 gene"
        ],
        [
          "Generic Role"
        ],
        [
          "Activation action"
        ],
        [
          "Arrested progression"
        ],
        [
          "Logical Condition"
        ],
        [
          "Negation"
        ],
        [
          "Proline"
        ],
        [
          "Expression procedure"
        ],
        [
          "Papillomavirus Transforming Protein E7"
        ],
        [
          "ABL1 wt Allele"
        ],
        [
          "CDK2 protein, human"
        ],
        [
          "Retinoblastoma Protein"
        ],
        [
          "Tumor regression"
        ],
        [
          "Immortalization"
        ],
        [
          "geographic population"
        ],
        [
          "Connective Tissue - Fibroblasts (MMHCC)"
        ],
        [
          "Inactivation"
        ],
        [
          "Entire cell"
        ],
        [
          "SKP2 gene"
        ],
        [
          "Primary operation"
        ],
        [
          "Triggered by"
        ],
        [
          "Telomere Shortening"
        ],
        [
          "MAPK14 protein, human"
        ],
        [
          "Apoptosis"
        ],
        [
          "PTEN gene"
        ],
        [
          "CDKN2A gene"
        ],
        [
          "Hydrogen Peroxide"
        ],
        [
          "Etiology aspects"
        ],
        [
          "Associated with"
        ],
        [
          "Response process"
        ],
        [
          "MYC gene"
        ],
        [
          "NOX1 gene"
        ],
        [
          "CDKN1A gene"
        ],
        [
          "BRAF protein, human"
        ],
        [
          "Singular"
        ],
        [
          "Proliferation (morphologic abnormality)"
        ],
        [
          "NOX4 gene"
        ],
        [
          "Experimental Result"
        ],
        [
          "Protein Overexpression"
        ],
        [
          "Telomerase"
        ],
        [
          "Cells"
        ],
        [
          "Adjacent"
        ],
        [
          "Sustained"
        ],
        [
          "Mus"
        ],
        [
          "Metabolic Suppression"
        ],
        [
          "Intrinsic drive"
        ],
        [
          "% deficient"
        ],
        [
          "Transforming Growth Factors"
        ],
        [
          "Levels (qualifier value)"
        ],
        [
          "Sufficient"
        ],
        [
          "histone deacetylase 2"
        ],
        [
          "suggestion"
        ],
        [
          "Lymphoma"
        ],
        [
          "mitogen-activated protein kinase p38"
        ],
        [
          "Proliferation"
        ],
        [
          "Causing"
        ],
        [
          "Inappropriate"
        ],
        [
          "Promotion (action)"
        ],
        [
          "Neoplastic Cell Transformation"
        ],
        [
          "Cellular"
        ],
        [
          "Oxidase"
        ],
        [
          "Cell Cycle Arrest"
        ],
        [
          "Cell Cycle"
        ],
        [
          "Stimulus"
        ],
        [
          "Fusion Proteins, bcr-abl"
        ],
        [
          "DNA repair protein"
        ],
        [
          "Phenotype"
        ],
        [
          "Reactive Oxygen Species"
        ],
        [
          "Initiate (source type)"
        ],
        [
          "Laboratory culture"
        ],
        [
          "Protein p53"
        ],
        [
          "Proto-Oncogene Proteins B-raf"
        ],
        [
          "Report (document)"
        ],
        [
          "Does play"
        ],
        [
          "caveolin 1"
        ],
        [
          "Diversity"
        ],
        [
          "In Vivo"
        ],
        [
          "Mechanism (attribute)"
        ],
        [
          "Biochemical Pathway"
        ],
        [
          "Reduced"
        ],
        [
          "Including (qualifier)"
        ],
        [
          "Papillomaviridae"
        ],
        [
          "CDISC SEND Tumor Findings Results Terminology"
        ],
        [
          "ZHX2 gene"
        ],
        [
          "SUCLA2 gene"
        ],
        [
          "ELF4 gene"
        ],
        [
          "MAP2K1 gene"
        ],
        [
          "RAF1 wt Allele"
        ],
        [
          "Natures"
        ],
        [
          "Werner Syndrome"
        ],
        [
          "AKT1 gene"
        ]
      ],
      "id": "5309f8f5970c65fa6b000001",
      "ideal_answer": "We review and discuss here evidence for Myc-induced senescence - which is detectable to a limited degree as a cell-autonomous, direct response to Myc action, but occurs predominantly in a non-cell-autonomous fashion via crosstalk of the oncogene-driven cell population with non-neoplastic bystanders, namely cells of the host immune system, prompting them to release pro-senescent cytokines that strike back onto adjacent proliferating tumor cells. Myc-evoked apoptosis serves as a signal for macrophage attraction and activation, followed by the secretion of TGF-Î² as a cytokine that is capable of terminally arresting Myc-driven lymphoma cells without causing further DNA damage and without launching a senescence-associated, pro-inflammatory, and, therefore, potentially detrimental cytokine response in the target population. genetic Skp2 inactivation evokes cellular senescence even in oncogenic conditions in which the p19(Arf)-p53 response is impaired, whereas a Skp2-SCF complex inhibitor can trigger cellular senescence in p53/Pten-deficient cells and tumour regression in preclinical studies. Oncogenic activation of the mitogen-activated protein (MAP) kinase cascade in murine fibroblasts initiates a senescence-like cell cycle arrest that depends on the ARF/p53 tumor suppressor pathway. Activated RAS/BRAF oncogenes induce cellular senescence as a tumor-suppressive barrier in early cancer development, at least in part, via an oncogene-evoked DNA damage response (DDR). "
    },
    {
      "id": "5309fa5e970c65fa6b000003",
      "ideal_answer": "In vitro, we show that pharmacologic inhibition of Hsp90 by IPI-504 exerts antiproliferative effects in a panel of pancreatic cancer cells in a dose- and time-dependent manner. Using a proteomic profiling analysis with isotope tags for relative and absolute quantitation labeling technique, we have identified 20 down-regulated proteins and 42 up-regulated proteins on IPI-504 treatment.tumor. Dicoumarol activity as an Hsp90 inhibitor is confirmed by smaller levels of Hsp90 clients in treated cells and inhibition of in vivo heat shock luciferase activity recovery assays. Dicoumarol, a long-established oral anticoagulant, is a new Hsp90 inhibitor that represses PTTG1/Securin gene expression and provokes apoptosis through a complex trait involving both intrinsic and extrinsic pathways. Likewise, established Hsp90 inhibitors (17-allylamino-geldanamycin and novobiocin) repress PTTG1/Securin gene expression. To document this field, we have studied two Hsp90 inhibitors (radicicol and geldanamycin), known to interact with the ATP-binding site of Hsp90 (the Bergerat fold),. One of these is the novel agent 17-allylamino-17-demethoxygeldanamycin that acts to inhibit the hsp90 molecular chaperone. Treatment of four human colon cancer cell lines with iso-effective concentrations of this agent resulted in depletion of c-raf-1 and akt and inhibition of signal transduction. "
    },
    {
      "id": "530a34eb970c65fa6b000004",
      "ideal_answer": "We report the first use of shotgun proteomics to detect the protein expression profile of buccal swabs and cloth samples from two 500-year-old Andean mummies. To determine whether a 2,700-year-old tumor can be reliably diagnosed using microscopic and proteomic techniques. Identification of ancient biological samples from the 1991-discovered and more than 5300-year-old Tyrolean mummy, also called iceman or Oetzi, is very difficult. Paleoproteomic study of the Iceman\u0027s brain tissue. T. "
    },
    {
      "exact_answer": [
        [
          "Uranium"
        ],
        [
          "Bioremediation"
        ],
        [
          "Geobacter"
        ],
        [
          "Geobacteraceae"
        ],
        [
          "Groundwater"
        ],
        [
          "Acetate"
        ],
        [
          "In situ"
        ],
        [
          "Metals"
        ],
        [
          "Species"
        ],
        [
          "Organism"
        ],
        [
          "Bed Status - Isolated"
        ],
        [
          "Rifle (physical object)"
        ],
        [
          "Contamination"
        ],
        [
          "Firmicutes"
        ],
        [
          "Sediment"
        ],
        [
          "Community"
        ],
        [
          "member"
        ],
        [
          "HM13 gene"
        ],
        [
          "Mediator brand of benfluorex hydrochloride"
        ],
        [
          "Dominant"
        ],
        [
          "Organism Strain"
        ],
        [
          "Aquifers"
        ],
        [
          "Roman Numeral III"
        ],
        [
          "Reduction - action"
        ],
        [
          "uranyl acetate"
        ],
        [
          "Transcript"
        ],
        [
          "Geobacter uraniireducens"
        ],
        [
          "Glucose"
        ],
        [
          "Study Site"
        ],
        [
          "Ferric"
        ],
        [
          "Energy, Physics"
        ],
        [
          "Calcification"
        ],
        [
          "microbial"
        ],
        [
          "Pseudomonas aeruginosa"
        ],
        [
          "Geobacter sp."
        ],
        [
          "Department of Energy"
        ],
        [
          "Responsible to"
        ],
        [
          "Detected (finding)"
        ],
        [
          "United States"
        ],
        [
          "Dietary Lead"
        ],
        [
          "Challenge"
        ],
        [
          "Cytochromes"
        ],
        [
          "Resistant (qualifier value)"
        ],
        [
          "field research"
        ],
        [
          "Bacterial 16S RNA"
        ],
        [
          "Reduced"
        ],
        [
          "Gene Library"
        ],
        [
          "Scientific Study"
        ],
        [
          "Internal-External Locus of Control Scale"
        ],
        [
          "Anaeromyxobacter dehalogenans"
        ],
        [
          "Rhodoferax"
        ],
        [
          "Genus Polaromonas"
        ],
        [
          "Capability"
        ],
        [
          "Genus Dechloromonas"
        ],
        [
          "Previous"
        ],
        [
          "Ridging"
        ],
        [
          "Poor - qualifier"
        ],
        [
          "Delftia"
        ],
        [
          "Lysinibacillus"
        ],
        [
          "Negation"
        ],
        [
          "Chryseobacterium"
        ],
        [
          "Microbacterium"
        ],
        [
          "Chromobacterium"
        ],
        [
          "Betaproteobacteria"
        ],
        [
          "Shewanella oneidensis"
        ],
        [
          "Paenibacillus"
        ],
        [
          "Hypokinesia"
        ],
        [
          "Ralstonia"
        ],
        [
          "Desulfovibrio"
        ],
        [
          "Quercus"
        ],
        [
          "Amendment"
        ],
        [
          "Amended"
        ],
        [
          "Predominate"
        ],
        [
          "Exertion"
        ],
        [
          "Microbiology subtype strains"
        ],
        [
          "Microorganism"
        ],
        [
          "Add - instruction imperative"
        ],
        [
          "Motile"
        ],
        [
          "Klebsiella"
        ],
        [
          "Intellectual scale"
        ],
        [
          "Branched"
        ],
        [
          "Clostridium"
        ],
        [
          "Catalysis"
        ],
        [
          "Immobilization"
        ],
        [
          "Rod Shape"
        ],
        [
          "% precipitation"
        ],
        [
          "Nucleic Acid Sequence Based Analysis"
        ],
        [
          "Promotion (action)"
        ],
        [
          "Sulfates, Inorganic"
        ],
        [
          "Microarray Analysis"
        ],
        [
          "Anatomic Site"
        ],
        [
          "Experiment Object"
        ],
        [
          "Clone"
        ],
        [
          "Bacillus \u003cbacterium\u003e"
        ],
        [
          "electrode"
        ],
        [
          "ISOLATE COMPOUND"
        ],
        [
          "DNA Integration"
        ],
        [
          "Fracture"
        ],
        [
          "Soil sample"
        ],
        [
          "sulfate reducing bacteria"
        ]
      ],
      "id": "530a3e18970c65fa6b000005",
      "ideal_answer": ". Constant levels of Geobacter ompB transcripts were detected in groundwater during a field experiment in which acetate was added to the subsurface to promote in situ uranium bioremediation. As part of an effort to diagnose the physiological status of Geobacter species during in situ bioremediation of uranium-contaminated groundwater,. A Gram-negative, rod-shaped, motile bacterium, strain Rf4T, which conserves energy from dissimilatory Fe(III) reduction concomitant with acetate oxidation, was isolated from subsurface sediment undergoing uranium bioremediation. Our previous studies have demonstrated that the microbial communities involved in uranium bioremediation and energy harvesting are both dominated by microorganisms in the family Geobacteraceae and that the organisms in this family are responsible for uranium bioremediation and electron transfer to electrodes. Geobacter species are known to be important members of the microbial community: (1) a uranium-contaminated aquifer located in Rifle, CO, USA undergoing in situ bioremediation;. Geobacter species are often the dominant members of the groundwater community during active bioremediation and the primary organisms catalysing U(VI) reduction. "
    },
    {
      "id": "530a3f8a970c65fa6b000006",
      "ideal_answer": "Marine community proteomic studies have verified the importance of nutrient transport, energy generation, and carbon fixation functions in bacteria and archaea and revealed spatial and temporal shifts in the expressed functions of communities. Metaproteomic studies of whole microbial communities from environmental samples (e.g., soil, sediments, freshwater, seawater, etc.) have rapidly increased in recent years due to many technological advances in mass spectrometry (MS). Metaproteomics has been employed in very diverse environments, and this review discusses the recent advances achieved in the context of human biology, soil, marine and freshwater environments as well as natural and bioengineered systems. Advances in tandem mass spectrometry (tandem MS) and sequencing have enabled the field of community proteomics, which seeks to identify expressed proteins, their sequence variability, and the physiological responses of organisms to variable environmental conditions. Metaproteomics is a new field within the \u0027omics\u0027 science which investigates protein expression from a complex biological system and provides direct evidence of physiological and metabolic activities. Metaproteomic analysis and protein-stable isotope probing revealed Burkholderiales, Actinomycetales, and Rhizobiales as the most active microorganisms in the groundwater communities. "
    },
    {
      "exact_answer": [
        [
          "Substrate Device Component"
        ],
        [
          "Proteins"
        ],
        [
          "Amine Group"
        ],
        [
          "Final Labeling"
        ],
        [
          "Peptide Hydrolases"
        ]
      ],
      "id": "530a5117970c65fa6b000007",
      "ideal_answer": "Incorporating iTRAQ whole protein labeling with terminal amine isotopic labeling of substrates (iTRAQ-TAILS) to enrich the N-terminome by negative selection of the blocked mature original N-termini and neo-N-termini has many advantages. analysis of N- terminomics data generated by terminal amine isotopic labeling of substrates (TAILS) enables high confidence peptide to protein assignment, protein N-terminal characterization and annotation, and for protease analysis readily allows protease substrate discovery with high confidence. Here we present in detail the steps required to perform our recently described approach we call Terminal Amine Isotopic Labeling of Substrates (TAILS), a combined N-terminomics and protease substrate discovery degradomics platform for the simultaneous quantitative and global analysis of the N-terminome and proteolysis in one MS/MS experiment. Several approaches to studying proteolytic activity as it relates to biology, pathophysiology, and drug therapy have been published, including the recently described terminal amine isotopic labeling of substrates (TAILS) strategy by Kleifeld and colleagues. The degradomics screen terminal amine isotopic labeling of substrates (TAILS), which enriches for neo-N-terminal peptides of cleaved substrates, was used to identify 58 new native substrates in fibroblast secretomes after incubation with MT6-MMP. "
    },
    {
      "exact_answer": [
        [
          "Mass, a measure of quantity of matter"
        ],
        [
          "Lock - Remote control command"
        ],
        [
          "Instrument - device"
        ],
        [
          "fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether"
        ],
        [
          "Calibration"
        ]
      ],
      "id": "530b01a6970c65fa6b000008",
      "ideal_answer": "The use of mass calibrants (lock masses) to reduce the systematic error of mass-to-charge measurements has also been reported and, in some cases, incorporated in the instrument control software by the instrument manufacturers. Real time recalibration on the \"lock mass\" by corrections of mass shift removes mass error associated with calibration of the mass scale. To compensate for drifts in instrument calibration, a compound of known mass is often employed. We achieved absolute mass accuracies for intact proteins between 0.92 and 2.8 ppm using the \"lock mass\" mode of operation. Benzyldimethylphenylammonium was used as an internal lock mass. This \u0027lock mass\u0027 provides an internal mass standard in every spectrum. "
    },
    {
      "exact_answer": "yes",
      "id": "530b4f49970c65fa6b00000a",
      "ideal_answer": "Platelet biomarkers in Alzheimer\u0027s disease. Those include platelet-related disorders, such as storage pool disease, gray platelet syndrome, and Quebec platelet disorder; diseases where unwanted platelet activation is highly relevant, such as thrombosis and cardiovascular disease; and other diseases, such as cystic fibrosis, uremia, or Alzheimer\u0027s disease. platelets are the most important source of circulating forms of the amyloid precursor protein and other important proteins such as Tau and glycogen synthase kinase-3B. The success of these studies led to the application of platelet proteomics to the study of several pathologies where platelets play a fundamental role. Alternative plasma and platelet measures are described,. "
    },
    {
      "id": "530b7ae4970c65fa6b00000b",
      "ideal_answer": "Transforming growth factor beta, bone morphogenic protein and Wnt pathways interact to form a complex signaling network that is critical in regulating the fate choices of both stromal and tissue-specific resident stem cells (TSCs), determining whether functional regeneration or the formation of scar tissue follows an injury. Direct examination of heart regeneration after mechanical or genetic ablation injuries indicated that these pathways are activated in regenerating cardiomyocytes and that they can be pharmacologically manipulated to inhibit or enhance cardiomyocyte proliferation during adult heart regeneration. Transforming growth factor (TGF)-beta plays a crucial role in cardiac repair by suppressing inflammation while promoting myofibroblast phenotypic modulation and extracellular matrix deposition. Since TGFÎ² is activated in the myocardium in response to injury, our data suggest that CSps formation mimics an adaptive mechanism that could potentially be enhanced to increase in vivo or ex vivo regenerative potential of adult CPCs. Collectively, this data strongly suggests Wnt3a promotes the formation of a myofibroblast-like phenotype in cultured fibroblasts, in part, by upregulating TGF-Î² signaling through SMAD2 in a Î²-catenin-dependent mechanism. In the adult heart under pressure overload, Notch inhibited the development of cardiomyocyte hypertrophy and transforming growth factor-Î²/connective tissue growth factor-mediated cardiac fibrosis. "
    },
    {
      "exact_answer": "yes",
      "id": "530c7cfd970c65fa6b00000c",
      "ideal_answer": "This leads to a model in which Lys134 of LDB1 can be either mono-ubiquitinated, leading to stabilization, or poly-ubiquitinated, leading to degradation by the proteasome pathway. wild type Smad4 is a relatively stable protein that undergoes mono- or oligo-ubiquitination, a modification not linked to protein degradation. Our observations support a novel functional relationship between parkin and Hsc/Hsp70 and support the notion that parkin is a multi-purpose E3 ubiquitin ligase capable of modifying proteins either via attachment of alternatively linked poly-ubiquitin chains or through multiple mono-ubiquitination to achieve alternate biological outcomes. Expression of p34 promotes PTEN poly-ubiquitination, leading to PTEN protein degradation, whereas p34 knockdown results in PTEN mono-ubiquitination. Our results suggest that oxidative stress induces not only poly-ubiquitination but also mono-ubiquitination of LDH-A, which may be involved in its lysosomal degradation during unloading. These fingers possess E3 activities of mono-ubiquitination and poly-ubiquitination, respectively, with ubiquitin-conjugating enzyme (E2)-binding capabilities. PS1 ubiquitination after PI3K inhibition is represented by the multiple mono-ubiquitination, instead of poly-ubiquitination. our results indicate that Hsp70 facilitates CHIP-mediated poly-ubiquitination of Smad1 whereas it attenuates CHIP-meditated mono-ubiquitination of Smad1. The yeast G protein alpha subunit Gpa1 represents a rare example of a protein that undergoes both mono- and poly-ubiquitination. "
    },
    {
      "exact_answer": [
        [
          "oxantel"
        ],
        [
          "Anthelmintics"
        ],
        [
          "Plankton"
        ],
        [
          "Law enforcement arrest"
        ],
        [
          "Microbial Biofilms"
        ]
      ],
      "id": "530c7f52970c65fa6b000010",
      "ideal_answer": "Oxantel disrupts polymicrobial biofilm development of periodontal pathogens. Oxantel, a cholinergic anthelmintic and fumarate reductase inhibitor, significantly inhibited biofilm formation by P. gingivalis and disrupted established biofilms at concentrations below its MIC against planktonic cells. he anthelmintic drug oxantel has been shown to inhibit fumarate reductase (Frd) activity in some pathogenic bacteria and inhibit P. gingivalis homotypic biofilm formation. "
    },
    {
      "exact_answer": "yes",
      "id": "530c7fa4970c65fa6b000012",
      "ideal_answer": "The results show that the epithelial-enriched protein Erbin controls the function of the NF2 tumor suppressor Merlin by determining the output of Merlin\u0027s physical interactions with active PAK2. Erbin controls Merlin tumor suppressor function by switching the functional valence of PAK2 binding. Erbin and the NF2 tumor suppressor Merlin cooperatively regulate cell-type-specific activation of PAK2 by TGF-beta. "
    },
    {
      "exact_answer": [
        [
          "Mutation"
        ],
        [
          "MT-ND6 gene"
        ],
        [
          "Leigh Disease"
        ],
        [
          "Dystonia Disorders"
        ],
        [
          "DNA, Mitochondrial"
        ],
        [
          "Optic Atrophy, Hereditary, Leber"
        ],
        [
          "Identified"
        ],
        [
          "Blepharoptosis"
        ],
        [
          "Encephalomyopathy"
        ],
        [
          "Genetic Hotspot"
        ],
        [
          "PNP wt Allele"
        ],
        [
          "Proband (finding)"
        ],
        [
          "Dystonia"
        ],
        [
          "Positioning Attribute"
        ],
        [
          "Seizures, intractable"
        ],
        [
          "Confirmation"
        ],
        [
          "Accounting (activity)"
        ],
        [
          "Basal ganglia degeneration"
        ],
        [
          "combination of objects"
        ],
        [
          "Representation (action)"
        ],
        [
          "Optic Atrophy"
        ],
        [
          "Blind Vision"
        ],
        [
          "Etiology aspects"
        ],
        [
          "Pediatric"
        ],
        [
          "Unusual"
        ],
        [
          "Clinical presentation"
        ],
        [
          "Phenotype"
        ],
        [
          "majority"
        ],
        [
          "Adult onset"
        ],
        [
          "Point A"
        ],
        [
          "Leading"
        ],
        [
          "Relationship by association"
        ],
        [
          "Experimental Result"
        ],
        [
          "Genes"
        ],
        [
          "Range"
        ],
        [
          "Large"
        ],
        [
          "Tissue specific"
        ],
        [
          "Disease"
        ],
        [
          "Associated with"
        ]
      ],
      "id": "530c844e970c65fa6b000014",
      "ideal_answer": "MTND6 genes were identified as \u0027hotspots\u0027 of mutations, with Leigh syndrome accounting for the large majority of associated phenotypes. Representative of these mutations is a heteroplasmic mutation in MTND6 at np 14459 whose clinical presentations range from adult-onset blindness to pediatric dystonia and basal ganglial degeneration. These results confirm the association of the MTND6*LDYT14459A mutation with Leber\u0027s hereditary optic neuropathy and/or dystonia. he 14487T\u003eC mutation in MTND6 were present in two probands with Leigh\u0027s-like and Leigh\u0027s syndrome, respectively. A novel point mutation in the ND6 subunit of complex I at position 14,459 of the mitochondrial DNA (MTND6*LDY T14459A) was identified as a candidate mutation for the highly tissue-specific disease. It was shown that m14487T\u003eC can also cause the unusual combination of optic atrophy, ptosis, and encephalomyopathy leading to intractable seizures. Leber\u0027s hereditary optic neuropathy plus dystonia. "
    },
    {
      "exact_answer": "yes",
      "id": "530cefaaad0bf1360c000001",
      "ideal_answer": "The patient failed to respond to standard ALL induction chemotherapy, but achieved complete remission following treatment with a fludarabine and alemtuzumab-based regimen. Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia. For example, most patients with T-cell prolymphocytic leukemia, including those with large tumor burdens and high peripheral white blood cell counts, will enter complete remission using the antibody CAMPATH-1H without any evidence of tumor lysis. With the introduction of alemtuzumab, most patients who progressed despite treatment with pentostatin had a major response with a complete remission rate higher than that obtained with pentostatin when used as a first line. Here we present a rare case of concurrent T-PLL and Kaposi sarcoma who achieved a complete hematologic and cytogenetic remission after a very short course of treatment with alemtuzumab. Currently, the best treatment for T-PLL is IV alemtuzumab, which has resulted in very high response rates of more than 90% when given as frontline treatment and a significant improvement in survival. The conclusion is that CAMPATH-1H is an effective therapy in T-PLL, producing remissions in more than two thirds of patients. "
    },
    {
      "exact_answer": [
        [
          "Nucleus Accumbens"
        ],
        [
          "Deep Brain Stimulation"
        ],
        [
          "Depressive Disorder, Treatment-Resistant"
        ],
        [
          "Stimulation procedure"
        ],
        [
          "Major Depressive Disorder"
        ],
        [
          "Obsessive-Compulsive Disorder"
        ],
        [
          "Therapeutic procedure"
        ],
        [
          "Target"
        ],
        [
          "Depressive Symptoms"
        ],
        [
          "Lateral habenular nucleus"
        ],
        [
          "Unresponsive to Treatment"
        ],
        [
          "Entire caudate nucleus"
        ],
        [
          "Habenula"
        ],
        [
          "Antidepressive Agents"
        ],
        [
          "Prominent"
        ],
        [
          "Ventral"
        ],
        [
          "Patients"
        ],
        [
          "Mental Depression"
        ],
        [
          "Hypothesis"
        ],
        [
          "Better"
        ],
        [
          "Major"
        ],
        [
          "Area"
        ],
        [
          "Small"
        ],
        [
          "Functional Relationship"
        ],
        [
          "Barakat syndrome"
        ],
        [
          "Gyrus Cinguli"
        ],
        [
          "HARS gene"
        ],
        [
          "Biospecimen"
        ],
        [
          "pleasurable emotion"
        ],
        [
          "Anhedonia"
        ],
        [
          "physiopathological"
        ],
        [
          "Rewards"
        ],
        [
          "Electrophysiology studies"
        ],
        [
          "Entire head of caudate nucleus"
        ],
        [
          "Caudate nucleus structure"
        ],
        [
          "suggestion"
        ],
        [
          "Structure of median forebrain bundle"
        ],
        [
          "Ventral Striatum"
        ],
        [
          "Internal capsule of brain"
        ],
        [
          "Deterioration"
        ],
        [
          "Manifestation of"
        ],
        [
          "promise"
        ],
        [
          "Massive"
        ],
        [
          "Property (attribute)"
        ],
        [
          "Disease remission"
        ],
        [
          "Electrode Device Component"
        ],
        [
          "Guide device"
        ],
        [
          "Professional guide"
        ],
        [
          "Anatomical position"
        ],
        [
          "Limb structure"
        ],
        [
          "Records"
        ],
        [
          "Mental Suffering"
        ],
        [
          "Focal"
        ],
        [
          "treatment options"
        ],
        [
          "Anxiety"
        ],
        [
          "Scientific Evaluation"
        ],
        [
          "Preliminary"
        ],
        [
          "Feature"
        ],
        [
          "Device Component System"
        ],
        [
          "Possibly Related to Intervention"
        ],
        [
          "lateral inhibition"
        ],
        [
          "clinical depression"
        ],
        [
          "Cerebral cortex"
        ],
        [
          "month"
        ],
        [
          "Anterior"
        ],
        [
          "Clinical Trial [Publication Type]"
        ],
        [
          "Clear"
        ],
        [
          "clinical aspects"
        ],
        [
          "therapeutic aspects"
        ],
        [
          "findings aspects"
        ],
        [
          "strategy"
        ],
        [
          "Resistant (qualifier value)"
        ],
        [
          "Metabolic Inhibition"
        ],
        [
          "Practice Experience"
        ],
        [
          "Stimulation (motivation)"
        ],
        [
          "Status post"
        ],
        [
          "Comparison"
        ],
        [
          "Application procedure"
        ],
        [
          "Initial sample"
        ],
        [
          "Activities"
        ],
        [
          "Assessed"
        ],
        [
          "Direct (qualifier)"
        ],
        [
          "High frequency"
        ],
        [
          "Active"
        ],
        [
          "Result"
        ],
        [
          "Approach"
        ],
        [
          "Clinical Research"
        ],
        [
          "Evidence of"
        ],
        [
          "Case (situation)"
        ],
        [
          "Including (qualifier)"
        ],
        [
          "Observed"
        ],
        [
          "Clinical"
        ],
        [
          "Data"
        ]
      ],
      "id": "530cefaaad0bf1360c000002",
      "ideal_answer": "We recorded electrophysiological activity directly from the nucleus accumbens of five patients undergoing deep brain stimulation for treatment of refractory major depression. Comparisons of clinical outcomes and anatomical data on electrode positioning showed that caudate nucleus stimulation preferentially alleviated OCD manifestations, whereas nucleus accumbens stimulation improved depressive symptoms. Because a prominent clinical feature of depression is anhedonia--the inability to experience pleasure from previously pleasurable activities--and because there is clear evidence of dysfunctions of the reward system in depression, DBS to the nucleus accumbens might offer a new possibility to target depressive symptomatology in otherwise treatment-resistant depression. These preliminary findings suggest that DBS to the nucleus accumbens might be a hypothesis-guided approach for refractory major depression. No neuropsychological deterioration was observed, indicating that DBS of the ventral caudate nucleus could be a promising strategy in the treatment of refractory cases of both OCD and major depression. Deep brain stimulation of the ventral caudate nucleus markedly improved symptoms of depression and anxiety until their remission, which was achieved at 6 months after the start of stimulation (HDRS \u003c or \u003d 7 and HARS \u003c or \u003d 10). "
    },
    {
      "exact_answer": [
        [
          "alemtuzumab"
        ],
        [
          "Campath 1H"
        ],
        [
          "Relapsing course"
        ],
        [
          "Antibodies, Monoclonal, Humanized"
        ],
        [
          "Campath"
        ],
        [
          "Multiple Sclerosis"
        ],
        [
          "Ms. - Title"
        ],
        [
          "Disability"
        ],
        [
          "Multiple Sclerosis, Relapsing-Remitting"
        ],
        [
          "human leukocyte interferon"
        ],
        [
          "Interferon beta-1a"
        ],
        [
          "Therapeutic procedure"
        ],
        [
          "Patients"
        ],
        [
          "Monoclonal Antibodies"
        ],
        [
          "CD52 antigen"
        ],
        [
          "alphanumeric label - 1A"
        ],
        [
          "Sodium Cation"
        ],
        [
          "Lymphocyte"
        ],
        [
          "Comparison"
        ],
        [
          "Remitting"
        ],
        [
          "natalizumab"
        ],
        [
          "Direct type of relationship"
        ],
        [
          "Target"
        ],
        [
          "Recombinant Interferon Beta"
        ],
        [
          "Membrane Glycoproteins"
        ],
        [
          "Phase 3 Clinical Trials"
        ],
        [
          "rituximab"
        ],
        [
          "Condition activity"
        ],
        [
          "Benefits"
        ],
        [
          "Reduced"
        ],
        [
          "RNA Recognition Motif"
        ],
        [
          "Did not receive therapy or drug for"
        ],
        [
          "Specific qualifier value"
        ],
        [
          "Reduction - action"
        ],
        [
          "Early"
        ],
        [
          "Treated with"
        ],
        [
          "Phase 2 Clinical Trials"
        ],
        [
          "Venezuela"
        ],
        [
          "antineoplaston A10"
        ],
        [
          "Risk"
        ],
        [
          "Negation"
        ],
        [
          "Current (present time)"
        ],
        [
          "Integrin alpha4beta1"
        ],
        [
          "Monocytes"
        ],
        [
          "Daclizumab"
        ],
        [
          "Rate"
        ],
        [
          "Mediator brand of benfluorex hydrochloride"
        ],
        [
          "Active Comparator"
        ],
        [
          "Choose (action)"
        ],
        [
          "Providing (action)"
        ],
        [
          "Rebif"
        ],
        [
          "Mechanism (attribute)"
        ],
        [
          "United States"
        ],
        [
          "Staphylococcal Protein A"
        ],
        [
          "Active"
        ],
        [
          "P prime"
        ],
        [
          "Sustained"
        ],
        [
          "Clinical Trials"
        ],
        [
          "H NOS Antibodies"
        ],
        [
          "Stage level 2"
        ],
        [
          "Pharmacologic Substance"
        ],
        [
          "Effectiveness"
        ],
        [
          "Term (temporal)"
        ],
        [
          "Approved"
        ],
        [
          "Lineage"
        ],
        [
          "Treatment Effectiveness"
        ],
        [
          "Lymphocyte Depletion"
        ],
        [
          "Complement System Proteins"
        ],
        [
          "Therapeutic Intervention"
        ],
        [
          "year"
        ],
        [
          "First-Line Therapy"
        ],
        [
          "Observed"
        ],
        [
          "Blood group antibody A"
        ],
        [
          "Prolonged"
        ],
        [
          "Experimental Result"
        ],
        [
          "Efficacy Study"
        ],
        [
          "Disease"
        ],
        [
          "Rapid"
        ],
        [
          "Immune"
        ],
        [
          "Data"
        ],
        [
          "MS gene"
        ],
        [
          "Levels (qualifier value)"
        ],
        [
          "physiological aspects"
        ],
        [
          "Unknown"
        ],
        [
          "Clinical"
        ],
        [
          "Associated with"
        ],
        [
          "Immune system"
        ],
        [
          "Membrane Proteins"
        ],
        [
          "Surface"
        ],
        [
          "First (number)"
        ],
        [
          "Proteins"
        ],
        [
          "Preposition For"
        ],
        [
          "Protium"
        ],
        [
          "Study"
        ],
        [
          "utilization qualifier"
        ],
        [
          "Base - General Qualifier"
        ],
        [
          "Arabic numeral 71"
        ],
        [
          "T-Lymphocyte"
        ],
        [
          "Lymphocyte positive for CD52 antigen"
        ],
        [
          "Hypokinesia"
        ]
      ],
      "id": "530cefaaad0bf1360c000003",
      "ideal_answer": "Alemtuzumab\u0027s consistent safety profile and benefit in terms of reductions of relapse support its use for patients with previously untreated relapsing-remitting multiple sclerosis; however, benefit in terms of disability endpoints noted in previous trials was not observed here. Following encouraging initial data from other centres we report our open label experience of using Campath 1-H as a treatment in aggressive relapsing multiple sclerosis in a consecutive series of 39 highly selected patients treated across three regional centres and followed for a mean of 1.89 years. Alemtuzumab is currently under review to treat relapsing multiple sclerosis (MS) in the United States, based on positive Phase II and Phase III trials in both treatment-naÃ¯ve and treated relapsing MS patients. Alemtuzumab-treatment of MS patients with relapsing-remitting forms of the disease significantly reduced the risk of relapse and accumulation of disability compared to interferon Î²-1a treatment in a phase II trial. Since then, one phase II and two phase III trials have shown that alemtuzumab reduces the relapse rate, compared with the active comparator interferon beta-1a (IFNÎ²-1a), in treatment-naÃ¯ve and treatment-experienced MS up to 10 years from disease onset. "
    },
    {
      "id": "530cefaaad0bf1360c000006",
      "ideal_answer": "The lunar cycle seems to affect the incidence of intracranial aneurysm rupture, with the new moon being associated with an increased risk of aneurysmal SAH. We found no correlation between incidence of aneurysmal SAH, location of the aneurysm, initial clinical presentation, or amount of subarachnoid blood and the lunar cycle. The moon influences neither the incidence of aneurysmal SAH nor the grade of initial neurological deterioration or amount of subarachnoid blood. We did not observe any significant impact of the lunar cycle on the incidence of aneurysmal subarachnoid haemorrhage in 717 consecutive patients (p\u003d0.84). Recently, it has been reported that moon phases correlate with the incidence of aneurysmal subarachnoid hemorrhage (SAH), however, another author found no such association. An incidence peak for aneurysm rupture (28 patients) was seen during the phase of new moon, which was statistically significant (p \u003c 0.001). The impact of the lunar cycle on aneurysmal subarachnoid haemorrhage is a myth rather than reality. "
    },
    {
      "exact_answer": [
        [
          "solanezumab"
        ],
        [
          "bapineuzumab"
        ],
        [
          "Antibodies, Monoclonal, Humanized"
        ],
        [
          "Monoclonal Antibodies"
        ],
        [
          "Alzheimer\u0027s Disease Pathway KEGG"
        ],
        [
          "ponezumab"
        ],
        [
          "SUCLA2 gene"
        ],
        [
          "Blood group antibody A"
        ],
        [
          "Greek letter tau"
        ],
        [
          "Caucasoid Race"
        ],
        [
          "LY 2062430"
        ],
        [
          "Amyloid beta"
        ],
        [
          "Singular"
        ],
        [
          "Japanese race"
        ],
        [
          "Safety Study"
        ],
        [
          "APP protein, human"
        ],
        [
          "APP wt Allele"
        ],
        [
          "Passive"
        ],
        [
          "pharmacodynamic aspects"
        ],
        [
          "Patients"
        ],
        [
          "Serum amyloid A protein"
        ],
        [
          "N not otherwise specified Antibody"
        ],
        [
          "Alzheimer\u0027s disease treatment"
        ],
        [
          "Changing"
        ],
        [
          "Dose number:Number:Point in time:^Patient:Quantitative"
        ],
        [
          "P Blood group antibodies"
        ],
        [
          "Tolerability Study"
        ],
        [
          "Dosage"
        ],
        [
          "Mild to moderate"
        ],
        [
          "Evaluation"
        ],
        [
          "Pharmacokinetic aspects"
        ],
        [
          "Clinical Trial, Phase III (publication)"
        ],
        [
          "Evaluation procedure"
        ],
        [
          "Clinical Trials"
        ],
        [
          "Beta (qualifier)"
        ],
        [
          "Study"
        ],
        [
          "Design"
        ],
        [
          "First (number)"
        ],
        [
          "Circumferential Supracrestal Fiberotomy"
        ],
        [
          "Death Adverse Event Due to Disease Progression Not Associated with More Specific CTCAE Term"
        ],
        [
          "Vasogenic Edema"
        ],
        [
          "Kilogram"
        ],
        [
          "Apolipoprotein E4"
        ],
        [
          "Randomization"
        ],
        [
          "Third Party - RoleCode"
        ],
        [
          "AAB-001"
        ],
        [
          "Treatment intent"
        ],
        [
          "With - dosing instruction fragment"
        ],
        [
          "Add - instruction imperative"
        ],
        [
          "Alzheimer disease type 1"
        ],
        [
          "Radionuclide Imaging"
        ],
        [
          "Visit"
        ],
        [
          "Sequencing - Ascending"
        ],
        [
          "Ascending"
        ],
        [
          "Expanding"
        ],
        [
          "Antibodies, Anti-Idiotypic"
        ],
        [
          "4-iodobenzenesulfonamide"
        ],
        [
          "Investigates"
        ],
        [
          "Immunotherapy"
        ],
        [
          "biologic degeneration"
        ],
        [
          "Reflecting"
        ],
        [
          "Representation (action)"
        ],
        [
          "In Cerebrospinal Fluid"
        ],
        [
          "Pet Animal"
        ],
        [
          "Amyloid deposition"
        ],
        [
          "immunization administration"
        ],
        [
          "Immunization"
        ],
        [
          "passive immunization procedure"
        ],
        [
          "Genetic Carriers"
        ],
        [
          "Processed"
        ],
        [
          "Immunotherapy, Passive"
        ],
        [
          "Passive Method"
        ],
        [
          "Neuronal degeneration"
        ],
        [
          "Downstream"
        ],
        [
          "PF-04360365"
        ],
        [
          "Patient Load"
        ],
        [
          "Homeostasis"
        ],
        [
          "Placebo Control"
        ],
        [
          "Cohort"
        ],
        [
          "Slow"
        ],
        [
          "Adverse event"
        ],
        [
          "Baseline"
        ],
        [
          "Pathological aspects"
        ],
        [
          "monoclonal"
        ],
        [
          "Structure of cortex of kidney"
        ],
        [
          "Numerous"
        ],
        [
          "Case unit dose"
        ],
        [
          "Relationships"
        ],
        [
          "Advanced phase"
        ],
        [
          "therapeutic aspects"
        ],
        [
          "Biological Markers"
        ],
        [
          "Having administered"
        ],
        [
          "Phase 2 Clinical Trials"
        ],
        [
          "Set scale"
        ],
        [
          "Now (temporal qualifier)"
        ],
        [
          "Study Condition"
        ],
        [
          "Comparison"
        ],
        [
          "Efficacy Study"
        ],
        [
          "Knowledge"
        ],
        [
          "Therapeutic procedure"
        ]
      ],
      "id": "530cefaaad0bf1360c000007",
      "ideal_answer": "To our knowledge, this study is the first to show that passive AÎ² immunotherapy with bapineuzumab results in decreases in CSF T-tau and P-tau, which may indicate downstream effects on the degenerative process. The second set of baseline scans was from the EXPanding alzhEimer\u0027s Disease InvestigaTIONs (EXPEDITION) studies examining solanezumab, an anti-AÎ² monoclonal antibody (cohort 2, n \u003d 2141). The safety, tolerability, and pharmacokinetics (PKs) of bapineuzumab (AAB-001), a humanized monoclonal antibody to amyloid beta, were evaluated in patients with mild-to-moderate Alzheimer disease in a phase 1, randomized, third-party unblinded, placebo-controlled, single ascending dose trial. The first passive immunotherapy trial with bapineuzumab, a humanized monoclonal antibody against the end terminus of Abeta, also encountered some dose dependent adverse events during the Phase II portion of the study, vasogenic edema in 12 cases, which were significantly over represented in ApoE4 carriers. The most developmentally advanced monoclonal antibody directly targeting Abeta is bapineuzumab, now being studied in a large Phase III clinical trial. Bapineuzumab, a humanized anti-amyloid-beta (Abeta) monoclonal antibody for the potential treatment of Alzheimer disease (AD), was evaluated in a multiple ascending dose, safety, and efficacy study in mild to moderate AD. "
    },
    {
      "id": "530cefaaad0bf1360c000009",
      "ideal_answer": "Using data from the Western Australian Autism Biological Registry, this study found that LBW and maternal SSRI use during pregnancy were associated with greater sleep disturbances and a greater number of gastrointestinal complaints in children with ASD, respectively. The only published study that focused on prenatal SSRI exposure and ASD found an increased risk with exposure to SSRIs, especially during the first trimester. Although the number of children exposed prenatally to selective serotonin reuptake inhibitors in this population was low, results suggest that exposure, especially during the first trimester, may modestly increase the risk of ASD. In adjusted logistic regression models, we found a 2-fold increased risk of ASD associated with treatment with selective serotonin reuptake inhibitors by the mother during the year before delivery (adjusted odds ratio, 2.2 [95% confidence interval, 1.2-4.3]),. Though the majority of studies conducted in infants and children suggest prenatal exposure to SSRIs does not affect neurodevelopment, interpretation must be tempered given small sample sizes. "
    },
    {
      "id": "530cefaaad0bf1360c00000a",
      "ideal_answer": "The clinical trials of Solanezumab were mainly based on the readout of AÎ² levels in CSF and plasma, whereas those of Bapineuzumab were based on cognition; however, little is known about the mechanisms altering these biomarker levels, and no biomarker has yet been proven to be a successful predictor for AD therapy. Clinical trials on various drugs, including AN1792, bapineuzumab, and solanezumab, have been carried out; however, all trials have failed to demonstrate apparent clinical benefits. The second set of baseline scans was from the EXPanding alzhEimer\u0027s Disease InvestigaTIONs (EXPEDITION) studies examining solanezumab, an anti-AÎ² monoclonal antibody (cohort 2, n \u003d 2141). As of the beginning of 2013, our \"Antibodies to watch\" list includes 28 single mAbs and one mAb mixture that are undergoing evaluation in Phase 3 studies for inflammatory or immunological disorders, cancers, high cholesterol, osteoporosis, Alzheimer disease and infectious disease. Specimens from Phase 2 studies of the Î³-secretase inhibitor semagacestat and the therapeutic antibody solanezumab at baseline and following 12-14 weeks of treatment were also tested. A single dose of solanezumab was generally well tolerated, although infusion reactions similar to those seen with administration of other proteins may occur with higher doses. "
    },
    {
      "id": "530cefaaad0bf1360c00000b",
      "ideal_answer": "Overall, the authors conclude that the h index metric is a reasonable measure of academic productivity in the pediatric neurosurgery arena that provides a robust measure of an individual\u0027s contribution to the pediatric neurosurgery literature. On average, an increase of the h index by 5 appears to correspond to the next highest academic rank, with the exception of chairperson. The h index calculation also reveals the productivity of the pediatric neurosurgeons to be on par with the productivity of neurosurgeons in general. The h-index frequency distribution conformed to both the log-linear variation of a power law (r                         (2)â\u003dâ.99) and the beta distribution with the same fitting exponents as previously described in a power law analysis of the productivity of neurosurgeons. However, when stratified by academic rank, a trend was observed showing greater mean h-index scores for those who completed fellowships. Overall, being a senior faculty member corresponds with a greater h-index score, regardless of whether a fellowship was completed. "
    },
    {
      "exact_answer": [
        [
          "Pentostatin"
        ],
        [
          "Purine analog"
        ],
        [
          "nelarabine"
        ],
        [
          "alemtuzumab"
        ],
        [
          "Continuance of life"
        ],
        [
          "Campath 1H"
        ],
        [
          "Prolymphocytic Leukemia"
        ],
        [
          "fludarabine"
        ],
        [
          "T-Cell Prolymphocytic Leukemia"
        ],
        [
          "Antineoplastic Agents"
        ],
        [
          "Frequency of Responses"
        ],
        [
          "Chemotherapy Regimen"
        ],
        [
          "Patients"
        ],
        [
          "Response process"
        ],
        [
          "Monoclonal Antibodies"
        ],
        [
          "Therapeutic procedure"
        ],
        [
          "Experimental Result"
        ],
        [
          "Poor - qualifier"
        ],
        [
          "Tonsillectomy and adenoidectomy"
        ],
        [
          "Forecast of outcome"
        ],
        [
          "Indolent"
        ],
        [
          "T prime"
        ],
        [
          "Salvage Therapy"
        ],
        [
          "Combine"
        ],
        [
          "Minority Groups"
        ],
        [
          "Primary malignant neoplasm"
        ],
        [
          "Thymus Gland"
        ],
        [
          "Document completion status - Documented"
        ],
        [
          "combination of objects"
        ],
        [
          "Line Specimen"
        ],
        [
          "promise"
        ],
        [
          "Lymphoid"
        ],
        [
          "Neoplastic Cell"
        ],
        [
          "In complete remission"
        ],
        [
          "Target Awareness - partial"
        ],
        [
          "Treatment Protocols"
        ],
        [
          "Receive"
        ],
        [
          "Aggressive course"
        ],
        [
          "Aggressive Clinical Course"
        ],
        [
          "Entire cell"
        ],
        [
          "predictive"
        ],
        [
          "leukemia"
        ],
        [
          "Population Median"
        ],
        [
          "posterior lateral line system development"
        ],
        [
          "Providing (action)"
        ],
        [
          "Value Above Reference Range"
        ],
        [
          "Effectiveness"
        ],
        [
          "month"
        ],
        [
          "Anterior"
        ],
        [
          "Determination Aspects"
        ],
        [
          "Half"
        ],
        [
          "Resistant (qualifier value)"
        ],
        [
          "Clinical Trials"
        ],
        [
          "alone - group size"
        ],
        [
          "Tests (qualifier value)"
        ],
        [
          "Post"
        ],
        [
          "Complete"
        ],
        [
          "Short Value"
        ],
        [
          "Cancer Therapeutic Procedure"
        ],
        [
          "Rare"
        ],
        [
          "Standard (document)"
        ],
        [
          "Better"
        ],
        [
          "chronic"
        ],
        [
          "Treated with"
        ],
        [
          "Major"
        ],
        [
          "Disease Response"
        ],
        [
          "Observed"
        ],
        [
          "Levels (qualifier value)"
        ],
        [
          "Increased"
        ],
        [
          "9-beta-D-arabinofuranosylguanosine 5\u0027-triphosphate"
        ],
        [
          "*Activity (kind of quantity)"
        ]
      ],
      "id": "530cefaaad0bf1360c00000c",
      "ideal_answer": "Nelarabine is an effective regimen against indolent leukemias, and combining it with fludarabine was most promising. Trials using DCF or other purine analogues alone or in combination with standard chemotherapeutic agents in front-line or salvage therapy are warranted to improve the prognosis of patients with prolymphocytic leukemia. Fifteen patients with T-PLL, most of whom had received the purine analog deoxycoformycin (DCF), were treated with CAMPATH-1H. Treatment with purine analogues and alemtuzumab has resulted in significantly higher response rates and improved survival. Treatment with purine analogs and the monoclonal antibody alemtuzumab has resulted in significantly higher response rates and increased survival. With the use of the purine analogue pentostatin more than half of patients will have a major response and a minority will have a complete remission, usually lasting months. It has generally been resistant to alkylating chemotherapy, but some effect has been observed with the purine analog 2-deoxycoformicin with documented partial or complete response rates in up to 45% of patients. Pentostatin (2\u0027-deoxycoformycin; DCF) is a purine analogue that has shown activity in treatment of chronic lymphoid malignancies. T-cell prolymphocytic leukemia has an aggressive course with short median survival and poor response to chemotherapy. "
    },
    {
      "exact_answer": [
        [
          "Williams Syndrome"
        ],
        [
          "Endemic Cretinism"
        ],
        [
          "Somatropin"
        ],
        [
          "teratologic"
        ],
        [
          "Hydrocortisone"
        ]
      ],
      "id": "530cefaaad0bf1360c00000d",
      "ideal_answer": "Williams syndrome (WS) is characterized by cardiovascular disease (elastin arteriopathy, peripheral pulmonary stenosis, supravalvular aortic stenosis, hypertension), distinctive facies, connective tissue abnormalities, intellectual disability (usually mild), a specific cognitive profile, unique personality characteristics, growth abnormalities, and endocrine abnormalities (hypercalcemia, hypercalciuria, hypothyroidism, and early puberty). Therefore, the possibility of congenital hypothyroidism should always be taken into consideration too and, even if congenital hypothyroidism neonatal screening is negative, thyroid (morphology and function) evaluation should be regularly assessed when the diagnosis is made and, thereafter, every year in the first years of life. Ultrasound examination of the neck showed a significant thyroid hypoplasia, whereas (99m)Tc-pertechnetate thyroid scintigraphy evidenced a thyroid gland in normal position, with reduced shape and overall weak fixation. These patients were found to have significantly higher mean baseline calcium concentrations, delayed clearance of calcium after intravenous calcium loading, and blunted calcitonin responses after calcium infusion, compared with a group of seven normal children. Involvement of the calcitonin/CGRP gene in Williams syndrome is postulated on the basis that Williams syndrome children often have infantile hypercalcemia and deficient expression of calcitonin, a hormone that lowers serum calcium levels. "
    },
    {
      "id": "530cefaaad0bf1360c00000e",
      "ideal_answer": "The CAP and ProtecT trials (ISRCTN92187251 and ISRCTN20141217) will help resolve the prostate cancer screening debate, define the optimum treatment for localised disease and generate evidence to improve men\u0027s health. To date, the AIDIT team has established a website to facilitate communication between project collaborators (www.impact-study.co.uk), has been represented at several international meetings and has facilitated a conference for the IMPACT study to bring together international research teams, clinicians and policy makers. National guidance (executive letter) EL(97)12 stated that population screening should not be provided by the NHS, or be offered to the public until there is effective screening technology for prostate cancer. This postal questionnaire survey reveals that 81% (95% CI 75% to 87%) of responding general practitioners in North Staffordshire agreed with EL(97)12 and one in ten said that the executive letter changed their views, suggesting that such national guidance has an effect. Test rates varied 100-fold across general practices, a finding not explained by sociodemographic factors, but one which reflects differential adherence to national guidelines, suggesting that general practitioners are key targets for attempting to rationalise the use of the PSA test. "
    },
    {
      "exact_answer": "yes",
      "id": "530cefaaad0bf1360c00000f",
      "ideal_answer": "The association between bruxism, feeding and smoking habits and digestive disorders may lead to serious consequences to dental and related structures, involving dental alterations (wear, fractures and cracks), periodontal signs (gingival recession and tooth mobility) and muscle-joint sensitivity, demanding a multidisciplinary treatment plan. This paper presents a case report in which bruxism associated with acid feeding, smoking habit and episodes of gastric reflow caused severe tooth wear and great muscular discomfort with daily headache episodes. This article presents a case report of a 27-year-old male smoker with tooth wear and dentin sensitivity caused by GERD associated with bruxism. Chronic regurgitation of gastric acids in patients with gastroesophageal reflux disease may cause dental erosion, which can lead in combination with attrition or bruxism to extensive loss of coronal tooth tissue. These results suggest that most jaw muscle activities, ie, RMMA, single short-burst, and clenching episodes, occur in relation to gastroesophageal reflux mainly in the supine position. Gastroesophageal reflux disease by itself or in combination with attrition, abrasion or bruxism may be responsible for the loss. There was a statistical trend towards tooth wear progression being associated with gastric risk factors (p \u003c 0.05). "
    },
    {
      "exact_answer": "yes",
      "id": "530cefaaad0bf1360c000010",
      "ideal_answer": "Organophosphate-induced delayed polyneuropathy is a sensory-motor distal axonopathy which usually occurs after exposure of certain OP insecticides. We found no evidence of sensory neuropathy or isolated peripheral abnormalities among subjects with long-term chlorpyrifos exposure at levels known to be associated with the manufacturing process. The patient was a 32-year-old female who self-injected undetermined amounts of malathion over the median nerve trace on the forearm crease in a suicide attempt which resulted in peripheral neuropathy. Following accidental or suicidal exposure, these anticholinesterases lead to three well defined neurological syndromes i.e. initial life threatening acute cholinergic crisis which often requires management in intensive care unit, intermediate syndrome in which cranial nerve palsies, proximal muscle weakness and respiratory muscle weakness are common and patients often require respiratory support and delayed organophosphate induced polyneuropathy. These results suggest that previously reported cases of organophosphate-induced delayed polyneuropathy may represent only the worst disease in a spectrum of impairment, a sequela of exposure that may be much more common than previously thought. "
    },
    {
      "exact_answer": [
        [
          "Problems - What subject filter"
        ],
        [
          "Headache"
        ],
        [
          "Sleeplessness"
        ],
        [
          "Adverse Event Associated with Syndromes"
        ],
        [
          "Symptoms"
        ],
        [
          "Exanthema"
        ],
        [
          "Asthenia"
        ],
        [
          "Disorientation"
        ],
        [
          "Memory Loss"
        ],
        [
          "Characterization"
        ],
        [
          "Arthralgia"
        ],
        [
          "Erectile dysfunction"
        ],
        [
          "Lymphadenopathy"
        ],
        [
          "Confusion"
        ],
        [
          "Impaired cognition"
        ],
        [
          "Fatigue"
        ],
        [
          "Reporting"
        ],
        [
          "Changing"
        ],
        [
          "Cluster"
        ],
        [
          "Memory"
        ],
        [
          "Variety (taxon)"
        ],
        [
          "Gulf War"
        ],
        [
          "Apraxias"
        ],
        [
          "Including (qualifier)"
        ],
        [
          "Imbrication (procedure)"
        ],
        [
          "Mood swings"
        ],
        [
          "Night sweats"
        ],
        [
          "Persian Gulf Syndrome"
        ],
        [
          "Phobic anxiety disorder"
        ],
        [
          "EXTREMITY PARESTHESIA"
        ],
        [
          "Unspecified"
        ],
        [
          "Integer +5"
        ],
        [
          "Integer +2"
        ],
        [
          "Myalgia"
        ],
        [
          "Unintentional weight loss"
        ],
        [
          "N-(3-N-(benzyloxycarbonyl)amino-1-carboxypropyl)leucyl-O-methyltyrosine N-methylamide"
        ],
        [
          "Diplopia"
        ],
        [
          "Difficulty lifting"
        ],
        [
          "Amnesia"
        ],
        [
          "DAYTIME SLEEPINESS"
        ],
        [
          "Vertigo"
        ],
        [
          "shared attribute"
        ],
        [
          "Reasoning"
        ],
        [
          "Thinking and speaking disturbances"
        ],
        [
          "1990s"
        ],
        [
          "Unable to concentrate"
        ],
        [
          "Cough Adverse Event"
        ],
        [
          "Ataxia"
        ],
        [
          "Incontinence"
        ],
        [
          "Neuropsychological Tests"
        ],
        [
          "Gait"
        ],
        [
          "Joints"
        ],
        [
          "Depressed mood"
        ],
        [
          "Neuropathy"
        ],
        [
          "Nonspecific"
        ],
        [
          "Generalized fatigue"
        ],
        [
          "Muscle Fatigue"
        ],
        [
          "Representation (action)"
        ],
        [
          "Line Specimen"
        ],
        [
          "Return to"
        ],
        [
          "Balance disturbances"
        ],
        [
          "Alteration"
        ],
        [
          "Mental Suffering"
        ],
        [
          "Fever"
        ],
        [
          "statistical cluster"
        ],
        [
          "Concern"
        ],
        [
          "Male gender"
        ],
        [
          "organic sexual dysfunction"
        ],
        [
          "United States"
        ],
        [
          "morphological"
        ],
        [
          "Severe cognitive impairment"
        ],
        [
          "Memory impairment"
        ],
        [
          "Mental association"
        ],
        [
          "Mental Depression"
        ],
        [
          "Urinary system"
        ],
        [
          "Impaired health"
        ],
        [
          "Anterior"
        ],
        [
          "Marked"
        ],
        [
          "Visual"
        ],
        [
          "Surgical aspects"
        ],
        [
          "respiratory"
        ],
        [
          "Involvement with"
        ],
        [
          "Attention"
        ],
        [
          "Strong"
        ],
        [
          "History of previous events"
        ],
        [
          "Affect (mental function)"
        ],
        [
          "Muscle"
        ],
        [
          "per year"
        ],
        [
          "\u003c3 (qualifier value)"
        ],
        [
          "Revealed"
        ],
        [
          "Early"
        ],
        [
          "Identified"
        ],
        [
          "Health"
        ],
        [
          "Report (document)"
        ],
        [
          "Function"
        ],
        [
          "Disease"
        ]
      ],
      "id": "530cefaaad0bf1360c000011",
      "ideal_answer": "The symptoms include incapacitating fatigue, musculoskeletel and joint pains, headaches, neuropsychiatric disorders, affect changes, confusion, visual problems, changes of gait, loss of memory, lymphadenopathies, respiratory impairment, impotence, and urinary tract morphological and functional alterations. Syndromes 1 (\"impaired cognition,\" characterized by problems with attention, memory, and reasoning, as well as insomnia, depression, daytime sleepiness, and headaches), 2 (\"confusion-ataxia,\" characterized by problems with thinking, disorientation, balance disturbances, vertigo, and impotence), and 3 (\"arthro-myo-neuropathy,\" characterized by joint and muscle pains, muscle fatigue, difficulty lifting, and extremity paresthesias) represented strongly clustered symptoms; whereas, syndromes 4 (\"phobia-apraxia\"), 5 (\"fever-adenopathy\"), and 6 (\"weakness-incontinence\") involved weaker clustering and mostly overlapped syndromes 2 and 3. A cluster of common health problems included: skin rash, cough, depression, unintentional weight loss, insomnia, and memory problems. In early 1992, U.S. troops returning from the Gulf War began reporting a variety of nonspecific symptoms such as fatigue, skin rash, headache, muscle and joint pain, and loss of memory. His history revealed several front-line operations in 1990 and 1991 during the Gulf War. The strongest associations were for mood swings (OR 20.9, 95%CI 16.2-27.0),. night sweats (OR 9.9, 95% CI 6.5-15.2),. and sexual dysfunction (OR 4.6, 95%CI 3.2-6.6). "
    },
    {
      "exact_answer": [
        [
          "Restless Legs Syndrome"
        ],
        [
          "Iron"
        ],
        [
          "Dopamine Hydrochloride"
        ],
        [
          "Iron deficiency"
        ],
        [
          "Ferritin"
        ]
      ],
      "id": "530cefaaad0bf1360c000012",
      "ideal_answer": "We describe a unique case of a 23-yr-old female patient affected by a homozygous loss of function mutation in the L-ferritin gene, idiopathic generalized seizures, and atypical restless leg syndrome (RLS). Our results demonstrate for the first time the pathophysiological consequences of L-ferritin deficiency in a human and help to define the concept for a new disease entity hallmarked by idiopathic generalized seizure and atypical RLS. Clinical and animal studies that support the benefits of iron supplementation, independent of increasing hemoglobin, such as those on immune function, physical performance, thermoregulation, cognition, and restless leg syndrome and aluminum absorption is the subject of this narrative review. The results are consistent with the hypothesis that a primary iron insufficiency produces a dopaminergic abnormality characterized as an overly activated dopaminergic system as part of the RLS pathology. Diurnal effects on motor control are evident in the human disease of Restless Leg Syndrome (RLS), which is purported to be linked to brain iron deficiency as well as alterations in dopaminergic systems. Clinical studies have implicated the dopaminergic system in RLS, while others have suggested that it is associated with insufficient levels of brain iron. "
    },
    {
      "exact_answer": "yes",
      "id": "530cf4c54a5037880c000002",
      "ideal_answer": "The use of high-flow nasal cannulae was noninferior to the use of nasal CPAP, with treatment failure occurring in 52 of 152 infants (34.2%) in the nasal-cannulae group and in 39 of 151 infants (25.8%) in the CPAP group (risk difference, 8.4 percentage points; 95% confidence interval, -1.9 to 18.7). An alternative to the use of nasal continuous positive airway pressure (NCPAP) as a non-invasive modality to support respiratory distress in premature infants has been the recent introduction of high flow nasal cannula (HFNC) devices in many neonatal units. High-flow nasal cannulae (HFNC) are gaining in popularity as a form of non-invasive respiratory support for preterm infants in neonatal intensive care units around the world. The use of high-flow nasal cannulae is an increasingly popular alternative to nasal continuous positive airway pressure (CPAP) for noninvasive respiratory support of very preterm infants (gestational age, \u003c32 weeks) after extubation. Although the result for the primary outcome was close to the margin of noninferiority, the efficacy of high-flow nasal cannulae was similar to that of CPAP as respiratory support for very preterm infants after extubation. "
    },
    {
      "exact_answer": [
        [
          "MAP3K8 protein, human"
        ],
        [
          "MAP3K8 gene"
        ],
        [
          "Kinase Inhibitors [MoA]"
        ],
        [
          "quinoline"
        ],
        [
          "Pyrimidines"
        ],
        [
          "MAP3K8 wt Allele"
        ],
        [
          "kinase inhibitor"
        ],
        [
          "literary novel"
        ],
        [
          "Poor - qualifier"
        ],
        [
          "Modeling"
        ],
        [
          "Integer +2"
        ],
        [
          "AMINOQUINOLINE"
        ],
        [
          "naphthyridine"
        ],
        [
          "Series - set of composite instances"
        ],
        [
          "Potential"
        ],
        [
          "Discover"
        ],
        [
          "1+ Score, WHO"
        ],
        [
          "1+ Score"
        ],
        [
          "derivatives"
        ],
        [
          "Class"
        ],
        [
          "1 Hour"
        ],
        [
          "Report (document)"
        ],
        [
          "Initial (abbreviation)"
        ],
        [
          "Imidazole"
        ],
        [
          "GPR162 gene"
        ],
        [
          "Identification (Psychology)"
        ],
        [
          "Wheeled Stretchers"
        ],
        [
          "Optimization"
        ],
        [
          "Base - General Qualifier"
        ],
        [
          "Indazoles"
        ],
        [
          "Visual halos (disorder)"
        ],
        [
          "Pyridines"
        ],
        [
          "Paper Authorization"
        ],
        [
          "Cyclical"
        ],
        [
          "Lipopolysaccharides"
        ],
        [
          "Exertion"
        ],
        [
          "In Vivo"
        ],
        [
          "4-aminoquinoline"
        ],
        [
          "cyclic amine"
        ],
        [
          "Amine Group"
        ],
        [
          "User Group"
        ],
        [
          "\u003c3 (qualifier value)"
        ],
        [
          "Percent inhibition"
        ],
        [
          "3+ Score"
        ],
        [
          "Structural modification"
        ],
        [
          "Dietary Lead"
        ],
        [
          "tumor necrosis factor production"
        ],
        [
          "Preparation"
        ],
        [
          "Induce (action)"
        ],
        [
          "Enzyme Inhibitors"
        ],
        [
          "Appropriate"
        ],
        [
          "Anti-Inflammatory Agents"
        ],
        [
          "Efficacy Study"
        ],
        [
          "Synthesis"
        ],
        [
          "Structure-Activity Relationship"
        ],
        [
          "3/4"
        ],
        [
          "described"
        ],
        [
          "In Vitro [Publication Type]"
        ],
        [
          "Identified"
        ],
        [
          "Pb4+"
        ],
        [
          "*Activity (kind of quantity)"
        ],
        [
          "2-Dimensional"
        ]
      ],
      "id": "530cf4d5e2bfff940c000003",
      "ideal_answer": "ynthesis, modeling and structure-activity relationship of indazoles as inhibitors of Tpl2 kinase are described. report here the synthesis and SAR of a new series of thieno[3,2-d]pyrimidines as potent Tpl2 kinase inhibitors. identified a novel series of 2,4-disubstituted thieno[2,3-c]pyridines as COT kinase inhibitors. have previously reported the discovery and initial SAR of the [1,7]naphthyridine-3-carbonitriles and quinoline-3-carbonitriles as Tumor Progression Loci-2 (Tpl2) kinase inhibitors. Further structure-activity based modifications led to the identification of 8-bromo-4-(3-chloro-4-fluorophenylamino)-6-[(1-methyl-1H-imidazol-4-yl)methylamino]quinoline-3-carbonitrile, which demonstrated in vitro as well as in vivo efficacy in inhibition of LPS-induced TNF-alpha production. We have discovered that 8-halo-4-(3-chloro-4-fluoro-phenylamino)-6-[(1H-[1,2,3]triazol-4-ylmethyl)-amino]-quinoline-3-carbonitriles (4) are potent inhibitors of this enzyme. Optimization of these cyclic amine groups led to the identification of 8-chloro-4-(3-chloro-4-fluorophenylamino)-6-((1-(1-ethylpiperidin-4-yl)-1H-1,2,3-triazol-4-yl)methylamino)quinoline-3-carbonitrile (34). Initial 4-anilino-6-aminoquinoline-3-carbonitrile leads showed poor selectivity for Tpl2. In this paper, we report new SAR efforts which have led to the identification of 4-alkylamino-[1,7]naphthyridine-3-carbonitriles. novel quinoline-3-carbonitrile derivatives as Tpl2 kinase inhibitors. a novel class of selective Tpl2 kinase inhibitors: 4-Alkylamino-[1,7]naphthyridine-3-carbonitriles. selectivity and in vivo antiinflammatory activity of novel 8-substituted-4-anilino-6-aminoquinoline-3-carbonitriles. The 8-substituted-4-anilino-6-aminoquinoline-3-carbonitriles were prepared from the appropriate 2-substituted 4-nitroanilines. "
    },
    {
      "exact_answer": [
        [
          "Base - General Qualifier"
        ],
        [
          "Genes"
        ],
        [
          "Candidate Disease Gene"
        ],
        [
          "Network"
        ],
        [
          "Homo sapiens"
        ],
        [
          "Approach"
        ],
        [
          "MAL gene"
        ],
        [
          "Rank"
        ],
        [
          "Publications"
        ],
        [
          "FAVOR"
        ],
        [
          "algorithm"
        ],
        [
          "Phenotype"
        ],
        [
          "Disease"
        ],
        [
          "Widening"
        ],
        [
          "Genes, vif"
        ],
        [
          "Genome"
        ],
        [
          "Similarity"
        ],
        [
          "utilization qualifier"
        ],
        [
          "Scientific Study"
        ],
        [
          "Methods"
        ],
        [
          "Laboratory mice"
        ],
        [
          "Negation"
        ],
        [
          "Involvement with"
        ],
        [
          "Knowledge"
        ],
        [
          "Data"
        ],
        [
          "Call (Instruction)"
        ],
        [
          "Computational Technique"
        ],
        [
          "Expression procedure"
        ],
        [
          "Text Mining"
        ],
        [
          "Computer software"
        ],
        [
          "Interaction"
        ],
        [
          "Internet"
        ],
        [
          "Dispense Method - Traditional"
        ],
        [
          "Restart"
        ],
        [
          "Numerous"
        ],
        [
          "Walking (activity)"
        ],
        [
          "Pinta"
        ],
        [
          "Test Method"
        ],
        [
          "Manuscripts"
        ],
        [
          "Introduces"
        ],
        [
          "Arts"
        ],
        [
          "Blood group antibody I"
        ],
        [
          "Comparison"
        ],
        [
          "Combine"
        ],
        [
          "Geographic state"
        ],
        [
          "Plug (physical object)"
        ],
        [
          "List"
        ],
        [
          "Data Sources"
        ],
        [
          "Evaluation"
        ],
        [
          "Inference"
        ],
        [
          "Extension"
        ],
        [
          "Open"
        ],
        [
          "Etiology"
        ],
        [
          "Distributing"
        ],
        [
          "Availability of"
        ],
        [
          "HTTP"
        ],
        [
          "Model"
        ],
        [
          "user - individual"
        ],
        [
          "Web Site"
        ],
        [
          "Annotations"
        ],
        [
          "Function"
        ],
        [
          "Pathway Analysis"
        ],
        [
          "Prior Medication Usage"
        ],
        [
          "Protein Interaction Maps"
        ],
        [
          "PROPOSED"
        ],
        [
          "Various patch test substance"
        ],
        [
          "Techniques"
        ],
        [
          "Gene Ontology"
        ],
        [
          "Property (attribute)"
        ],
        [
          "Performed"
        ],
        [
          "Procedural approach"
        ],
        [
          "Staphylococcal Protein A"
        ],
        [
          "suggestion"
        ],
        [
          "biology (field)"
        ],
        [
          "Persons"
        ],
        [
          "Random"
        ],
        [
          "Genomics"
        ],
        [
          "accessibility"
        ],
        [
          "As Much as Desired"
        ],
        [
          "Biological Markers"
        ],
        [
          "Representation Component"
        ],
        [
          "Microarray"
        ],
        [
          "Physiological Processes"
        ],
        [
          "Proton Pump Inhibitors"
        ],
        [
          "Saccharomyces cerevisiae"
        ],
        [
          "Biomedicine"
        ],
        [
          "Evidence of"
        ],
        [
          "Potassium Ion"
        ],
        [
          "Internal-External Locus of Control Scale"
        ],
        [
          "Performance"
        ],
        [
          "Relationship by association"
        ],
        [
          "Question (inquiry)"
        ],
        [
          "Score"
        ],
        [
          "Device Component System"
        ],
        [
          "Suite - ActCode"
        ],
        [
          "Free (available (qualifier))"
        ],
        [
          "TBATA gene"
        ],
        [
          "Learning"
        ],
        [
          "Role Class - access"
        ],
        [
          "Task"
        ]
      ],
      "id": "530cf4d5e2bfff940c000004",
      "ideal_answer": "o-expression network analysis and genetic algorithms for gene prioritization. The traditional approach to reduce the number of candidate genes entails fine-mapping studies using markers and pedigrees. We present biomarker identification problem using gene prioritization method called gene prioritization from microarray data based on shortest paths, extended with structural and biological properties and edge flux using voting scheme (GP-MIDAS-VXEF). Using a training set of genes known to be involved in a biological process of interest, our approach consists of (i) inferring several models (based on various genomic data sources), (ii) applying each model to the candidate genes to rank those candidates against the profile of the known genes and (iii) merging the several rankings into a global ranking of the candidate genes. this web site is free and open to all users and does not require a login to access) is a one-stop portal for (i) gene list functional enrichment, (ii) candidate gene prioritization using either functional annotations or network analysis and (iii) identification and prioritization of novel disease candidate genes in the interactome. "
    },
    {
      "exact_answer": [
        [
          "Cardiomyopathies"
        ],
        [
          "MYH7 gene"
        ],
        [
          "Associated with"
        ],
        [
          "Experimental Result"
        ],
        [
          "actin binding"
        ]
      ],
      "id": "530cf4e0c8a0b4a00c000002",
      "ideal_answer": "A novel alpha-tropomyosin mutation associates with dilated and non-compaction cardiomyopathy and diminishes actin binding. We show that a mutation in TPM1 is associated with DCM and a lethal, early onset form of NCCM, probably as a result of diminished actin binding caused by weakened charge-charge interactions. These results confirm the genetic heterogeneity of NCCM and suggest that the molecular classification of cardiomyopathies includes an MYH7-associated spectrum of NCCM with HCM, RCM, and DCM. We describe, in two separate autosomal-dominant NCCM families, the identification of mutations in the sarcomeric cardiac beta-myosin heavy chain gene (MYH7), known to be associated with hypertrophic cardiomyopathy (HCM), restricted cardiomyopathy (RCM), and dilated cardiomyopathy (DCM). "
    },
    {
      "exact_answer": [
        [
          "Myosin Heavy Chains"
        ],
        [
          "Myosin ATPase"
        ],
        [
          "Glutamine"
        ],
        [
          "Alpha heavy chain"
        ],
        [
          "Alpha"
        ],
        [
          "Mutation"
        ],
        [
          "Mus"
        ],
        [
          "Troponin I"
        ],
        [
          "GTP-Binding Protein alpha Subunits, Gs"
        ],
        [
          "Fluorides"
        ],
        [
          "Cardiomyopathy, Hypertrophic, Familial"
        ],
        [
          "M NOS ANTIBODY"
        ],
        [
          "MYH6 gene"
        ],
        [
          "Mutation Abnormality"
        ],
        [
          "Missense Mutation"
        ],
        [
          "Male Gender, Self Report"
        ],
        [
          "Harbor"
        ],
        [
          "Uncertainty"
        ],
        [
          "Introduction procedure"
        ],
        [
          "Phenotype"
        ],
        [
          "Induce (action)"
        ],
        [
          "Laboratory mice"
        ],
        [
          "Generation (action)"
        ],
        [
          "Transverse - anatomical location"
        ],
        [
          "Females"
        ],
        [
          "Stenosis"
        ],
        [
          "Characteristics"
        ],
        [
          "Model"
        ],
        [
          "Analysis of substances"
        ],
        [
          "Mutant"
        ],
        [
          "Pressure- physical agent"
        ],
        [
          "Formed"
        ],
        [
          "Enhance (action)"
        ],
        [
          "Mouse Model"
        ],
        [
          "Study"
        ],
        [
          "Negation"
        ],
        [
          "Conclude Resin"
        ],
        [
          "TNNI3 gene"
        ],
        [
          "Property (attribute)"
        ],
        [
          "Base - General Qualifier"
        ],
        [
          "Lower - spatial qualifier"
        ],
        [
          "teratologic"
        ],
        [
          "Sudden Death Adverse Event Not Associated with More Specific CTCAE Term"
        ],
        [
          "WK-30"
        ],
        [
          "Crossbreeding"
        ],
        [
          "Cardiomyopathies"
        ],
        [
          "Unmarried person"
        ],
        [
          "Proband (finding)"
        ],
        [
          "Cardiac Electrophysiology"
        ],
        [
          "Electrophysiology (science)"
        ],
        [
          "unidirectional conjugation"
        ],
        [
          "Stricture of aorta"
        ],
        [
          "strip medical device"
        ],
        [
          "Comprehension"
        ],
        [
          "Hypertrophic Cardiomyopathy"
        ],
        [
          "Hemodynamics"
        ],
        [
          "Aortic arch structure"
        ],
        [
          "Approximate"
        ],
        [
          "House mice"
        ],
        [
          "Creation"
        ],
        [
          "Papillary muscle of left ventricle"
        ],
        [
          "Offspring"
        ],
        [
          "Intrinsic drive"
        ],
        [
          "Manipulation procedure"
        ],
        [
          "Sudden onset (attribute)"
        ],
        [
          "Unaffected"
        ],
        [
          "Protein Isoforms"
        ],
        [
          "paradigm"
        ],
        [
          "Alleles"
        ],
        [
          "Mammals"
        ],
        [
          "Ionic Strength"
        ],
        [
          "Histologic"
        ],
        [
          "Largest"
        ],
        [
          "Designated"
        ],
        [
          "Science of Etiology"
        ],
        [
          "Carrying"
        ],
        [
          "Disruption"
        ],
        [
          "Absent"
        ],
        [
          "Bearing Device Component"
        ],
        [
          "Protein Overexpression"
        ],
        [
          "Amplitude"
        ],
        [
          "Device Display Device Component"
        ],
        [
          "Assembly (group of parts)"
        ],
        [
          "Aortic Pressure"
        ],
        [
          "Causing"
        ],
        [
          "Demonstrates"
        ],
        [
          "Health maintenance"
        ],
        [
          "Exercise Pain Management"
        ],
        [
          "Impaired"
        ],
        [
          "Mechanical Methods"
        ],
        [
          "Motor function"
        ],
        [
          "per month (qualifier value)"
        ],
        [
          "Experimental Finding"
        ],
        [
          "Biochemical"
        ],
        [
          "Length of Trial"
        ],
        [
          "Gene Mutation"
        ],
        [
          "Wild Type Mouse"
        ],
        [
          "Wild Type"
        ],
        [
          "Pathogenesis"
        ],
        [
          "Skin"
        ]
      ],
      "id": "530cf4e0c8a0b4a00c000004",
      "ideal_answer": "This model (designated TnI-203/MHC-403) was generated by crossbreeding mice with the Gly203Ser cardiac troponin I (TnI-203) and Arg403Gln alpha-myosin heavy chain (MHC-403) FHC-causing mutations. To understand further the pathogenesis of familial hypertrophic cardiomyopathy, we determined how the cardiomyopathy induced by an Arg403--\u003eGln missense mutation in the alpha-myosin heavy chain (403) is affected by chronically enhancing sympathetic drive by mating the mice with those overexpressing G(s)alpha (G(s)alpha x403). A mouse model of familial hypertrophic cardiomyopathy (FHC) was generated by the introduction of an Arg 403 --\u003e Gln mutation into the alpha cardiac myosin heavy chain (MHC) gene. Genetically-manipulated mice harboring an alpha-myosin heavy chain Arg403Gln missense mutation (alpha-MHC403/+) display a phenotype characteristic of familial hypertrophic cardiomyopathy (FHC). Male but not female mice carrying a single R403Q missense allele for cardiac alpha-myosin heavy chain (M-alphaMHC(R403Q/+) and F-alphaMHC(R403Q/+), respectively) develop significant hypertrophic cardiomyopathy (HCM) compared with male and female wild-type mice (M-alphaMHC(+/+) and F-alphaMHC(+/+), respectively) after approximately 30 wk of age. A new mouse cardiac electrophysiology method was used to study mice harboring an alpha-myosin heavy chain Arg403Gln missense mutation (alpha-MHC403/+), which results in histological and hemodynamic abnormalities characteristic of familial hypertrophic cardiomyopathy (FHC) and sudden death of uncertain etiology during exercise. "
    },
    {
      "exact_answer": [
        [
          "Mitral Valve Prolapse Syndrome"
        ],
        [
          "Marfan Syndrome"
        ],
        [
          "Regurgitates after swallowing"
        ],
        [
          "Manifestation of"
        ],
        [
          "FBN1 gene"
        ],
        [
          "Heart"
        ],
        [
          "Ptosis"
        ],
        [
          "Aortic root dilation"
        ],
        [
          "Mitral Valve Insufficiency"
        ],
        [
          "Connective Tissue Diseases"
        ],
        [
          "Aortic Valve Insufficiency"
        ],
        [
          "Tissue Dissection"
        ],
        [
          "Severe (severity modifier)"
        ],
        [
          "Temporal -Temporal Qualifier"
        ],
        [
          "Supraaortic valve area structure"
        ],
        [
          "Presence"
        ],
        [
          "Dural ectasia"
        ],
        [
          "Congenital aneurysm of ascending aorta"
        ],
        [
          "Sequencing - Ascending"
        ],
        [
          "Dilatation of aorta"
        ],
        [
          "Aortic root dilatation"
        ],
        [
          "Enlargement procedure"
        ],
        [
          "Including (qualifier)"
        ],
        [
          "mitral"
        ],
        [
          "Aneurysm"
        ],
        [
          "Multiple congenital anomalies"
        ],
        [
          "Usual"
        ],
        [
          "Rupture of aorta"
        ],
        [
          "Adrenergic beta-Antagonists"
        ],
        [
          "Aorta"
        ],
        [
          "Science of Etiology"
        ],
        [
          "Etiology aspects"
        ],
        [
          "Root body part"
        ],
        [
          "Aortic diameter"
        ],
        [
          "Score"
        ],
        [
          "disorder classification"
        ],
        [
          "Contribution"
        ],
        [
          "Diameter (qualifier value)"
        ],
        [
          "Child"
        ],
        [
          "Progressive"
        ],
        [
          "Biological Evolution"
        ],
        [
          "Numerous"
        ],
        [
          "Cardiovascular Abnormalities"
        ],
        [
          "Cardiovascular finding"
        ],
        [
          "Phase II/III Trial"
        ],
        [
          "criteria"
        ],
        [
          "Cardiovascular system"
        ],
        [
          "Estimated"
        ],
        [
          "Systemic"
        ],
        [
          "Main"
        ],
        [
          "incidence of cases"
        ],
        [
          "Therapeutic procedure"
        ],
        [
          "Genetic"
        ],
        [
          "Diagnosis"
        ],
        [
          "Major"
        ],
        [
          "1+ Score, WHO"
        ],
        [
          "Clinical"
        ]
      ],
      "id": "530cf4e0c8a0b4a00c000005",
      "ideal_answer": "Cardiac manifestations of Marfan syndrome include aortic root dilation and mitral valve prolapse (MVP). The typical cardiac manifestations of Marfan syndrome are aortic regurgitation with progressive dilatation of the aortic root, which may cause dissection and rupture of the ascending aorta, mitral valve prolapse and mitral valve regurgitation. the presence of mitral valve prolapse, aortic root diameter, mitral and aortic valves regurgitation, and aortic enlargement during beta-blocker therapy. Dural ectasia and the presence of mitral valve prolapse (MVP) contribute to its systemic score. To describe the clinical cardiac manifestations and temporal evolution of Marfan syndrome in children; to estimate the incidence of annuloaortic ectasia and mitral valve prolapse. Marfan syndrome is a hereditable disorder of connective tissue that causes several distinct cardiovascular abnormalities, including aortic regurgitation, dissection, and aneurysm. The major cardiac diagnoses were aortic dilatation (1/3) and mitral valve prolapse with severe mitral regurgitation (2/3). Marfan syndrome (MFS) is a genetic disorder of the connective tissue. Aortic root dilation is a main criterion of the Ghent Nosology. Cardiovascular manifestations in Marfan syndrome. "
    },
    {
      "exact_answer": [
        [
          "shared attribute"
        ],
        [
          "Hypertrophic Cardiomyopathy"
        ],
        [
          "Sudden onset (attribute)"
        ],
        [
          "Athletes"
        ],
        [
          "Cause of Death"
        ]
      ],
      "id": "530cf4e0c8a0b4a00c000006",
      "ideal_answer": "Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death (SCD) in young people, including trained athletes. Hypertrophic cardiomyopathy (HCM) is regarded as the most common cause of sudden cardiac death in young people (including trained athletes). Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden cardiac death in young people, including trained athletes. Hypertrophic cardiomyopathy is regarded as the most common cause of sudden cardiac death in young people (including trained athletes). Hypertrophic cardiomyopathy (HCM) is one of the most common inherited primary cardiac disorders and the most common cause of sudden cardiac death in young athletes. The most common cause of sudden cardiac death in individuals aged less than 35 years, including competitive athletes, is the inherited disorder hypertrophic cardiomyopathy (HCM). The most common cause of sudden cardiac death in athletes is hypertrophic cardiomyopathy. Hypertrophic cardiomyopathy (HC) is probably the most common cause of sudden cardiac death in youthful athletes, and this diagnosis has represented a contraindication to continued participation in competitive sports. HCM is the most common cause of sudden death in young competitive athletes and preparticipation screening programs have to be implemented to avoid these tragic fatalities. "
    },
    {
      "exact_answer": [
        [
          "Commotio Cordis"
        ],
        [
          "Electric Countershock"
        ],
        [
          "Continuance of life"
        ],
        [
          "Cardiopulmonary Resuscitation"
        ],
        [
          "Event"
        ]
      ],
      "id": "530cf4e0c8a0b4a00c000007",
      "ideal_answer": "At their commotio cordis event, 216 study patients were 0.2-51 years old (mean age 15Â±9 years); 95% were males. In the 2 groups, events were largely similar demographically, including frequency of survival (26% in U.S. vs 25%; P \u003d .84),. Only 21 (16%) individuals survived their event, with particularly prompt cardiopulmonary resuscitation/defibrillation (most commonly reversing ventricular fibrillation) the only identifiable factor associated with a favorable outcome. Survival rates for commotio cordis are low, even with prompt CPR and defibrillation. Survival is low, even when resuscitation is performed. Death occurred in 156 individuals (72%), while the other 60 (28%) survived. Survival of commotio cordis has risen from 10% to 15% since 2001. "
    },
    {
      "exact_answer": [
        [
          "Narcolepsy"
        ],
        [
          "H1N1"
        ],
        [
          "Vaccination"
        ],
        [
          "orexins"
        ],
        [
          "pandemrix"
        ]
      ],
      "id": "530cf54dab4de4de0c000009",
      "ideal_answer": "Although no formal link can be established, the unusual characteristics of the reported cases and the striking temporal relationship suggests that narcolepsy may be the result of an autoimmune reaction triggered by H1N1Â vaccination in susceptible individuals. In 2010, the peak seasonal onset of narcolepsy was phase delayed by 6 months relative to winter H1N1 infections, and the correlation was independent of H1N1 vaccination in the majority of the sample. H1N1 vaccination was strongly associated with an increased risk of narcolepsy-cataplexy in both children and adults in France. n China, narcolepsy onset is highly correlated with seasonal and annual patterns of upper airway infections, including H1N1 influenza. Recently identified autoantibodies to Tribbles homologue 2 in some patients, as well as cases associated with H1N1 vaccination, support an autoimmune mechanism. The proposed mechanism for postvaccination narcolepsy is one in which an environmental trigger causes or enhances an antibody-mediated autoimmune response in patients with a preexisting genetic susceptibility. Pandemrix vaccination is a precipitating factor for narcolepsy, especially in combination with HLA-DQB1*0602. The loss of hypothalamic hypocretin/orexin (hcrt) producing neurons causes narcolepsy with cataplexy. An autoimmune basis for the disease has long been suspected and recent results have greatly strengthened this hypothesis. "
    },
    {
      "exact_answer": [
        [
          "Biospecimen"
        ],
        [
          "Ms. - Title"
        ],
        [
          "Proteins"
        ],
        [
          "Specimen panels"
        ],
        [
          "Interested"
        ]
      ],
      "id": "530cf54dab4de4de0c00000c",
      "ideal_answer": "it is a valuable resource for the selection of candidate proteotypic peptides for targeted proteomic experiments via Selected Reaction Monitoring (SRM) or SWATH-MS. SWATH-MS is a data-independent acquisition method that generates, in a single measurement, a complete recording of the fragment ion spectra of all the analytes in a biological sample for which the precursor ions are within a predetermined m/z versus retention time window. ew strategies, such as SWATHâ¢ MS, which allows us to systematically characterize and quantify query sample sets of \u0027any protein of interest\u0027 in complex biological samples,. Here we present a new strategy that systematically queries sample sets for the presence and quantity of essentially any protein of interest. "
    },
    {
      "id": "530d7e8a38c1322806000001",
      "ideal_answer": "Thus, we show M31 overexpression to have two contrasting effects which are dependent on chromosomal context: (i) it enhanced PEV in those lines with centromeric or pericentromeric transgene locations; and (ii) it suppressed PEV when the transgene was non-centromeric. Furthermore, by overexpressing a mammalian homologue (M31) of Drosophila melanogaster heterochromatin protein 1 (HP1; refs 7,8) in transgenic mouse lines that exhibit PEV, it is possible to modify the proportion of cells that silence the transgene in a dose-dependent manner. Study of the distribution of a murine HP1-like chromodomain protein, M31, during spermatogenesis revealed spreading from the tip of the XY body in mid-stage pachytene spermatocytes to include the whole of the XY body in late-pachytene spermatocytes. First, forced expression of full-length SUV39H1 (412 amino acids) redistributes endogenous M31 (HP1beta) and induces abundant associations with inter- and metaphase chromatin. Together, our data reveal a dominant role(s) for the SET domain of SUV39H1 in the distribution of prominent heterochromatic proteins and suggest a possible link between a chromosomal SU(VAR) protein and histone H3. "
    },
    {
      "exact_answer": [
        [
          "NF-kappa B"
        ],
        [
          "Cytoplasm"
        ],
        [
          "NFKBIA gene"
        ],
        [
          "I Kappa B-Alpha"
        ],
        [
          "I-kappa B Proteins"
        ],
        [
          "REL Protein"
        ],
        [
          "Blood group antibody I"
        ],
        [
          "cytoplasmic sequestering of NF-kappaB"
        ],
        [
          "Sequestered"
        ],
        [
          "IL17RD gene"
        ],
        [
          "Sequestration"
        ],
        [
          "Ankyrins"
        ],
        [
          "Retained"
        ],
        [
          "Inhibition"
        ],
        [
          "Gene Products, tax"
        ],
        [
          "Unstimulated"
        ],
        [
          "lyt-10 protein"
        ],
        [
          "Interphase Cell"
        ],
        [
          "Kappa"
        ],
        [
          "dimer"
        ],
        [
          "Protein Precursors"
        ],
        [
          "tax protein, Human T-lymphotrophic virus 1"
        ],
        [
          "complex (molecular entity)"
        ],
        [
          "Viral Proteins"
        ],
        [
          "Cells"
        ],
        [
          "TRANSCRIPTION FACTOR"
        ],
        [
          "Cytoplasmic"
        ],
        [
          "cytokine"
        ],
        [
          "Mechanism Component of Device"
        ],
        [
          "RNA Sequence"
        ],
        [
          "Transcription, Genetic"
        ],
        [
          "Proteins"
        ],
        [
          "Alpha"
        ],
        [
          "Cell Nucleus"
        ],
        [
          "protein B"
        ],
        [
          "Protein Family"
        ],
        [
          "APEX1 gene"
        ],
        [
          "Specific qualifier value"
        ],
        [
          "utilization qualifier"
        ],
        [
          "Belarus"
        ],
        [
          "Taxes"
        ],
        [
          "Heterodimerization"
        ],
        [
          "Integer +2"
        ],
        [
          "cytoplasmic sequestering of transcription factor"
        ],
        [
          "Relieving"
        ],
        [
          "psychological masking"
        ],
        [
          "Adoptive Immunotherapy"
        ],
        [
          "Nuclear Import"
        ],
        [
          "Import"
        ],
        [
          "suggestion"
        ],
        [
          "Catabolism"
        ],
        [
          "Mutual"
        ],
        [
          "Reservoir Device Component"
        ],
        [
          "Autonomic nervous system"
        ],
        [
          "Encode (action)"
        ],
        [
          "Hypothalamic structure"
        ],
        [
          "establishment and maintenance of localization"
        ],
        [
          "Property (attribute)"
        ],
        [
          "Chromosomal translocation"
        ],
        [
          "activate biological process"
        ],
        [
          "Signal Transduction Inhibitor"
        ],
        [
          "*Activity (kind of quantity)"
        ],
        [
          "Similarity"
        ],
        [
          "Consequence of"
        ],
        [
          "Ligands"
        ],
        [
          "classical example"
        ],
        [
          "Family member"
        ],
        [
          "Cytokine Signaling"
        ],
        [
          "regional"
        ],
        [
          "Separate"
        ],
        [
          "T-Cell Leukemia Viruses, Human"
        ],
        [
          "Nuclear Localization Signals"
        ],
        [
          "Providing (action)"
        ],
        [
          "Effectiveness"
        ],
        [
          "Molecule"
        ],
        [
          "Viral"
        ],
        [
          "Induce (action)"
        ],
        [
          "inhibitors"
        ],
        [
          "Protein Domain"
        ],
        [
          "Death Domain"
        ],
        [
          "positive regulation of NF-kappaB transcription factor activity"
        ],
        [
          "NF-kappaB inhibitor"
        ],
        [
          "Inhibitor"
        ],
        [
          "Chemical Association"
        ],
        [
          "Inhibited"
        ],
        [
          "Binding action"
        ],
        [
          "Essential"
        ],
        [
          "Human T-lymphotropic virus 1"
        ],
        [
          "Ability"
        ],
        [
          "Containing (qualifier)"
        ],
        [
          "activation of NF-kappa B"
        ],
        [
          "Mechanism (attribute)"
        ],
        [
          "Binding (Molecular Function)"
        ],
        [
          "Identified"
        ],
        [
          "Presence"
        ],
        [
          "Potential"
        ],
        [
          "Model"
        ],
        [
          "Including (qualifier)"
        ],
        [
          "Control function"
        ],
        [
          "Pre-existing"
        ]
      ],
      "id": "530db83b38c1322806000002",
      "ideal_answer": "In unstimulated cells, NF-kappaB transcription factors are retained in the cytoplasm by inhibitory IkappaB proteins. The preexisting NF-kappa B proteins are retained in the cytoplasm of cells by association with inhibitory ankyrin-motif-containing I kappa B proteins, primarily I kappa B-alpha but also including the precursor proteins p105 (NF-kappa B1) and p100 (NF-kappa B2). According to the classical model, NF-ÎºB is retained in the cytoplasm of resting cells via binding to inhibitory, IÎºB proteins and translocates into the nucleus upon their ligand-induced degradation. The presence of a discrete nuclear import sequence in IkappaB alpha suggests that cytoplasmic sequestration of the NF-kappaB/Rel-IkappaB alpha complex is a consequence of the mutual masking of the NLS within NF-kappaB/Rel proteins and the import sequence within IkappaB alpha. IkappaBalpha is an inhibitory molecule that sequesters NF-kappaB dimers in the cytoplasm of unstimulated cells. The ability of the IkappaB alpha protein to sequester dimeric NF-kappaB/Rel proteins in the cytoplasm provides an effective mechanism for regulating the potent transcriptional activation properties of NF-kappaB/Rel family members. "
    },
    {
      "exact_answer": [
        [
          "Coils (formation)"
        ],
        [
          "Subarachnoid Route of Drug Administration"
        ],
        [
          "Comparison"
        ],
        [
          "Clinical Trials"
        ],
        [
          "Clipping"
        ],
        [
          "Ruptured behavior"
        ],
        [
          "Aneurysm, Ruptured"
        ],
        [
          "Endovascular"
        ],
        [
          "best (quality)"
        ],
        [
          "International"
        ],
        [
          "angiogram"
        ],
        [
          "Aneurysm clipping"
        ],
        [
          "Experimental Result"
        ],
        [
          "Randomization"
        ],
        [
          "Stenting"
        ],
        [
          "Clinical Trials, Randomized"
        ],
        [
          "Intracranial Aneurysm"
        ],
        [
          "Intracranial"
        ],
        [
          "Options"
        ],
        [
          "treatment options"
        ],
        [
          "classical example"
        ],
        [
          "Severe (severity modifier)"
        ],
        [
          "Therapeutic procedure"
        ],
        [
          "Conventional Treatment"
        ],
        [
          "Result"
        ],
        [
          "Patients"
        ],
        [
          "Report (document)"
        ],
        [
          "Clinical"
        ],
        [
          "Make - Instruction Imperative"
        ],
        [
          "Subgroup A Nepoviruses"
        ],
        [
          "Base - General Qualifier"
        ],
        [
          "Journalist"
        ],
        [
          "Barrow Eskimos"
        ],
        [
          "Continuance of life"
        ],
        [
          "Event Qualification - Dependency"
        ],
        [
          "Clip Device Component"
        ],
        [
          "Registries"
        ],
        [
          "Aneurysmal"
        ],
        [
          "Occluded"
        ],
        [
          "Subarachnoid Hemorrhage"
        ],
        [
          "Embolization coil"
        ],
        [
          "Aneurysm"
        ],
        [
          "Cerebral Aneurysm"
        ],
        [
          "Seizures"
        ],
        [
          "Acute hemorrhage"
        ],
        [
          "Treating Physician"
        ],
        [
          "Dental Occlusion"
        ],
        [
          "3+ Score"
        ],
        [
          "Observation - diagnostic procedure"
        ],
        [
          "Clinical Trial [Publication Type]"
        ],
        [
          "Continuous"
        ],
        [
          "Safety Study"
        ],
        [
          "objective (goal)"
        ],
        [
          "Research Design"
        ],
        [
          "Efficacy Study"
        ],
        [
          "Critical"
        ],
        [
          "PROPOSED"
        ],
        [
          "Flow"
        ],
        [
          "per year"
        ],
        [
          "Aim (idea)"
        ],
        [
          "acute"
        ],
        [
          "care activity"
        ],
        [
          "Functional"
        ],
        [
          "Including (qualifier)"
        ],
        [
          "Data"
        ],
        [
          "Study"
        ]
      ],
      "id": "530e0d6e5937551c09000001",
      "ideal_answer": "The objective of this ongoing randomized trial is to compare the safety and efficacy of microsurgical clip occlusion and endovascular coil embolization for the treatment of acutely ruptured cerebral aneurysms and to compare functional outcomes based on clinical and angiographic data. We report the design of the FIAT study, a clinical care trial aiming to compare angiographic and clinical outcomes following treatment with a Flow-Diverter or with the best conventional treatment option. The effect of clipping and coiling in acute severe subarachnoid hemorrhage after international subarachnoid aneurysmal trial (ISAT) results. Patients will be proposed randomization to either FD stenting or best conventional treatment option (observation, coiling, stenting, or clipping) as determined by the treating physician. International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion. International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised trial. A critical appraisal of the ISAT of microsurgical clipping versus coiling is used for comparison of our results. The authors report the 3-year results of the Barrow Ruptured Aneurysm Trial (BRAT). "
    },
    {
      "exact_answer": "yes",
      "id": "530e131b5937551c09000002",
      "ideal_answer": "Statins have been shown in two recent small phase I/II trials to be associated with a marked reduction in clinical and transcranial Doppler (TCD) evidence of vasospasm after aneurysmal subarachnoid haemorrhage (SAH). Recently, two randomized controlled phase II studies showed that acute initiation of statin treatment directly after aneurysmal subarachnoid hemorrhage (SAH) decreases the incidence of radiologic vasospasm and clinical signs of delayed cerebral ischemia (DCI), and even reduces mortality. Statins did not result in reduced TCD velocities, clinical or angiographic vasospasm, or improvements in global outcome at the time of hospital discharge. A recent meta-analysis investigating the efficacy of statin treatment in patients with aneurysmal subarachnoid hemorrhage reported a reduced incidence of vasospasm, delayed cerebral ischemia, and mortality in statin-treated patients. There were no differences in the incidence of symptomatic vasospasm (25.3 vs 30.5%; p \u003d 0.277), in-hospital mortality rate (18 vs 15%; p \u003d 0.468), length of hospitalization (21 +/- 15 vs 19 +/- 12 days; p \u003d 0.281), or poor outcome at discharge (Glasgow Outcome Scale Scores 1-2: 21.7 vs 18.2%; p \u003d 0.416) between the simvastatin and nonstatin cohorts. "
    },
    {
      "id": "530e1b205937551c09000003",
      "ideal_answer": "There was no significant association between glioma and alcohol consumption, smoking and mobile phone use. Regular cell phone use was not associated with an increased risk of neuroma (OR\u003d0,92; 95% confidence interval\u003d[0.53-1.59]),. Decreased survival of glioma cases with long-term and high cumulative use of wireless phones was found. Although these results are not statistically significant, a general tendency was observed for an increased risk of glioma among the heaviest users: long-term users, heavy users, users with the largest numbers of telephones. No significant increased risk for glioma, meningioma or neuroma was observed among cell phone users participating in Interphone. Our results, suggesting the possibility of an increased risk among the heaviest users, therefore need to be verified in the international INTERPHONE analyses. Case reports of brain tumours in users initiated this case-control study on brain tumours and use of cellular telephones. After 1983 and during the period with increasing prevalence of mobile phone users, the incidence has remained relatively stable for both men and women. The meta-analysis gave for glioma in the most exposed part of the brain, the temporal lobe, odds ratio (OR)\u003d1.71,. "
    },
    {
      "id": "530e42bf5937551c09000005",
      "ideal_answer": "There was a significant increase in neuronal cell number and improvement in cerebral dysfunction after TBI in the edaravone group compared with the saline group (P \u003c 0.01). Numbers of 8-OHdG-, 4-HNE-, and ssDNA-positive cells around the damaged area after TBI were significantly decreased in the edaravone group compared with the saline group (P \u003c 0.01). "
    },
    {
      "exact_answer": "yes",
      "id": "530e42e65937551c09000007",
      "ideal_answer": "A total of 37 patients were treated, and treatment was well tolerated: grade 3, 4 nonhematologic toxicity occurred in 30% of patients and consisted mainly of fatigue (14%) and neuropathy (5%); grade 3, 4 hematologic toxicity occurred in 37% of patients and consisted of thrombocytopenia (30%), lymphopenia (4%), and neutropenia (4%). Grade 3/4 toxicities included leukopenia (n \u003d 1), lymphopenia (n \u003d 2), thrombocytopenia (n \u003d 1), ALT elevation (n \u003d 3), AST elevation (n \u003d 1), CNS hemorrhage (n \u003d 1), fatigue (n \u003d 1), and thrombotic/embolic events (n \u003d 3); 8 patients required dose reduction. Bevacizumab-related toxicity included fatigue (16 patients; 4 grade 3), leukopenia (9; 1 grade 3), anemia (5; 0 grade 3), hypertension (7; 1 grade 3), deep vein thrombosis (4; 1 grade 3) and wound dehiscence (2; 1 grade 3). One patient treated with temozolomide plus isotretinoin plus thalidomide had dose-limiting grade 3 fatigue and rash, and 1 patient receiving all 4 agents had dose-limiting grade 4 neutropenia. The most common atrasentan-related toxicities were grade 1 or 2 rhinitis, fatigue, and edema. "
    },
    {
      "exact_answer": "yes",
      "id": "530f685c329f5fcf1e000002",
      "ideal_answer": "Varied persistent life cycles of Borna disease virus in a human oligodendroglioma cell line. Borna disease virus (BDV), a nonsegmented, negative-strand RNA virus, infects a wide variety of mammalian species and readily establishes a long-lasting, persistent infection in brain cells. To investigate the biological characteristics of field isolates of Borna disease virus (BDV), as well as to understand BDV infections outside endemic countries, we isolated the virus from brain samples of a heifer with Borna disease in Japan. Taken together, the present data are the first in vitro evidence that persistent BDV infection of neurons and astrocytes rather than direct exposure to the virus or dying neurons is critical for activating microglia. In addition, compared to uninfected mixed cultures, activation of microglia in BDV-infected mixed cultures was associated with a significantly greater lipopolysaccharide-induced release of tumor necrosis factor alpha, interleukin 1beta, and interleukin 10. In contrast, in the BDV-infected primary mixed cultures, we observed proliferation of microglia cells that acquired the round morphology and expressed major histocompatibility complex molecules of classes I and II. The neonatally infected rat with BDV exhibits developmental-neuromorphological abnormalities, neuronal cytolysis, and multiple behavioral and physiological alterations. "
    },
    {
      "id": "530f72fd329f5fcf1e000003",
      "ideal_answer": "Data suggest that patients with primary or metastatic brain tumours often have a high symptom burden and unmet needs for palliative care, and symptoms are hard to diagnose; patients suffer often and early from cognitive impairment but are rarely appropriately prepared concerning end-of-life wishes. Caregivers try to react to the illness of their relatives by mobilizing their physical reaction and growing their self-esteem, but they live with a clinically significant impairment of their quality of life, and experience a deep level of anxiety and depression. Although previous research has documented the stress, depression, anxiety, and burden associated with caregiving, when these conditions occur is not known. High depressive symptoms were associated with high trajectories for both anxiety and burden, lower caregivers age, income, and social support, and lower care recipient functioning. Studies suggest rates of depression and anxiety up to 48% in patients and up to 40% in caregivers, with many unmet needs and dissatisfaction with health care provider communication and information. Therefore, it is necessary to monitor and treat, if necessary, caregivers\u0027 anxious or depressive symptomatology that impacts their quality of life, making them more helpless, frustrated and less able to handle the situation of disease and caregiving situation. "
    },
    {
      "exact_answer": "yes",
      "id": "530f7cdde3eabad021000001",
      "ideal_answer": "We here provide a systematic overview of the therapeutic effects of amantadine, apomorphine and zolpidem in patients recovering from coma. Patients treated with PK-Merz exhibited the more significant restoration of consciousness and better dynamics (regress) of neurological deficit with the most intensive restoration of neurological deficit in the first day that allows to recommend the use of amantadine sulfate in the first hours of ischemic stroke and for the prevention of reperfusion damage in recanalisation therapy of ischemic stroke. Evidence from clinical trials using these commonly prescribed pharmacological agents suggests positive changes in the neurological status in patients, leading sometimes to dramatic improvements. Sporadic cases of dramatic recovery from DOC after the administration of various pharmacological agents, such as baclofen, zolpidem and amantadine, have been recently supported by intriguing scientific observations. Sporadic cases of recovery from a DOC have been reported after the administration of various pharmacological agents (baclofen, zolpidem, amantadine etc.). During the 4-week treatment period, recovery was significantly faster in the amantadine group than in the placebo group, as measured by the DRS score (difference in slope, 0.24 points per week; P\u003d0.007), indicating a benefit with respect to the primary outcome measure. "
    },
    {
      "id": "530f7d7fe3eabad021000002",
      "ideal_answer": "The neuropharmacological activities of TRH include an interesting arousal effect and an analeptic action on generalized depression of the CNS whether this depression is of natural origin, such as hibernation, or induced pharmacologically (barbiturates, ethanol) or of a traumatic origin (coma). This analeptic action is attributable to stimulation of cholinergic neurons in the septo-hippocampal area and to the presence of terminals containing TRH in the lateral septum and TRH receptors concentrated especially in the medial septum and diagonal band of Broca. Taken together with the finding that NS-3 did not bind to dopamine, adrenaline or muscarine receptors, it is suggested that NS-3 may restore the disturbance of consciousness by activating the brain dopamine, noradrenaline and acetylcholine neurons without stimulating these receptors directly. NS-3 shortened the latent periods to the recovery of the righting reflex (0.03-0.1 mg/kg, i.v.) and spontaneous motor activity (0.1 mg/kg, i.v.) following the head concussion. [Montirelin hydrate (NS-3), a TRH analog, improved the disturbance of consciousness caused by head concussion and pentobarbital in mice]. Since S. Konno and H. Wakui published cases of myelinolysis who dramatically improved after TRH treatment, the patient was given 0.6 mg i.v daily of TRH for six weeks. "
    },
    {
      "exact_answer": [
        [
          "Moyamoya Disease"
        ],
        [
          "Moyamoya disease 1"
        ],
        [
          "17q25"
        ],
        [
          "Familial"
        ],
        [
          "Chromosomes"
        ],
        [
          "Locus"
        ],
        [
          "genetic linkage"
        ],
        [
          "Autosomal dominant inheritance"
        ],
        [
          "Chromosome 12, 12p trisomy"
        ],
        [
          "MMD gene"
        ],
        [
          "Expressed Sequence Tags"
        ],
        [
          "Haplotypes"
        ],
        [
          "17q25.3"
        ],
        [
          "Maximum Value Derivation Technique"
        ],
        [
          "suggestion"
        ],
        [
          "3p24"
        ],
        [
          "Geographic Locations"
        ],
        [
          "Chromosomes, Human, Pair 3"
        ],
        [
          "17q11.2"
        ],
        [
          "Family"
        ],
        [
          "Japanese race"
        ],
        [
          "Genes"
        ],
        [
          "Genes, vif"
        ],
        [
          "Publications"
        ],
        [
          "Analysis of substances"
        ],
        [
          "Encode (action)"
        ],
        [
          "genetic pedigree"
        ],
        [
          "Neurofibromatosis 1"
        ],
        [
          "Lod Score"
        ],
        [
          "Negation"
        ],
        [
          "MTCP1 gene"
        ],
        [
          "Chromosomes, Human, Pair 2"
        ],
        [
          "Pericentric inversion"
        ],
        [
          "S100 calcium binding protein A10"
        ],
        [
          "Proteins"
        ],
        [
          "Links List"
        ],
        [
          "Evidence of"
        ],
        [
          "Relationships"
        ],
        [
          "Pathogenesis"
        ],
        [
          "Short Tandem Repeat"
        ],
        [
          "17p11.2"
        ],
        [
          "CD79A gene"
        ],
        [
          "Disease Screening"
        ],
        [
          "Singular"
        ],
        [
          "Mus"
        ],
        [
          "Span - parameter"
        ],
        [
          "PersonNameUse - assigned"
        ],
        [
          "Expression procedure"
        ],
        [
          "Performed"
        ],
        [
          "Patients"
        ],
        [
          "Case unit dose"
        ],
        [
          "Lesion"
        ],
        [
          "Trunk of lateral basal segmental artery"
        ],
        [
          "Penetrance"
        ],
        [
          "Offspring"
        ],
        [
          "X- linked recessive"
        ],
        [
          "Disease"
        ],
        [
          "Disease susceptibility"
        ],
        [
          "TECR gene"
        ],
        [
          "Study"
        ],
        [
          "Evaluation procedure"
        ],
        [
          "Abnormally low (qualifier value)"
        ],
        [
          "Characteristics"
        ],
        [
          "Chromosomes, Human, Pair 21"
        ],
        [
          "Sequence Analysis, DNA"
        ],
        [
          "Hybrid Cells"
        ],
        [
          "Approximate"
        ],
        [
          "Chromosome Deletion"
        ],
        [
          "genetic element"
        ],
        [
          "Down Syndrome"
        ],
        [
          "Major"
        ],
        [
          "Report (document)"
        ],
        [
          "regional"
        ],
        [
          "Revealed"
        ],
        [
          "NFI Transcription Factors"
        ],
        [
          "Region of chromosome"
        ],
        [
          "Data"
        ],
        [
          "17q"
        ],
        [
          "Involvement with"
        ],
        [
          "Molecular"
        ],
        [
          "Single Nucleotide Polymorphism"
        ],
        [
          "Classification"
        ],
        [
          "CMC4 gene"
        ],
        [
          "2p13.1"
        ],
        [
          "Annotated - DataType"
        ],
        [
          "Karyotype determination procedure"
        ],
        [
          "TRICHOHEPATOENTERIC SYNDROME"
        ],
        [
          "tissue inhibitor of metalloproteinase 4"
        ],
        [
          "PTGES3 gene"
        ],
        [
          "BRCC3 gene"
        ],
        [
          "6p25.3"
        ],
        [
          "Congenital Hemidysplasia with Ichthyosiform Erythroderma and Limb Defects"
        ],
        [
          "Hyperlink"
        ],
        [
          "Relationship by association"
        ],
        [
          "RAI1 gene"
        ],
        [
          "12p12"
        ],
        [
          "17q11"
        ],
        [
          "ACTA2 gene"
        ],
        [
          "Chromosome 6 Short Arm"
        ],
        [
          "Chromosome 3 Short Arm"
        ]
      ],
      "id": "5312280ce3eabad02100000a",
      "ideal_answer": "Here, we report on three unrelated families affected with an X-linked moyamoya syndrome characterized by the association of a moyamoya angiopathy, short stature, and a stereotyped facial dysmorphism. Haplotype analysis revealed segregation of a disease haplotype in all families but one, and informative crossovers enabled mapping of the MMD locus to a 3.5-Mb region between D17S1806 and the telomere of 17q, encompassing 94 annotated genes. Considering the function, we selected nine genes as candidates from a total of 65 genes identified in the 9-cM region of D17S785-D17S836 in chromosome 17q25, and performed sequence analysis on the DNA samples obtained from a pedigree of familial moyamoya disease, which showed a complete linkage to the region by a haplotype analysis. Investigations included neuroimaging, cardiologic and ophthalmologic evaluation, hormonal testing, hemoglobin electrophoresis, chromosomal karyotyping, muscle biopsy for morphology, immunohistochemistry and enzyme assays, mtDNA mutation screening, and haplotype analysis of 2 loci previously linked to moyamoya, on chromosomes 10 (ACTA2) and 17. In the present study, we searched for loci linked to the disease in 12 Japanese families using 428 microsatellite markers and found significant evidence for linkage to 8q23 [maximum LOD score (MLS) of 3.6] and suggestive evidence for linkage to 12p12 (MLS\u003d2.3). "
    },
    {
      "exact_answer": [
        [
          "Sirolimus"
        ],
        [
          "Molecular Target"
        ],
        [
          "Tor"
        ],
        [
          "MTOR gene"
        ]
      ],
      "id": "53124bdae3eabad02100000b",
      "ideal_answer": "molecular target of rapamycin (mTOR. molecular target of rapamycin (mTOR). the molecular Target Of Rapamycin, TOR. molecular target of rapamycin (mTOR),. "
    },
    {
      "exact_answer": "yes",
      "id": "53124e84e3eabad02100000c",
      "ideal_answer": "endostatin (antiangiogenic factor. antiangiogenic factors include thrombospondin-1, angiostatin, and endostatin. the antiangiogenic factors, cystatin C and endostatin, were measured. Thrombospondin-1 (Tsp1), endostatin, and tumstatin are extracellular matrix-associated proteins that inhibit angiogenesis. Circulating and cellular proangiogenic and antiangiogenic proteins such as vascular endothelial growth factor (VEGF) and endostatin contribute to the local angiogenic balance. antiangiogenic factors (pigment epithelium-derived factor [PEDF]; angiostatin; restin; and endostatin. Some of these are synthesized by specific cells in different organs, and others are created by extracellular proteolytic cleavage of plasma-derived or extracellular matrix-localized proteins. Endostatin, a peptide derived from proteolysis of collagen XVIII, is an endogenous inhibitor of angiogenesis and tumor growth. Endostatin is the first endogenous angiogenesis inhibitor to enter clinical trials. In this review, we focus on angiostatin, endostatin,. Angiostatin and endostatin are two powerful inhibitors of angiogenesis in experimental models. human endostatin (rh-endostatin), a potential antiangiogenic agent,. A number of endogenous inhibitors of angiogenesis are found in the body. Angiostatin and endostatin are endogenous inhibitors of angiogenesis with anticancer effects. accumulation of endostatin and Abeta peptides which have been shown to be antiangiogenic. antioangiogenic factors such as pigment epithelial derived factor (PEDF), angiostatin, endostatin. "
    },
    {
      "id": "5312f0f0e3eabad02100000d",
      "ideal_answer": "DNA topoisomerase II inhibitors are a major class of cancer chemotherapeutics, which are thought to eliminate cancer cells by inducing DNA double-strand breaks. We show that anthracyclines promote histone eviction irrespective of their ability to induce DNA double-strand breaks. Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. The histone variant H2AX, which is a key component of the DNA damage response, is also evicted by anthracyclines, and H2AX eviction is associated with attenuated DNA repair. We define a novel mechanism of action of anthracycline anticancer drugs doxorubicin and daunorubicin on chromatin biology, with important consequences for DNA damage responses, epigenetics, transcription. The results we have obtained clearly indicate that topoisomerase II poisons induce cell death by apoptosis. Histone eviction deregulates the transcriptome in cancer cells. Induction of apoptotic cell death by DNA topoisomerase II inhibitors. "
    },
    {
      "exact_answer": [
        [
          "Bertolotti\u0027s syndrome"
        ],
        [
          "Transitional vertebra"
        ],
        [
          "Marketing basis - Transitional"
        ],
        [
          "Bone structure of sacrum"
        ],
        [
          "Entire transverse process of vertebra"
        ]
      ],
      "id": "5313058de3eabad02100000e",
      "ideal_answer": "We surgically treated 16 patients with Bertolotti\u0027s syndrome (chronic, persistent low back pain and radiographically diagnosed transitional lumbar vertebra). Bertolotti\u0027s syndrome is a spine disorder characterized by the occurrence of a congenital lumbar transverse mega-apophysis in a transitional vertebral body that usually articulates with the sacrum or the iliac bone. Bertolotti\u0027s syndrome (BS), a form of lumbago in lumbosacral transitional vertebrae, is an important cause of low back pain in young patients. Bertolotti\u0027s syndrome is characterised by anomalous enlargement of the transverse process(es) of the most caudal lumbar vertebra which may articulate or fuse with the sacrum or ilium and cause isolated L4/5 disc disease. We suggest that the intractable sciatica in this syndrome could arise from impingement of the nerve root extraforaminally by compression caused by the enlarged transverse process. Radiographic investigation revealed an anomalous enlargement of the left transverse process of the fifth lumbar vertebra forming a pseudarthrosis with the infrajacent ala of the sacrum. Patients with Bertolotti\u0027s syndrome have characteristic lumbosacral anomalies and often have severe sciatica. Radiofrequency sensory ablation as a treatment for symptomatic unilateral lumbosacral junction pseudarticulation (Bertolotti\u0027s syndrome): a case report. "
    },
    {
      "exact_answer": [
        [
          "Non-Sustained Ventricular Tachycardia"
        ],
        [
          "Holter Electrocardiography"
        ],
        [
          "Nonsustained ventricular tachycardia"
        ],
        [
          "Left Ventricular Hypertrophy"
        ],
        [
          "risk factors"
        ],
        [
          "Risk"
        ],
        [
          "Patients"
        ],
        [
          "Cardiac - anatomy qualifier"
        ],
        [
          "Health maintenance"
        ],
        [
          "Negation"
        ],
        [
          "Hypertrophic Cardiomyopathy"
        ],
        [
          "Intervention regimes"
        ],
        [
          "Extreme"
        ],
        [
          "Syncope"
        ],
        [
          "Gadolinium"
        ],
        [
          "Appropriate"
        ],
        [
          "Hydrocortisone"
        ],
        [
          "Family history of sudden death"
        ],
        [
          "Sudden Cardiac Death"
        ],
        [
          "Young"
        ],
        [
          "Conclusion"
        ],
        [
          "Structure of superior cerebellar artery"
        ],
        [
          "j waves"
        ],
        [
          "Singular"
        ],
        [
          "Associated with"
        ],
        [
          "predictive"
        ],
        [
          "Stratification"
        ],
        [
          "Increase"
        ],
        [
          "Primary Prevention"
        ],
        [
          "Positive Predictive Value of Diagnostic Test"
        ],
        [
          "Conclude Resin"
        ],
        [
          "Including (qualifier)"
        ],
        [
          "Preposition For"
        ],
        [
          "Personal appearance"
        ],
        [
          "Sudden Death Adverse Event Not Associated with More Specific CTCAE Term"
        ],
        [
          "Arabic numeral 65"
        ],
        [
          "MYH7 gene"
        ],
        [
          "Integer +5"
        ],
        [
          "Integer +2"
        ],
        [
          "Cameroon"
        ],
        [
          "Implantable defibrillator"
        ],
        [
          "Duplicate"
        ],
        [
          "Neurally-mediated syncope"
        ],
        [
          "Upright"
        ],
        [
          "Hypotensive"
        ],
        [
          "shared attribute"
        ],
        [
          "Add - instruction imperative"
        ],
        [
          "Increment"
        ],
        [
          "Independence"
        ],
        [
          "Cardiac Arrhythmia"
        ],
        [
          "Refractive surgery enhancement"
        ],
        [
          "RF"
        ],
        [
          "Associate - relationship"
        ],
        [
          "Episodes of ventricular tachycardia"
        ],
        [
          "Sustained ventricular tachycardia"
        ],
        [
          "SURVIVE"
        ],
        [
          "Act Code - risk factors"
        ],
        [
          "Ventricular Fibrillation"
        ],
        [
          "Prior Medication Usage"
        ],
        [
          "combination of objects"
        ],
        [
          "Mutation Abnormality"
        ],
        [
          "Immature"
        ],
        [
          "Sudden death"
        ],
        [
          "History of Sudden Cardiac Death"
        ],
        [
          "Sudden onset (attribute)"
        ],
        [
          "Sudden Cardiac Arrest"
        ],
        [
          "Inadequate (qualifier)"
        ],
        [
          "Massive"
        ],
        [
          "Predictor"
        ],
        [
          "Numerical value"
        ],
        [
          "ST segment"
        ],
        [
          "Mutation Carrier"
        ],
        [
          "Cardiac Arrest"
        ],
        [
          "Patient Discharge"
        ],
        [
          "Discharge, body substance"
        ],
        [
          "Myocardial fibrosis"
        ],
        [
          "Fibrosis"
        ],
        [
          "Scientific Study"
        ],
        [
          "Devices"
        ],
        [
          "Disease Predictive Factor"
        ],
        [
          "Negative Predictive Value of Diagnostic Test"
        ],
        [
          "Predictive Value"
        ],
        [
          "Sustained"
        ],
        [
          "Causing"
        ],
        [
          "consider"
        ],
        [
          "Cohort"
        ],
        [
          "Magnitude"
        ],
        [
          "Documented"
        ],
        [
          "Support, device"
        ],
        [
          "Replacement"
        ],
        [
          "Appearance"
        ],
        [
          "Observation Method - Magnetic resonance"
        ],
        [
          "Exercise Pain Management"
        ],
        [
          "Exercise"
        ],
        [
          "Exercise stress test"
        ],
        [
          "Young Child [Disease/Finding]"
        ],
        [
          "Numbers"
        ],
        [
          "Variable (uniformity)"
        ],
        [
          "Risk Marker"
        ],
        [
          "Experimental Finding"
        ]
      ],
      "id": "531375a6e3eabad021000011",
      "ideal_answer": "Cardiac magnetic resonance (CMR) is used in the diagnosis and risk stratification of hypertrophic cardiomyopathy (HCM) and can detect myocardial replacement fibrosis (anindependent predictor of adverse cardiac outcomes) using late gadolinium enhancement (LGE). A number of risk markers are used to assess the magnitude of risk, including family history of premature sudden death; extreme left ventricular (LV) hypertrophy (\u003e 30 mm) in young patients; nonsustained ventricular tachycardia on Holter electrocardiographic recording; unexplained (not neurally mediated) syncope, particularly in young patients; and blood pressure decrease or inadequate increase during upright exercise. The following risk factors were analyzed: 1) previous cardiac arrest or sustained ventricular tachycardia; 2) family history of sudden cardiac death; 3) high-risk genetic mutations; 4) syncope; 5) non-sustained ventricular tachycardia; 6) hypotensive response to exercise; and 7) marked left ventricular hypertrophy. Measured risk factors for sudden death included family history of sudden death, massive left ventricular hypertrophy, nonsustained ventricular tachycardia on Holter monitoring, and unexplained prior syncope. In conclusion, our cohort study results do not support LVOTO as an independent risk factor for SD in patients with hypertrophic cardiomyopathy. "
    },
    {
      "exact_answer": [
        [
          "PLN gene"
        ],
        [
          "Gram per Deciliter"
        ],
        [
          "Mutation"
        ],
        [
          "Health maintenance"
        ],
        [
          "Apical"
        ],
        [
          "Protein Truncation Abnormality"
        ],
        [
          "Family"
        ],
        [
          "Promoter"
        ],
        [
          "Cardiomyopathy, Hypertrophic, Familial"
        ],
        [
          "Hypertrophic Cardiomyopathy"
        ],
        [
          "Transcription Initiation Site"
        ],
        [
          "Promoter Regions, Genetic"
        ],
        [
          "Nucleotides"
        ],
        [
          "Identified"
        ],
        [
          "Patients"
        ],
        [
          "CALR3 gene"
        ],
        [
          "Suspected qualifier"
        ],
        [
          "Rattus norvegicus"
        ],
        [
          "Cardiomyopathies"
        ],
        [
          "Heterozygote"
        ],
        [
          "Proband (person)"
        ],
        [
          "Singular"
        ],
        [
          "Laboratory Order Panels"
        ],
        [
          "Mutation, Nonsense"
        ],
        [
          "suggestion"
        ],
        [
          "Open Reading Frames"
        ],
        [
          "Generic Role"
        ],
        [
          "Neonatal Clinical Nurse Specialist"
        ],
        [
          "Action Code - No change"
        ],
        [
          "Mutation Abnormality"
        ],
        [
          "Genetic Carriers"
        ],
        [
          "Upstream"
        ],
        [
          "Exogenous Factors"
        ],
        [
          "Benign"
        ],
        [
          "Transition Mutation"
        ],
        [
          "Case unit dose"
        ],
        [
          "Novel Mutation"
        ],
        [
          "Gene Mutation"
        ],
        [
          "development aspects"
        ],
        [
          "Late"
        ],
        [
          "Involvement with"
        ],
        [
          "Onset of (contextual qualifier)"
        ],
        [
          "Family History Domain"
        ],
        [
          "Genetic screening method"
        ],
        [
          "Myocytes, Cardiac"
        ],
        [
          "Does play"
        ],
        [
          "incidence of cases"
        ],
        [
          "Well adult"
        ],
        [
          "Negative"
        ],
        [
          "Genetic"
        ],
        [
          "Active"
        ],
        [
          "Formation"
        ],
        [
          "Current (present time)"
        ],
        [
          "Presence"
        ],
        [
          "Increased"
        ],
        [
          "Associated with"
        ]
      ],
      "id": "531376c8e3eabad021000012",
      "ideal_answer": "The PLN -42 C\u003eG mutation is associated with a benign form of apical hypertrophic cardiomyopathy in this family, though the presence of a healthy adult carrier suggests that other genetic and environmental factors could be involved. The PLN -42 C\u003eG mutation was found in one patient with late onset familial apical hypertrophic cardiomyopathy. one L39X nonsense mutation was identified in 1 of 1,064 HCM proband cases with a family history of HCM, previously found to be negative for the current HCM genetic test panel. We found a heterozygous single nucleotide transition from A to G at -77-bp upstream of the transcription start site in the phospholamban promoter region of one patient with familial hypertrophic cardiomyopathy. Using neonatal rat cardiomyocytes, the mutation, -77A--\u003eG, increased the phospholamban promoter activity. No nucleotide change in the phospholamban coding region was found in 99 patients with cardiomyopathy. This mutation cosegregated with incidence of HCM in a multigenerational family. We suspect that the mutation plays an important role in the development of hypertrophic cardiomyopathy. Two novel mutations in the CALR3 gene were identified (Lys82Arg, Arg73Gln) and one truncation mutation in the PLN gene (Leu39Ter). "
    },
    {
      "exact_answer": "yes",
      "id": "5313b049e3eabad021000013",
      "ideal_answer": "While prostate cancers that express high levels of HER-2 are resistant to the killing effects of trastuzumab, they can be targeted for selective gene expression and destruction by lentiviruses with envelope proteins engineered to bind to this therapeutic antibody. we found that although prostate cancers that express high levels of HER-2 are resistant to the killing effects of trastuzumab, they can be targeted for selective gene expression and destruction by viruses with envelope proteins engineered to bind this antibody. The clinical interpretation of c-erbB-2 abnormalities should reflect the complexity of c-erbB-2 mediated regulatory pathway and explain why tumours with overexpression/amplification of c-erbB-2 very often do not respond to therapy using Herceptin. a targeted drug delivery system based on cationic emulsion covalently linked to anti-HER2 monoclonal antibody (Herceptin), in a well-established in vivo pharmacologic model of metastatic prostate cancer that overexpresses the HER2 receptor. We conclude that Her2/neu expression in the peripheral blood mononuclear cell fraction of prostate cancer patients is frequent and therefore this assay may potentially be useful to detect the presence of micrometastatic disease in men with prostate cancer and for monitoring patients enrolled in trastuzumab-based therapeutic protocols. "
    },
    {
      "exact_answer": [
        [
          "Malaria"
        ],
        [
          "Enzymes"
        ],
        [
          "Enhance (action)"
        ],
        [
          "Erythrocytes"
        ],
        [
          "Infected"
        ]
      ],
      "id": "53147b52e3eabad021000015",
      "ideal_answer": "G6PD enzyme activity was directly related to susceptibility to malaria in the Brazilian Amazon, where P. vivax predominates. A central position of the PPP for malaria parasites is supported by the fact that human G6PD deficiency protects to a certain degree from malaria infections. This may inhibit parasite growth, enhance uptake of infected RBCs by spleen macrophages, and/or cause less cytoadherence of the infected cells to capillary endothelium. The beneficial effect of thalassemia minor, sickle-cell trait, and glucose-6-phosphate dehydrogenase deficiency on survival of malaria infection may well be due to the shared feature of enhanced oxidative stress. In conclusion, genetic variants that confer resistance to malaria are associated with RBC traits in African-Americans. Severe G6PDd was associated with considerable higher risk of malaria-related transfusions. G6PD deficiency has been positively selected by malaria, and recent knowledge seems to show that it also confers an advantage against the development of cancer, reduces the risk of coronary diseases and has a beneficial effect in terms of longevity. "
    },
    {
      "exact_answer": [
        [
          "TNNC1 gene"
        ],
        [
          "Hypertrophic Cardiomyopathy"
        ],
        [
          "Mutation Abnormality"
        ],
        [
          "Calcium"
        ],
        [
          "Troponin C"
        ],
        [
          "Cardiac troponin I"
        ],
        [
          "Property (attribute)"
        ],
        [
          "Cyclic AMP-Dependent Protein Kinases"
        ],
        [
          "Mutation"
        ],
        [
          "Glutamine"
        ],
        [
          "Integer +2"
        ],
        [
          "Leucine"
        ],
        [
          "Increased Sensitivy"
        ],
        [
          "Health maintenance"
        ],
        [
          "Actin myofilament"
        ],
        [
          "Troponin I"
        ],
        [
          "Adenosinetriphosphatase"
        ],
        [
          "Troponin"
        ],
        [
          "Positioning Attribute"
        ],
        [
          "Site of"
        ],
        [
          "Novel Mutation"
        ],
        [
          "Sudden Cardiac Death"
        ],
        [
          "Cardiomyopathy, Hypertrophic, Familial"
        ],
        [
          "Investigates"
        ],
        [
          "Ventricular Fibrillation"
        ],
        [
          "Links List"
        ],
        [
          "Report (document)"
        ],
        [
          "Calcium Binding"
        ],
        [
          "Bed Status - Isolated"
        ],
        [
          "Force"
        ],
        [
          "Phosphorylation"
        ],
        [
          "Relationships"
        ],
        [
          "Changing"
        ],
        [
          "Associated with"
        ],
        [
          "Domain (area of knowledge)"
        ],
        [
          "Mutant"
        ],
        [
          "Dependent - ability"
        ],
        [
          "pathogenic aspects"
        ],
        [
          "Myocytes, Cardiac"
        ],
        [
          "Superkingdom (taxonomic category)"
        ],
        [
          "Cardiac - anatomy qualifier"
        ],
        [
          "Genes, vif"
        ],
        [
          "literary novel"
        ],
        [
          "aborted - QueryStatusCode"
        ],
        [
          "Proband (person)"
        ],
        [
          "Patients"
        ],
        [
          "Frameshift Mutation function"
        ],
        [
          "troponin C binding"
        ],
        [
          "Type - attribute"
        ],
        [
          "Pediatric discipline"
        ],
        [
          "Missense Mutation"
        ],
        [
          "P prime"
        ],
        [
          "Infrequent"
        ],
        [
          "Firstly"
        ],
        [
          "Open Reading Frames"
        ],
        [
          "Non-functional"
        ],
        [
          "Episode of"
        ],
        [
          "Kind of quantity - Equilibrium"
        ],
        [
          "De novo mutation"
        ],
        [
          "Subtype (attribute)"
        ],
        [
          "Summary (document)"
        ],
        [
          "Reporting"
        ],
        [
          "Unrelated to Intervention"
        ],
        [
          "Molecular Conformation"
        ],
        [
          "Muscle Contraction"
        ],
        [
          "Closed"
        ],
        [
          "Signal Transduction"
        ],
        [
          "On (qualifier value)"
        ],
        [
          "Regulator"
        ],
        [
          "Analysis of substances"
        ],
        [
          "Causing"
        ],
        [
          "Percent normal"
        ],
        [
          "Percent inhibition"
        ],
        [
          "2+ Score"
        ],
        [
          "Comprehensive"
        ],
        [
          "Dietary Lead"
        ],
        [
          "Death Related to Adverse Event"
        ],
        [
          "exchange"
        ],
        [
          "Characterization"
        ],
        [
          "encoding mental process"
        ],
        [
          "Enhance (action)"
        ],
        [
          "Preparation"
        ],
        [
          "Numerous"
        ],
        [
          "Dynamic"
        ],
        [
          "Length of Trial"
        ],
        [
          "Splice-Site Mutation"
        ],
        [
          "Open"
        ],
        [
          "objective (goal)"
        ],
        [
          "Point A"
        ],
        [
          "Skin"
        ],
        [
          "Male Gender, Self Report"
        ],
        [
          "Activation action"
        ],
        [
          "Binding action"
        ],
        [
          "Muscle Cells"
        ],
        [
          "Evaluation"
        ],
        [
          "Assessed"
        ],
        [
          "per year"
        ],
        [
          "Characteristics"
        ],
        [
          "Functional Relationship"
        ],
        [
          "Before values"
        ]
      ],
      "id": "5314a7a4dae131f847000003",
      "ideal_answer": "Familial hypertrophic cardiomyopathy related cardiac troponin C L29Q mutation alters length-dependent activation and functional effects of phosphomimetic troponin I*. The Ca(2+) binding properties of the FHC-associated cardiac troponin C (cTnC) mutation L29Q were examined in isolated cTnC, troponin complexes, reconstituted thin filament preparations, and skinned cardiomyocytes. Effects of calcium binding and the hypertrophic cardiomyopathy A8V mutation on the dynamic equilibrium between closed and open conformations of the regulatory N-domain of isolated cardiac troponin C. The objective of this work was to investigate the effect of hypertrophic cardiomyopathy-linked A8V and E134D mutations in cardiac troponin C (cTnC) on the response of reconstituted thin filaments to calcium upon phosphorylation of cardiac troponin I (cTnI) by protein kinase A. This mutation leads to a leucine-glutamine exchange at position 29 in the nonfunctional calcium-binding site of cTnC. Here, we report clinical and functional characterization of a novel TNNC1 mutation, A31S, identified in a pediatric HCM proband with multiple episodes of ventricular fibrillation and aborted sudden cardiac death. We report the first frameshift mutation (c.363dupG or p.Gln122AlafsX30) in Troponin C causing hypertrophic cardiomyopathy (and sudden cardiac death) in a 19-year-old male, and have demonstrated that the mutation segregates with hypertrophic cardiomyopathy within the family. "
    },
    {
      "id": "5318813ab166e2b806000016",
      "ideal_answer": "ropionic acidemia (PA, MIM 232000 and 232050) is caused by a deficiency of mitochondrial biotin-dependent propionyl-CoA carboxylase (PCC, EC 6.4.1.3),. ropionic acidemia (PA) is a recessive disorder caused by a deficiency of propionyl-CoA carboxylase (PCC), a dodecameric enzyme composed of two different proteins alpha-PCC and beta-PC. propionic acidemia (PA) can result from mutations in either of the genes PCCA or PCCB, which encode the alpha and beta subunits, respectively, of the mitochondrial enzyme propionyl CoA-carboxylase. Propionic acidemia is a common organic acidemia, caused by deficiency of propionyl-CoA carboxylase (PCC), which catalyzes the carboxylation of propionyl-CoA to D-methylmalonyl-CoA. PCC is a dodecameric enzyme of alpha-PCC and beta-PCC subunits, nuclearly encoded by genes PCCA and PCCB, respectively. Propionyl-CoA carboxylase (PCC) is a mitochondrial biotin-dependent enzyme composed of an equal number of alpha and beta subunits. PA is caused by mutations in either the PCCA or PCCB genes encoding the Î±- and Î²-subunits of the PCC enzyme. plicing defects account for 16% of the mutant alleles in the PCCA and PCCB genes, encoding both subunits of the propionyl-CoA carboxylase (PCC) enzyme, defective in propionic acidemia. "
    },
    {
      "exact_answer": "yes",
      "id": "531a31a1b166e2b806000035",
      "ideal_answer": "non-synonymous genetic rare variant, rs75932628-T (p.R47H), in the TREM2 gene has recently been reported to be a strong genetic risk factor for Alzheimer\u0027s disease (AD). Moreover, a rare TREM2 exon 2 variant (p.R47H) was reported to increase the risk of Alzheimer\u0027s disease (AD) with an odds ratio as strong as that for APOEÎµ4. Given the reported antiinflammatory role of TREM2 in the brain, the R47H substitution may lead to an increased predisposition to Alzheimer\u0027s disease through impaired containment of inflammatory processes. works have demonstrated a rare functional variant (R47H) in triggering receptor expressed on myeloid cells (TREM) 2 gene, encoding TREM2 protein, increase susceptibility to late-onset Alzheimer\u0027s disease (AD), with an odds ratio similar to that of the apolipoprotein E Îµ4 allele. Under the hypothesis that low-prevalence variants showing moderate-to-high effect size may be associated with risk for sAD, two independent research groups have demonstrated that a rare variant (rs75932628, encoding a substitution of arginine by histidine at residue 47 (R47H), in the TREM2 gene, which encodes the triggering receptor expressed on myeloid cells 2) is significantly associated with an increased susceptibility to sAD. "
    },
    {
      "exact_answer": [
        [
          "clopidogrel"
        ],
        [
          "CYP2C19 protein, human"
        ],
        [
          "P2RY12 gene"
        ],
        [
          "PON1 gene"
        ],
        [
          "Alleles"
        ]
      ],
      "id": "531a34d5b166e2b806000036",
      "ideal_answer": "This study investigated the effect of coexisting polymorphisms of CYP2C19 and P2Y12 on clopidogrel responsiveness and adverse clinical events in Chinese patient. Variability in clopidogrel response might be influenced by polymorphisms in genes coding for drug metabolism enzymes (cytochrome P450 [CYP] family), transport proteins (P-glycoprotein) and/or target proteins for the drug (adenosine diphosphate-receptor P2Y12). The aim of this study was to investigate the effect of the CYP2C19, ABCB1, and PON1 variants on clopidogrel pharmacodynamics and clinical outcomes in these patients. ssociation of a functional polymorphism in the clopidogrel target receptor gene, P2Y12. Carriers of the CYP2C19*17 T-allele, with increased clopidogrel activation, had a 37% relative reduction in the TLR incidence, the primary end point. The cytochrome P450 (CYP) 2C19*2 polymorphism is associated with reduced responsiveness to clopidogrel and poor clinical outcome after stent implantation. From these results it is suggested that CYP2C19*2 polymorphism is associated with subclinical thrombus formation among Japanese patients receiving clopidogrel. However, there were not significant differences in clopidogrel pharmacodynamics and clinical outcomes across the ABCB1 and PON1 genotype groups; bleeding was not significantly different across the CYP2C19, ABCB1, and PON1 genotype groups. "
    },
    {
      "exact_answer": [
        [
          "Human Papillomavirus"
        ],
        [
          "Vaccination"
        ],
        [
          "Human Papilloma Virus Vaccine"
        ],
        [
          "Vaccines"
        ],
        [
          "Relationships"
        ]
      ],
      "id": "531a3a58b166e2b806000037",
      "ideal_answer": "Nevertheless women up to 45 years of age have been shown to exhibit strong immune responses to the bivalent HPV vaccine which might be expected to reduce the risk of HPV re-infection and address the second peak of HPV related malignancy in later life, evident over 45 years of age. The most effective strategy therein was vaccination of 12-year-olds, plus a temporary 12-24-year-old catch-up program covering both sexes; whereby HPV 6/11/16/18-related cervical cancer, high-grade cervical precancer, and genital wart incidence was reduced by 84-98% during year 50 following vaccine introduction. the introduction of cervical screening programs, the incidence and mortality of cervical cancer has been drastically reduced. Vaccine efficacy in prevention of CIN 2 or higher lesions in HPV 16 or HPV 18 negative women, who received all vaccination doses, ranges between 98% and 100%. Besides cost, there are several socio-cultural and ethical issues involved with the implementation of already developed vaccines including the acceptability of HPV vaccination by preadolescent girls and their parents in India. Reduced costs, simple vaccine regimes and strengthening vaccine delivery platforms for adolescents should eventually facilitate HPV vaccine introduction in developing countries. "
    },
    {
      "exact_answer": "yes",
      "id": "531a3fe3b166e2b806000038",
      "ideal_answer": "Although limited in size, the fully prospective nature of the safety follow-up of these women vaccinated during pregnancy is unique and offers an important degree of reassurance for the use of the AS03 adjuvanted H1N1 (2009) vaccine in this high risk group for H1N1 infection. Vaccination of pregnant women against influenza A (H1N1) by Russian subunit formulation (MonoGrippol plus) showed reactogenicity comparable to control group by the level of influence on general metabolic and immunologic homeostasis and on the course of pregnancy, which is an evidence of its safety. During the influenza A(H1N1)pmd09 pandemic, although many cases occurred in younger adults, the risk factors identified for severe infections and complications were similar to those for seasonal influenza, including chronic respiratory, renal, liver, and heart diseases. Our results suggest that second- or third-trimester H1N1 vaccination was associated with improved fetal and neonatal outcomes during the recent pandemic. regnant women were at increased risk for serious outcomes of 2009 pandemic influenza A virus subtype H1N1 (influenza A[H1N1]pdm09) infection, but little is known about the overall impact of the pandemic on neonatal and maternal outcomes. "
    },
    {
      "exact_answer": [
        [
          "Axial R"
        ],
        [
          "Locus"
        ],
        [
          "Negation"
        ],
        [
          "Alleles"
        ],
        [
          "Identified"
        ]
      ],
      "id": "531af8cbb166e2b80600003a",
      "ideal_answer": "Large genome-wide association studies (GWAS) have identified more than 30 loci involved in RA pathogenesis. An additional 11 SNPs replicated at P \u003c 0.05, many of which are validated autoimmune risk alleles, suggesting that most represent genuine rheumatoid arthritis risk alleles. Genome-Wide Association Studies (GWAS) have allowed the characterization of more than 40 new susceptibility genes and the confirmation of a marked differential genetic background between patients expressing anti-cyclic citrullinated peptide antibodies (ACPA, approximately 80% of all RA patients) and ACPA negative RA patients. Genome-wide association studies (GWASs) added about 10 new loci to the list of already more than 20 loci associated with RA, so the list is now over 30. Genome-wide association studies have expanded the number of validated RA risk loci beyond HLA-DRB1 \"shared epitope\" alleles to include additional major histocompatibility complex (MHC) risk alleles and more than 10 regions outside the MHC. This paper compares corresponding non-MHC genomic regions identified in rodent and human genome-wide association studies (GWAS). To date, over 30 non-MHC RA-associated loci have been identified in humans, and over 100 arthritis-associated loci have been identified in rodent models of RA. "
    },
    {
      "exact_answer": [
        [
          "Histone H3"
        ],
        [
          "Lysine"
        ],
        [
          "Polycomb Repressive Complex 2"
        ],
        [
          "PHF19 gene"
        ],
        [
          "Chromatin"
        ],
        [
          "Polycomb"
        ],
        [
          "Negation"
        ],
        [
          "complex (molecular entity)"
        ],
        [
          "PRC1 gene"
        ],
        [
          "Target"
        ],
        [
          "DNMT3B protein, human"
        ],
        [
          "Associated with"
        ],
        [
          "Binding (Molecular Function)"
        ],
        [
          "Requirement"
        ],
        [
          "Transcription Repressor/Corepressor"
        ],
        [
          "Polycomb protein, Drosophila"
        ],
        [
          "Mediate"
        ],
        [
          "Enrich"
        ],
        [
          "DNA"
        ],
        [
          "Affinity"
        ],
        [
          "Simplexvirus"
        ],
        [
          "Superkingdom (taxonomic category)"
        ],
        [
          "KRT9 gene"
        ],
        [
          "Binding action"
        ],
        [
          "Qualifier (concept)"
        ],
        [
          "ME3 gene"
        ],
        [
          "SUZ12 gene"
        ],
        [
          "Proteins"
        ],
        [
          "Promoter"
        ],
        [
          "BMI1 gene"
        ],
        [
          "p300/CBP-Associated Factor"
        ],
        [
          "methylate"
        ],
        [
          "EIF4E wt Allele"
        ],
        [
          "Component (part)"
        ],
        [
          "study of epigenetics"
        ],
        [
          "Mus"
        ],
        [
          "Heterochromatin"
        ],
        [
          "Compact discs"
        ],
        [
          "Add - instruction imperative"
        ],
        [
          "suggestion"
        ],
        [
          "Repression, Psychology"
        ],
        [
          "Acetylation"
        ],
        [
          "Protein Acetylation"
        ],
        [
          "Firstly"
        ],
        [
          "Generic Role"
        ],
        [
          "Associate - relationship"
        ],
        [
          "Transcriptional Repression"
        ],
        [
          "Primary malignant neoplasm"
        ],
        [
          "Histone Code"
        ],
        [
          "Exhibits as Topic"
        ],
        [
          "Subgroup"
        ],
        [
          "histone modification"
        ],
        [
          "preference"
        ],
        [
          "Mathematical Factor"
        ],
        [
          "Massive"
        ],
        [
          "Genome - anatomical entity"
        ],
        [
          "Recruitment"
        ],
        [
          "Embryo"
        ],
        [
          "Lost"
        ],
        [
          "Deposition"
        ],
        [
          "Residue"
        ],
        [
          "Scientific Study"
        ],
        [
          "Enzymatic Activity [MoA]"
        ],
        [
          "Device Display Device Component"
        ],
        [
          "Embryonic Stem Cells"
        ],
        [
          "ResponseLevel - modification"
        ],
        [
          "Subunit"
        ],
        [
          "Genes, Developmental"
        ],
        [
          "Global"
        ],
        [
          "Providing (action)"
        ],
        [
          "Numerous"
        ],
        [
          "Recognition (Psychology)"
        ],
        [
          "Mouse Stem Cell"
        ],
        [
          "Full"
        ],
        [
          "Late"
        ],
        [
          "Formed"
        ],
        [
          "Induce (action)"
        ],
        [
          "Cell Differentiation process"
        ],
        [
          "Patterns"
        ],
        [
          "Activation action"
        ],
        [
          "Does play"
        ],
        [
          "Good"
        ],
        [
          "Direct type of relationship"
        ],
        [
          "Specific site"
        ],
        [
          "Loss"
        ],
        [
          "Transcription, Genetic"
        ],
        [
          "Experimental Result"
        ],
        [
          "Active"
        ],
        [
          "Genes"
        ],
        [
          "Order (document)"
        ],
        [
          "Structure"
        ],
        [
          "Evidence of"
        ],
        [
          "Increase"
        ],
        [
          "Some (qualifier value)"
        ],
        [
          "Function"
        ],
        [
          "*Activity (kind of quantity)"
        ]
      ],
      "id": "531b1e3cb166e2b80600003b",
      "ideal_answer": "They bind the genome at specific sites, forming chromatin domains of associated histone modifications as well as higher-order chromatin structures. The PcG proteins are well-conserved chromatin factors that repress transcription of numerous target genes. Here we show that direct recognition of methylated histone H3 Lys36 (H3K36me), a mark associated with activation, by the PRC2 subunit Phf19 is required for the full enzymatic activity of the PRC2 complex. Here we show that the HSV DNA first associates with histone H3, with later recruitment of Polycomb repressor complex 2 (PRC2) and trimethylation of the lysine 27 residue of histone H3 (H3K27me3), a modification associated with heterochromatin. We found that a component of the PRC1 complex (Bmi1), which binds to H3K27me3, was not enriched at promoters found previously to be enriched for H3K27me3. The Polycomb repressive complex 2 (PRC2) catalyzes trimethylation (me3) of histone H3 lysine 27 (K27), and it is believed that this activity mediates transcriptional repression. During differentiation, binding of polycomb repressive complex 2 (PRC2), which mediates trimethylation of lysine 27 on histone H3 (K27me3), is lost on developmental genes that are transcriptionally induced. "
    },
    {
      "exact_answer": [
        [
          "Nesiritide"
        ],
        [
          "Congestive heart failure"
        ],
        [
          "Free triiodothyronine"
        ],
        [
          "Triiodothyronine"
        ],
        [
          "Body Site Modifier - Lower"
        ]
      ],
      "id": "531b2fc3b166e2b80600003c",
      "ideal_answer": "The authors conclude that among elderly patients with heart failure, lower triiodothyronine concentrations are more prevalent and are associated with a worse prognosis. Cumulative survival was significantly lower among patients with free triiodothyronine \u003c 2.12 pg/mL and among patients with brain natriuretic peptide \u003e 686 pg/mL. Low T(3) levels are an independent predictor of mortality in patients with chronic heart failure, adding prognostic information to conventional clinical and functional cardiac parameters. A low free T3 index/reverse T3 ratio is associated with poor ventricular function and nutritional status and is the strongest predictor yet identified for short-term outcome in patients with advanced heart failure. In multivariate analysis, the significant independent predictors of major cardiac events were age, free triiodothyronine, and brain natriuretic peptide. Sixteen patients (14%) died during the follow-up period; their fT3/fT4 ratio was significantly lower than the patients who survived (1.31+/-0.37 vs. 2.01+/-0.72,. fT4 (p\u003d0.016) and fT3/fT4 (p\u003c0.0001) were associated with heart failure progression but multivariate analysis showed that only TSH considered as a continuous variable (p \u003d 0.001) as well as subclinical hypothyroidism (TSH \u003e 5.5 mUI/l; p\u003d0.014) remained significantly associated with the events. fT3 and BNP hold an independent and additive prognostic value in HF. "
    },
    {
      "exact_answer": [
        [
          "CDH17 gene"
        ],
        [
          "SIRT1 gene"
        ],
        [
          "Induce (action)"
        ],
        [
          "ZEB1 gene"
        ],
        [
          "Fluorides"
        ],
        [
          "Mediator brand of benfluorex hydrochloride"
        ],
        [
          "SNAI1 gene"
        ],
        [
          "PARD6A gene"
        ],
        [
          "PARD3 gene"
        ],
        [
          "NUMB gene"
        ],
        [
          "cell-cell adhesion"
        ],
        [
          "Prostate"
        ],
        [
          "metastatic qualifier"
        ],
        [
          "JTB protein, human"
        ],
        [
          "Nicotinamide adenine dinucleotide (NAD)"
        ],
        [
          "CDH1 gene"
        ],
        [
          "ZEB1 wt Allele"
        ],
        [
          "Cells"
        ],
        [
          "Little\u0027s Disease"
        ],
        [
          "beta catenin"
        ],
        [
          "TRANSCRIPTION FACTOR"
        ],
        [
          "Expression procedure"
        ],
        [
          "Transforming Growth Factor beta"
        ],
        [
          "Cell-cell adhesion molecule"
        ],
        [
          "epithelial to mesenchymal transition"
        ],
        [
          "Generic Role"
        ],
        [
          "Histone Deacetylase"
        ],
        [
          "Changing"
        ],
        [
          "Staurosporine"
        ],
        [
          "Entire cell"
        ],
        [
          "Loss"
        ],
        [
          "Proliferation (morphologic abnormality)"
        ],
        [
          "Regulation of biological process"
        ],
        [
          "Increase"
        ],
        [
          "Active"
        ],
        [
          "cooperation"
        ],
        [
          "Morphologically altered structure"
        ],
        [
          "Transforming Growth Factors"
        ],
        [
          "Mesenchymal"
        ],
        [
          "Migration, Cell"
        ],
        [
          "Polarity"
        ],
        [
          "Biological Markers"
        ],
        [
          "Proteins"
        ],
        [
          "Pathway (interactions)"
        ],
        [
          "Prostate carcinoma"
        ],
        [
          "Decrease"
        ],
        [
          "Tumor cells, malignant"
        ],
        [
          "CDH2 gene"
        ],
        [
          "Transcription, Genetic"
        ],
        [
          "Nervous - anatomy qualifier"
        ],
        [
          "Increased"
        ],
        [
          "SNAI2 gene"
        ],
        [
          "Mechanism (attribute)"
        ],
        [
          "complex (molecular entity)"
        ],
        [
          "Delaware"
        ],
        [
          "Belarus"
        ],
        [
          "Potential"
        ],
        [
          "VIM gene"
        ],
        [
          "actin bundling"
        ],
        [
          "AMH gene"
        ],
        [
          "literary novel"
        ],
        [
          "Lanthanum"
        ],
        [
          "Madin Darby Canine Kidney Cells"
        ],
        [
          "Processor Core"
        ],
        [
          "actin filament depolymerization"
        ],
        [
          "Confidentiality - sensitive"
        ],
        [
          "Character String Data Type"
        ],
        [
          "silence"
        ],
        [
          "cohesion"
        ],
        [
          "Loosening"
        ],
        [
          "Focal Adhesions"
        ],
        [
          "Migratory (qualifier value)"
        ],
        [
          "Short Hairpin RNA"
        ],
        [
          "Light Emitting Diode Device Component"
        ],
        [
          "Couple (action)"
        ],
        [
          "actin filament polymerization"
        ],
        [
          "alternate pathway"
        ],
        [
          "EGF Signaling Pathway"
        ],
        [
          "Transcriptional Repression"
        ],
        [
          "Prostatic Neoplasms"
        ],
        [
          "F-Actin"
        ],
        [
          "Intercellular Junctions"
        ],
        [
          "Neoplasm Metastasis"
        ],
        [
          "Tumor cells, uncertain whether benign or malignant"
        ],
        [
          "Polymerization"
        ],
        [
          "combination of objects"
        ],
        [
          "Polarization"
        ],
        [
          "Intrinsic drive"
        ],
        [
          "Promotion (action)"
        ],
        [
          "Helix (Snails)"
        ],
        [
          "Physiologic Organization"
        ],
        [
          "Line Specimen"
        ],
        [
          "Apical"
        ],
        [
          "Plasticity"
        ],
        [
          "Capability"
        ],
        [
          "establishment and maintenance of localization"
        ],
        [
          "Triggered by"
        ],
        [
          "Cell-Matrix Junction"
        ],
        [
          "Processed"
        ],
        [
          "Modulated"
        ]
      ],
      "id": "531b3ff3b166e2b80600003d",
      "ideal_answer": "unctional loss of the cell-cell adhesion molecule E-cadherin is an essential event for epithelial-mesenchymal transition (EMT), a process that allows cell migration during embryonic development and tumour invasion. Knockdown of Numb by shRNA in MDCK cells led to a lateral to apical translocation of E-cadherin and beta-catenin, active F-actin polymerization, mis-localization of Par3 and aPKC, a decrease in cell-cell adhesion and an increase in cell migration and proliferation. Here, we propose a novel mechanism through which the nicotinamide adenine dinucleotide-dependent histone deacetylase SIRT1 regulates EMT in prostate cancer cells through cooperation with the EMT inducing transcription factor ZEB1. In contrast, silencing SIRT1 in metastatic prostate tumor cells restores cell-cell adhesion and induces a shift toward an epithelial morphology concomitant with increased expression of E-cadherin and decreased expression of mesenchymal markers. ST in combination with EGF directed a greater EMT via actin depolymerisation and focal contact size reduction, resulting in a loosening of cell-ECM attachment along with Snail1-Zeb1/deltaEF1 induction. We propose that the regulation of EMT by SIRT1 involves modulation of, and cooperation with, the EMT inducing transcription factor ZEB1. "
    },
    {
      "exact_answer": "yes",
      "id": "531b4269b166e2b80600003e",
      "ideal_answer": "In these patients, the administration of synthetic triiodothyronine (T(3)) was well tolerated and induced significant improvement in cardiac function without increased heart rate and metabolic demand. These data indicate that T(3) replacement to euthyroid levels improves systolic function and tends to improve diastolic function, potentially through changes in myocardial gene expression. In DC patients, short-term synthetic L-T(3) replacement therapy significantly improved neuroendocrine profile and ventricular performance. Cardiac output increased with a reduction in systemic vascular resistance in patients receiving the largest dose, consistent with a peripheral vasodilatory effect. Triiodothyronine was well tolerated without episodes of ischemia or clinical arrhythmia. Early and sustained physiological restoration of circulating L-T3 levels after MI halves infarct scar size and prevents the progression towards heart failure. Patients with chronic heart failure and subclinical hypothyroidism significantly improved their physical performance when normal TSH levels were reached. This beneficial effect is likely due to enhanced capillary formation and mitochondrial protection. There was no significant change in heart rate or metabolic rate and there was minimal increase in core temperature. "
    },
    {
      "exact_answer": "yes",
      "id": "531c380db166e2b80600003f",
      "ideal_answer": "Healthy athletes developed subclinical increase in pulmonary water content immediately after an Ironman race at sea level, as shown by the increased number of ULCs related to cardiac changes occurring during exercise. Among them chest ultrasonography can detect and quantify the extravascular lung water, creating \"comet-tail\" ultrasound artefacts (ULCs) from water-thickened pulmonary interlobular septa. In top-level breath-hold divers, chest sonography frequently reveals an increased number of ULCs after immersion, indicating a relatively high prevalence of (often subclinical) reversible extravascular lung water accumulation. Increased EVLW is associated with estimated PCWP and indices of left ventricular systolic and diastolic dysfunction. The additional exercise-induced increase of PCWP, the worsening of left ventricular diastolic function, and extensive wall-motion abnormalities correlate with variations of EVLW. "
    },
    {
      "exact_answer": "yes",
      "id": "531d1279b166e2b806000042",
      "ideal_answer": "The multivariate analysis revealed that age (OR 2.39, p\u003d0.001), diabetes (OR 3.74, p\u003d0.001), creatinine (OR 2.06, p\u003d0.008), and smoking (OR 1.85, p\u003d0.045) were independent predictors for significant coronary artery disease, but TSH level did not predict coronary artery stenosis. The incidence of multi-vessel disease was higher in patients with high TSH level (p\u003d0.026). The results showed that higher levels of TSH within the reference range were independently associated with the presence of CAD only among subjects less than or equal to 65 years old, suggesting age might influence the relationship. These data in patients referred for coronary angiography suggest that variation of thyroid function within the statistical normal range may influence the presence and severity of coronary atherosclerosis. Prevalence of CHD was more common in hypothyroid and moderate SCH patients. The risk of coronary death was also increased among women with subclinical hypothyroidism or subclinical hyperthyroidism, compared to women with TSH of 0Â·50-1Â·4 mU/l. High TSH within the reference range was associated with increased risk of coronary death in women (P(trend) 0Â·005), but not in men. Lower fT3 levels were predictive of both single-vessel (p \u003d 0.012) and multivessel (p \u003d 0.009) CAD. "
    },
    {
      "exact_answer": [
        [
          "Reverse Triiodothyronine"
        ],
        [
          "Thyrotropin"
        ],
        [
          "Levels (qualifier value)"
        ],
        [
          "Abnormally high"
        ],
        [
          "Creatine Kinase"
        ]
      ],
      "id": "531d1998267d7dd053000001",
      "ideal_answer": "Thyroid dysfunction, particularly sick euthyroid syndrome, was found to be related to in-hospital and long term mortality in patients with STEMI undergoing primary percutaneous intervention. A low fT3 level, a common phenomenon in patients with acute myocardial infarctions, is a strong predictor of short-term and long-term poor prognoses in patients with acute myocardial infarctions. In-hospital cardiogenic shock (15% vs 3% in the control group; p\u003c0.01) and death (7% vs 1% in the control group; p\u003c0.01) were more frequently observed in the thyroid dysfunction group. Reverse T3 levels \u003e0.41 nmol/L were associated with an increased risk of 1-year mortality (hazard ratio \u003d 3.0; 95% confidence interval: 1.4 to 6.3; P \u003d 0.005), independent of age, previous myocardial infarction, prior angina, heart failure, serum creatinine level, and peak serum creatine kinase-MB fraction levels. Survivors in the AMI group had higher TT3, TT4, and lower FT4 levels, while the nonsurvivors in the AMI group had higher thyrotrophin and lower TT3, FT3 and FT4 levels than controls. Troponin T and creatine kinase-B with an M-type subunit levels were significantly higher in the nonsurvivors when compared with survivors. "
    },
    {
      "exact_answer": "yes",
      "id": "531d2aa5267d7dd053000003",
      "ideal_answer": "Such exercise significantly increased ANP and BNP levels in healthy men, and the increases could be partially attributed to myocardial damage during the race. The relatively high NT-proBNP levels after active recovery when psychophysical stress is higher, because of cycling and cold water immersion, suggest that not only endurance exercise, but also strenuous, stressful short exercise can induce an increase in NT-proBNP concentrations. Increases in NT-proBNP can be found in a major part of obviously healthy athletes after prolonged strenuous exercise. Pro-BNP was significantly increased immediately post-race (27+/-21 vs 7+/-2 pmol/L pre-race, P \u003c or \u003d 0.007), which 12-24 h later, decreased to 19+/-14 pmol/L (P \u003d 0.07 vs pre-race). In healthy cyclists, transient increases in NT-pro-BNP and cTnT are more likely to reflect cardiac fatigue than injury. NT-pro-BNP concentrations increased significantly (28 +/- 17.1 vs 795 +/- 823 ng x L, P \u003c 0.05), whereas postrace cTnT were elevated in just five athletes (20%). The release of BNP during and after exercise may not result from myocardial damage but may have cytoprotective and growth-regulating effects. NT-pro-BNP was significantly elevated postexercise in both adults and adolescents and remained above baseline at 24 h in both groups. "
    },
    {
      "exact_answer": "yes",
      "id": "531d34be267d7dd053000004",
      "ideal_answer": "Atypical findings such as marked cardiac dilation, reduced deformation, or small patches of delayed gadolinium enhancement may be commonly encountered in well-trained athletes, but, at present, the prognostic significance of such findings is unknown. Post-event cardiac MRI demonstrated the interval appearance of delayed enhancement of gadolinium at the inferior insertion of the right ventricle and in the interventricular septum-a novel finding that may represent subtle inflammation secondary to a combined exercise and altitude effect. On CMR, DGE localized to the interventricular septum was identified in 5 of 39 athletes who had greater cumulative exercise exposure and lower RVEF (47.1 Â± 5.9 vs. 51.1 Â± 3.7%, P \u003d 0.042) than those with normal CMR. No evidence of delayed enhancement of the left ventricular myocardium was found on CMR imaging, suggesting that the increase in cardiac biomarkers after the marathon may not have be due to myocardial necrosis. The CAD pattern of LGE was located in the territory of the left anterior descending coronary artery more frequently than was the non-CAD pattern (P \u003d .0027,. Of the 102 runners, five had a CAD pattern of LGE, and seven had a non-CAD pattern of LGE. "
    },
    {
      "exact_answer": "yes",
      "id": "531d3dc0267d7dd053000005",
      "ideal_answer": "As modern imaging further enhances our understanding of the spectrum of athlete\u0027s heart, its role may expand from the assessment of athletes with suspected disease to being part of comprehensive pre-participation screening in apparently healthy athletes. Finally we will address the role of CMR in pre-participation screening. "
    },
    {
      "exact_answer": [
        [
          "Clonazepam"
        ],
        [
          "Thioctic Acid"
        ],
        [
          "Restless Legs Syndrome"
        ],
        [
          "Alar"
        ],
        [
          "Therapeutic procedure"
        ],
        [
          "Capsaicin"
        ],
        [
          "Patients"
        ],
        [
          "novel AODU treatment method"
        ],
        [
          "Effectiveness"
        ],
        [
          "Catuama"
        ],
        [
          "Symptoms"
        ],
        [
          "Negation"
        ],
        [
          "Placebos"
        ],
        [
          "Protector Device Component"
        ],
        [
          "Average of Value Derivation Technique"
        ],
        [
          "Logical Condition"
        ],
        [
          "suggestion"
        ],
        [
          "Choose (action)"
        ],
        [
          "Tongue"
        ],
        [
          "prescription document"
        ],
        [
          "Dopaminergic Agents"
        ],
        [
          "Suggestive of"
        ],
        [
          "Subgroup"
        ],
        [
          "The science and art of healing"
        ],
        [
          "Usual"
        ],
        [
          "Pharmaceutical Preparations"
        ],
        [
          "Topical surface"
        ],
        [
          "Phenotypic variation"
        ],
        [
          "Drug Costs"
        ],
        [
          "Simultaneous"
        ],
        [
          "strategy"
        ],
        [
          "systemic administration"
        ],
        [
          "Clinical Trials"
        ],
        [
          "Medical History"
        ],
        [
          "Reduction - action"
        ],
        [
          "Previous"
        ],
        [
          "Active"
        ],
        [
          "drug response"
        ],
        [
          "Response process"
        ],
        [
          "Large"
        ],
        [
          "Treated with"
        ],
        [
          "Evidence of"
        ],
        [
          "Disease Response"
        ],
        [
          "Analysis"
        ],
        [
          "Disease"
        ],
        [
          "Clinical"
        ]
      ],
      "id": "531d7430267d7dd053000008",
      "ideal_answer": "We suggest that a subset of patients with BMS may be a phenotypic variant of RLS and a trial of dopaminergic drugs should be given in patients with BMS who has a history suggestive of RLS or in a patient who do not show a response to usual therapies for BMS. Topical clonazepam, which previous analyses of clinical evidence have shown to be the drug of choice for BMS, also proved to be the most cost-effective of the drugs analysed for this condition. The concomitant prescription of tongue protector and AV is effective for treating patients with BMS. On average, treatment with placebos produced a response that was 72% as large as the response to active drugs. Therapies that used capsaicin, alpha-lipoic acid (ALA), and clonazepam were those that showed more reduction in symptoms of BMS. The systemic administration of Catuama reduces the symptoms of BMS and may be a novel therapeutic strategy for the treatment of this disease. "
    },
    {
      "exact_answer": "yes",
      "id": "531d76a2267d7dd05300000a",
      "ideal_answer": "BMS is a chronic disorder that frequently affects women and is characterised by burning symptoms of the oral mucosa without clinical signs. It is observed principally in middle-aged patients and postmenopausal women and may be accompanied by xerostomia and altered taste. It occurs more commonly in middle-aged and elderly women and often affects the tongue tip and lateral borders, lips, and hard and soft palate. It mostly affects elderly citizens, especially postmenopausal women with prevalence up to 12-18%. "
    }
  ]
}